[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f12Ux1NWnmKek1Lbk50hn-aW_dtYXM1U4W1LDxwAKDkc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"National Heart, Lung, and Blood Institute (NHLBI)",[4],1137,false,89,123,10852656,51,847,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Cardiovascular Diseases",457,{"name":18,"count":19},"Heart Diseases",438,{"name":21,"count":22},"Coronary Disease",192,{"name":24,"count":25},"Hypertension",157,{"name":27,"count":28},"Lung Diseases",109,{"name":30,"count":31},"Atherosclerosis",75,{"name":33,"count":31},"Asthma",{"name":35,"count":36},"Obesity",73,[38,43,48,53,58,63,68,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT01500733","PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","2014-06-20","PCI 32765",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT01623167","Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia","2018-01-30","Cohort 1: hATG, CsA, EPAG Day 14 to Month 6",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT00977691","Haploidentical PBMC Transplant for Severe Congenital Anemias","2018-08-01","Alemtuzumab",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT02514083","A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL","2019-10-02","Ibrutinib",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03077542","Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease","2023-07-27","Sirolimus",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT03354390","HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma","2023-10-31","cell",{"nctId":69,"briefTitle":70,"date":71,"intervention":52},"NCT02105766","Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure","2023-12-31",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04304820","Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)","2024-12-18","Eltrombopag",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT05998408","JAK1\u002F2 Inhibitor Ruxolitinib for Relapsed\u002FRefractory Immune Bone Marrow Failure","2025-07-22","Ruxolitinib",{"nctId":83,"briefTitle":84,"date":85,"intervention":76},"NCT03206086","Eltrombopag for People With Fanconi Anemia","2025-08-01",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,133,151,169,187,205,223,241,259,277,295,313,331,362,455,646,735,766,850,886,908,930,1025,1144,1208,1241,1267,1302,1335,1358,1385,1403,1431,1454,1480,1498,1522,1548,1566,1590,1608,1626,1644,1709,1735,1758,1782,1804,1829,1854,1879,1924,1960,1987,2012,2030,2048,2074,2141,2198,2257,2307,2346,2398,2459,2485,2518,2552,2586,2627,2660,2691,2746,2772,2812,2842,2872,2898,2920,2942,2964,2989,3017,3039,3075,3106,3138,3168,3194,3226,3255,3288,3319,3341,3366,3395,3422,3444,3476,3498,3516,3537,3555,3573,3591,3609,3627,3657,3675,3693,3711,3729,3747,3771,3794,3812,3830,3853,3876,3902,3927,3950,3968,3989,4012,4036,4054,4072,4097,4115,4137,4155,4173,4197,4224,4242,4260,4285,4303,4326,4349,4373,4391,4409,4432,4450,4468,4486,4504,4522,4540,4558,4576,4594,4617,4635,4661,4679,4736,4766,4802,4833,4865,4887,4909,4938,4976,5012,5034,5066,5100,5133,5161,5187,5219,5241,5263,5286,5304,5322,5340,5365,5383,5409,5427,5445,5463,5491,5509,5532,5550,5573,5597,5623,5641,5667,5685,5703,5727,5752,5781,5799,5822,5845,5863,5881,5899,5923,5946,5972,5990,6008,6031,6056,6079,6097,6115,6133,6157,6181,6199,6217,6235,6257,6280,6304,6328,6352,6370,6388,6409,6431,6454,6479,6502,6525,6548,6569,6592,6610,6637,6655,6673,6691,6715,6739,6765,6792,6810,6834,6852,6870,6888,6909,6932,6950,6971,6989,7014,7032,7069,7095,7113,7136,7159,7182,7206,7224,7250,7268,7291,7314,7332,7357,7382,7400,7423,7447,7465,7488,7506,7531,7554,7576,7603,7628,7646,7670,7695,7743,7789,7827,7867,7913,7943,7965,7995,8017,8039,8069,8094,8112,8130,8157,8181,8205,8223,8241,8266,8284,8306,8327,8351,8369,8387,8410,8435,8453,8478,8496,8521],{"intervention":95,"totalTrials":96,"cells":97},"Fluzone",1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":131},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":114},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"NCT05170399","Vaccine Responses in Patients With B Cell Malignancies","RECRUITING",[91],"2026-08-16","2022-09-14",500,[118],"Lymphoma",[95,120,121,122,123,124,125,126,127,128,129,130],"Shingrix","Flucelvax","Afluria","PREVNAR 13","Heplisav -B","Pfizer-COVID-19 Vaccine","FluLaval","Fluarix","PNEUMOVAX 23","PREVNAR 20","AREXVY, ABRYSVO",{"trials":132,"activeCount":100},[],{"intervention":120,"totalTrials":96,"cells":134},{"EARLY_PHASE1":135,"PHASE1":137,"PHASE2":139,"PHASE3":141,"PHASE4":143,"NA":149},{"trials":136,"activeCount":100},[],{"trials":138,"activeCount":100},[],{"trials":140,"activeCount":100},[],{"trials":142,"activeCount":100},[],{"trials":144,"activeCount":96,"soonestReadout":114},[145],{"nctId":110,"briefTitle":111,"status":112,"phases":146,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":147,"interventions":148},[91],[118],[95,120,121,122,123,124,125,126,127,128,129,130],{"trials":150,"activeCount":100},[],{"intervention":121,"totalTrials":96,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":167},{"trials":154,"activeCount":100},[],{"trials":156,"activeCount":100},[],{"trials":158,"activeCount":100},[],{"trials":160,"activeCount":100},[],{"trials":162,"activeCount":96,"soonestReadout":114},[163],{"nctId":110,"briefTitle":111,"status":112,"phases":164,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":165,"interventions":166},[91],[118],[95,120,121,122,123,124,125,126,127,128,129,130],{"trials":168,"activeCount":100},[],{"intervention":122,"totalTrials":96,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":185},{"trials":172,"activeCount":100},[],{"trials":174,"activeCount":100},[],{"trials":176,"activeCount":100},[],{"trials":178,"activeCount":100},[],{"trials":180,"activeCount":96,"soonestReadout":114},[181],{"nctId":110,"briefTitle":111,"status":112,"phases":182,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":183,"interventions":184},[91],[118],[95,120,121,122,123,124,125,126,127,128,129,130],{"trials":186,"activeCount":100},[],{"intervention":123,"totalTrials":96,"cells":188},{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":203},{"trials":190,"activeCount":100},[],{"trials":192,"activeCount":100},[],{"trials":194,"activeCount":100},[],{"trials":196,"activeCount":100},[],{"trials":198,"activeCount":96,"soonestReadout":114},[199],{"nctId":110,"briefTitle":111,"status":112,"phases":200,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":201,"interventions":202},[91],[118],[95,120,121,122,123,124,125,126,127,128,129,130],{"trials":204,"activeCount":100},[],{"intervention":124,"totalTrials":96,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":213,"PHASE4":215,"NA":221},{"trials":208,"activeCount":100},[],{"trials":210,"activeCount":100},[],{"trials":212,"activeCount":100},[],{"trials":214,"activeCount":100},[],{"trials":216,"activeCount":96,"soonestReadout":114},[217],{"nctId":110,"briefTitle":111,"status":112,"phases":218,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":219,"interventions":220},[91],[118],[95,120,121,122,123,124,125,126,127,128,129,130],{"trials":222,"activeCount":100},[],{"intervention":125,"totalTrials":96,"cells":224},{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":231,"PHASE4":233,"NA":239},{"trials":226,"activeCount":100},[],{"trials":228,"activeCount":100},[],{"trials":230,"activeCount":100},[],{"trials":232,"activeCount":100},[],{"trials":234,"activeCount":96,"soonestReadout":114},[235],{"nctId":110,"briefTitle":111,"status":112,"phases":236,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":237,"interventions":238},[91],[118],[95,120,121,122,123,124,125,126,127,128,129,130],{"trials":240,"activeCount":100},[],{"intervention":126,"totalTrials":96,"cells":242},{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":251,"NA":257},{"trials":244,"activeCount":100},[],{"trials":246,"activeCount":100},[],{"trials":248,"activeCount":100},[],{"trials":250,"activeCount":100},[],{"trials":252,"activeCount":96,"soonestReadout":114},[253],{"nctId":110,"briefTitle":111,"status":112,"phases":254,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":255,"interventions":256},[91],[118],[95,120,121,122,123,124,125,126,127,128,129,130],{"trials":258,"activeCount":100},[],{"intervention":127,"totalTrials":96,"cells":260},{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":267,"PHASE4":269,"NA":275},{"trials":262,"activeCount":100},[],{"trials":264,"activeCount":100},[],{"trials":266,"activeCount":100},[],{"trials":268,"activeCount":100},[],{"trials":270,"activeCount":96,"soonestReadout":114},[271],{"nctId":110,"briefTitle":111,"status":112,"phases":272,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":273,"interventions":274},[91],[118],[95,120,121,122,123,124,125,126,127,128,129,130],{"trials":276,"activeCount":100},[],{"intervention":128,"totalTrials":96,"cells":278},{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":293},{"trials":280,"activeCount":100},[],{"trials":282,"activeCount":100},[],{"trials":284,"activeCount":100},[],{"trials":286,"activeCount":100},[],{"trials":288,"activeCount":96,"soonestReadout":114},[289],{"nctId":110,"briefTitle":111,"status":112,"phases":290,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":291,"interventions":292},[91],[118],[95,120,121,122,123,124,125,126,127,128,129,130],{"trials":294,"activeCount":100},[],{"intervention":129,"totalTrials":96,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":305,"NA":311},{"trials":298,"activeCount":100},[],{"trials":300,"activeCount":100},[],{"trials":302,"activeCount":100},[],{"trials":304,"activeCount":100},[],{"trials":306,"activeCount":96,"soonestReadout":114},[307],{"nctId":110,"briefTitle":111,"status":112,"phases":308,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":309,"interventions":310},[91],[118],[95,120,121,122,123,124,125,126,127,128,129,130],{"trials":312,"activeCount":100},[],{"intervention":130,"totalTrials":96,"cells":314},{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":329},{"trials":316,"activeCount":100},[],{"trials":318,"activeCount":100},[],{"trials":320,"activeCount":100},[],{"trials":322,"activeCount":100},[],{"trials":324,"activeCount":96,"soonestReadout":114},[325],{"nctId":110,"briefTitle":111,"status":112,"phases":326,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":327,"interventions":328},[91],[118],[95,120,121,122,123,124,125,126,127,128,129,130],{"trials":330,"activeCount":100},[],{"intervention":332,"totalTrials":96,"cells":333},"[18F]FAPI-74",{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":338,"PHASE3":340,"PHASE4":358,"NA":360},{"trials":335,"activeCount":100},[],{"trials":337,"activeCount":100},[],{"trials":339,"activeCount":100},[],{"trials":341,"activeCount":96,"soonestReadout":347},[342],{"nctId":343,"briefTitle":344,"status":345,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":357},"NCT07613099","Evaluation of Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74 PET\u002FCT Imaging)","NOT_YET_RECRUITING",[90],"2031-05-26","2033-05-26","2026-06-07",210,[352,353,354,355,356,15],"Allogeneic Stem Cell Transplantation","Lung Allograft Transplantation","Interstitial Lung Disease","Acute Lung Injury","Pulmonary Arterial Hypertension",[332],{"trials":359,"activeCount":100},[],{"trials":361,"activeCount":100},[],{"intervention":62,"totalTrials":363,"cells":364},7,{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":449,"PHASE4":451,"NA":453},{"trials":366,"activeCount":100},[],{"trials":368,"activeCount":100},[],{"trials":370,"activeCount":412,"soonestReadout":51},[371,383,397,405,417,429,437],{"nctId":372,"briefTitle":373,"status":374,"phases":375,"primaryCompletion":376,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":382},"NCT02979873","Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy","ACTIVE_NOT_RECRUITING",[89],"2025-09-04","2030-06-30","2016-12-19",84,[381],"Severe Aplastic Anemia",[62],{"nctId":69,"briefTitle":70,"status":374,"phases":384,"primaryCompletion":71,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":393},[89],"2027-12-31","2014-04-21",56,[389,390,391,392],"Sickle Cell Disease","Thalassemia","Stem Cell Transplantation","Graft vs Host Disease",[52,62,394,395,396],"Cyclophosphamide","Pentostatin","Filgrastim",{"nctId":49,"briefTitle":50,"status":374,"phases":398,"primaryCompletion":51,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":404},[88,89],"2026-09-10","2009-12-14",23,[403],"Sickle Cell Anemia",[52,62,394],{"nctId":406,"briefTitle":407,"status":374,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":414},"NCT06145282","Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function",[88,89],"2025-10-27","2027-11-26","2023-12-28",6,[389],[415,396,416,62,394],"Briquilimab","Abatacept",{"nctId":418,"briefTitle":419,"status":420,"phases":421,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":428},"NCT00061568","Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias","UNKNOWN",[88,89],"2023-01-20","2026-01-31","2004-07-16",130,[427,389],"Congenital Hemolytic Anemia",[52,62],{"nctId":59,"briefTitle":60,"status":374,"phases":430,"primaryCompletion":61,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":435},[88,89],"2026-08-31","2017-04-06",57,[389],[62,52,395,394,436,396],"Hydroxyurea",{"nctId":438,"briefTitle":439,"status":374,"phases":440,"primaryCompletion":423,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":446},"NCT05357482","Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia",[88,89],"2027-01-31","2022-05-12",40,[403,445],"Beta Thalassemia",[436,447,396,62,52,448],"briquilimab","Plerixafor",{"trials":450,"activeCount":100},[],{"trials":452,"activeCount":100},[],{"trials":454,"activeCount":100},[],{"intervention":394,"totalTrials":456,"cells":457},16,{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":631,"PHASE4":642,"NA":644},{"trials":459,"activeCount":100},[],{"trials":461,"activeCount":100},[],{"trials":463,"activeCount":630,"soonestReadout":51},[464,481,493,505,509,523,535,550,554,558,571,583,603,607,615],{"nctId":465,"briefTitle":466,"status":467,"phases":468,"completion":469,"enrollment":11,"conditions":470,"interventions":474},"NCT00066417","Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia","TERMINATED",[89],"2007-01",[471,472,473],"Chronic Myeloproliferative Disorders","Leukemia","Myelodysplastic\u002FMyeloproliferative Diseases",[475,476,477,478,479,480],"cyclophosphamide","cyclosporine","fludarabine phosphate","methylprednisolone","therapeutic allogeneic lymphocytes","thiotepa",{"nctId":482,"briefTitle":483,"status":112,"phases":484,"primaryCompletion":485,"completion":486,"start":487,"enrollment":387,"conditions":488,"interventions":492},"NCT03520647","Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis",[89],"2026-06-01","2028-06-01","2019-02-19",[489,490,491],"Severe Aplastic Anemia (SAA)","Hypo-Plastic Myelodysplastic Syndrome (MDS)","Paroxysmal Nocturnal Hemoglobinuria (PNH)",[394],{"nctId":494,"briefTitle":495,"status":496,"phases":497,"primaryCompletion":498,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":503},"NCT00001626","Comparing Therapies for the Treatment of Severe Aplastic Anemia","COMPLETED",[89],"2001-02-20","2008-03-03","1997-06-02",33,[489],[504,475,476],"antithymocyte globulin",{"nctId":69,"briefTitle":70,"status":374,"phases":506,"primaryCompletion":71,"completion":385,"start":386,"enrollment":387,"conditions":507,"interventions":508},[89],[389,390,391,392],[52,62,394,395,396],{"nctId":510,"briefTitle":511,"status":496,"phases":512,"primaryCompletion":513,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":520},"NCT01145209","Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL\u002FSLL",[89],"2017-10-31","2023-09-15","2010-07-01",32,[518,519],"Small Lymphocytic Lymphoma","CLL (Chronic Lymphocytic Leukemia)",[521,522,394],"Fludarabine Phosphate","Ofatumumab",{"nctId":524,"briefTitle":525,"status":496,"phases":526,"primaryCompletion":527,"completion":527,"start":528,"enrollment":96,"conditions":529,"interventions":533},"NCT01187017","A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia",[88,89],"2012-07","2010-08",[530,531,532,381],"Aplastic Anemia","Neutropenia","Pancytopenia",[394,534],"Fludarabine",{"nctId":536,"briefTitle":537,"status":496,"phases":538,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":548},"NCT00378534","Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants",[89],"2014-04","2006-09",116,[543,544,545,546,547],"Chronic Myelogenous Leukemia","Acute Myelogenous Leukemia","Chronic Lymphocytic Leukemia","Acute Lymphoblastic Leukemia","Myelodysplastic Syndrome",[534,549,394],"Cyclosporine",{"nctId":49,"briefTitle":50,"status":374,"phases":551,"primaryCompletion":51,"completion":399,"start":400,"enrollment":401,"conditions":552,"interventions":553},[88,89],[403],[52,62,394],{"nctId":406,"briefTitle":407,"status":374,"phases":555,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":556,"interventions":557},[88,89],[389],[415,396,416,62,394],{"nctId":559,"briefTitle":560,"status":467,"phases":561,"completion":562,"start":563,"conditions":564,"interventions":567},"NCT00003552","Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma",[88,89],"2002-10","1999-01",[565,566],"Stage IV Melanoma","Recurrent Melanoma",[568,569,475,570],"allogeneic lymphocytes","anti-thymocyte globulin","fludarabine",{"nctId":572,"briefTitle":573,"status":496,"phases":574,"completion":575,"start":576,"conditions":577,"interventions":580},"NCT00000596","Diffuse Fibrotic Lung Disease",[89],"1983-01","1978-06",[27,578,579],"Pulmonary Fibrosis","Sarcoidosis",[581,475,582],"prednisone","dapsone",{"nctId":584,"briefTitle":585,"status":496,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":597},"NCT02208037","Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)",[89],"2017-10","2014-08",279,[591,543,592,545,518,593,594,595,596],"Acute Leukemia","Myelodysplasia","Lymphoma, B-Cell","Lymphoma, Follicular","Lymphoma, Large B-Cell, Diffuse","Hodgkin's Lymphoma",[598,598,599,599,600,601,602,394],"Tacrolimus","Methotrexate","Maraviroc","Bortezomib","Mycophenolate mofetil",{"nctId":59,"briefTitle":60,"status":374,"phases":604,"primaryCompletion":61,"completion":431,"start":432,"enrollment":433,"conditions":605,"interventions":606},[88,89],[389],[62,52,395,394,436,396],{"nctId":608,"briefTitle":609,"status":496,"phases":610,"primaryCompletion":611,"completion":611,"start":528,"enrollment":612,"conditions":613,"interventions":614},"NCT01193283","Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia",[88,89],"2014-09",22,[530,531,532,381],[394,549],{"nctId":616,"briefTitle":617,"status":496,"phases":618,"primaryCompletion":619,"completion":619,"start":563,"enrollment":620,"conditions":621,"interventions":626},"NCT00029380","Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia",[89],"2006-08",30,[622,623,624,625],"Hematologic Diseases","Anemia, Sickle Cell","Beta-Thalassemia","Hematopoietic Stem Cell Transplantation",[627,394,628,629,549],"Sangstat","Busulfan","Mycophenolate Mofetil",5,{"trials":632,"activeCount":100},[633],{"nctId":634,"briefTitle":635,"status":496,"phases":636,"primaryCompletion":637,"completion":637,"start":638,"enrollment":639,"conditions":640,"interventions":641},"NCT02345850","Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)",[90],"2020-10-05","2015-08",346,[591,592],[394,598,599],{"trials":643,"activeCount":100},[],{"trials":645,"activeCount":100},[],{"intervention":52,"totalTrials":647,"cells":648},10,{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":650,"activeCount":100},[],{"trials":652,"activeCount":100},[],{"trials":654,"activeCount":630,"soonestReadout":51},[655,659,669,678,682,693,697,709,713,725],{"nctId":69,"briefTitle":70,"status":374,"phases":656,"primaryCompletion":71,"completion":385,"start":386,"enrollment":387,"conditions":657,"interventions":658},[89],[389,390,391,392],[52,62,394,395,396],{"nctId":660,"briefTitle":661,"status":112,"phases":662,"primaryCompletion":663,"completion":664,"start":349,"enrollment":665,"conditions":666,"interventions":668},"NCT07599176","Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors",[88,89],"2032-06-30","2035-06-30",90,[389,667],"Beta-thalassemia",[52,416],{"nctId":670,"briefTitle":671,"status":496,"phases":672,"primaryCompletion":673,"completion":673,"start":674,"enrollment":443,"conditions":675,"interventions":677},"NCT00217594","A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome",[89],"2017-02-06","2005-07-21",[676],"Myelodysplastic Syndromes",[52],{"nctId":49,"briefTitle":50,"status":374,"phases":679,"primaryCompletion":51,"completion":399,"start":400,"enrollment":401,"conditions":680,"interventions":681},[88,89],[403],[52,62,394],{"nctId":683,"briefTitle":684,"status":496,"phases":685,"primaryCompletion":686,"completion":687,"start":688,"enrollment":689,"conditions":690,"interventions":692},"NCT00345345","Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia",[89],"2017-08-01","2020-10-27","2006-10-17",29,[691],"T-LGL Lymphoproliferative Disorders",[52],{"nctId":418,"briefTitle":419,"status":420,"phases":694,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":695,"interventions":696},[88,89],[427,389],[52,62],{"nctId":698,"briefTitle":699,"status":496,"phases":700,"primaryCompletion":701,"completion":702,"start":703,"enrollment":704,"conditions":705,"interventions":708},"NCT00195624","Alemtuzumab to Treat Severe Aplastic Anemia",[89],"2014-04-14","2018-10-15","2005-09-15",47,[706,707],"Severe Aplastic Anemia, Refractory","Severe Aplastic Anemia, Relapse",[52,549],{"nctId":59,"briefTitle":60,"status":374,"phases":710,"primaryCompletion":61,"completion":431,"start":432,"enrollment":433,"conditions":711,"interventions":712},[88,89],[389],[62,52,395,394,436,396],{"nctId":714,"briefTitle":715,"status":496,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":723},"NCT00260689","Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia",[89],"2016-05-04","2005-11-28",136,[721,722,532,531],"Immunosuppresion","Thrombocytopenia",[724,724,549,52],"Anti-thymocyte globulin",{"nctId":438,"briefTitle":439,"status":374,"phases":726,"primaryCompletion":423,"completion":441,"start":442,"enrollment":443,"conditions":727,"interventions":728},[88,89],[403,445],[436,447,396,62,52,448],{"trials":730,"activeCount":100},[],{"trials":732,"activeCount":100},[],{"trials":734,"activeCount":100},[],{"intervention":396,"totalTrials":736,"cells":737},4,{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":739,"activeCount":100},[],{"trials":741,"activeCount":100},[],{"trials":743,"activeCount":736,"soonestReadout":61},[744,748,752,756],{"nctId":69,"briefTitle":70,"status":374,"phases":745,"primaryCompletion":71,"completion":385,"start":386,"enrollment":387,"conditions":746,"interventions":747},[89],[389,390,391,392],[52,62,394,395,396],{"nctId":406,"briefTitle":407,"status":374,"phases":749,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":750,"interventions":751},[88,89],[389],[415,396,416,62,394],{"nctId":59,"briefTitle":60,"status":374,"phases":753,"primaryCompletion":61,"completion":431,"start":432,"enrollment":433,"conditions":754,"interventions":755},[88,89],[389],[62,52,395,394,436,396],{"nctId":438,"briefTitle":439,"status":374,"phases":757,"primaryCompletion":423,"completion":441,"start":442,"enrollment":443,"conditions":758,"interventions":759},[88,89],[403,445],[436,447,396,62,52,448],{"trials":761,"activeCount":100},[],{"trials":763,"activeCount":100},[],{"trials":765,"activeCount":100},[],{"intervention":76,"totalTrials":363,"cells":767},{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":844,"PHASE4":846,"NA":848},{"trials":769,"activeCount":100},[],{"trials":771,"activeCount":100},[],{"trials":773,"activeCount":843,"soonestReadout":75},[774,782,790,801,813,822,834],{"nctId":83,"briefTitle":84,"status":374,"phases":775,"primaryCompletion":85,"completion":776,"start":777,"enrollment":778,"conditions":779,"interventions":781},[89],"2028-08-01","2018-11-02",25,[780],"Fanconi Anemia",[76],{"nctId":73,"briefTitle":74,"status":112,"phases":783,"primaryCompletion":75,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":788},[89],"2033-12-18","2020-05-07",80,[381],[76,549,789],"Horse-Anti-thymocyte-Globulin",{"nctId":791,"briefTitle":792,"status":496,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":798,"interventions":800},"NCT04269889","Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag",[88,89],"2022-08-16","2024-02-16","2020-12-01",15,[799],"Anemia, Diamond-Blackfan",[76],{"nctId":802,"briefTitle":803,"status":496,"phases":804,"primaryCompletion":805,"completion":806,"start":807,"enrollment":808,"conditions":809,"interventions":812},"NCT00922883","A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients",[89],"2013-05-07","2018-04-24","2009-05-29",43,[810,811,722],"Anemia, Aplastic","Anemia, Hypoplastic",[76],{"nctId":814,"briefTitle":815,"status":496,"phases":816,"primaryCompletion":817,"completion":818,"start":819,"enrollment":443,"conditions":820,"interventions":821},"NCT01891994","Extended Dosing With Eltrombopag for Severe Aplastic Anemia",[89],"2017-10-16","2022-08-24","2013-06-28",[489],[76],{"nctId":823,"briefTitle":824,"status":496,"phases":825,"primaryCompletion":826,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":833},"NCT01328587","Eltrombopag for Moderate Aplastic Anemia",[89],"2018-03-30","2026-01-06","2012-03-13",34,[831,832],"Moderate Aplastic Anemia","Unilineage Bone Marrow Failure Disorders",[76],{"nctId":835,"briefTitle":836,"status":496,"phases":837,"primaryCompletion":838,"completion":839,"start":840,"enrollment":620,"conditions":841,"interventions":842},"NCT00961064","A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)",[89],"2017-08-10","2021-12-30","2011-03-15",[676,722],[76],2,{"trials":845,"activeCount":100},[],{"trials":847,"activeCount":100},[],{"trials":849,"activeCount":100},[],{"intervention":395,"totalTrials":851,"cells":852},3,{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":880,"PHASE4":882,"NA":884},{"trials":854,"activeCount":100},[],{"trials":856,"activeCount":100},[],{"trials":858,"activeCount":843,"soonestReadout":61},[859,863,876],{"nctId":69,"briefTitle":70,"status":374,"phases":860,"primaryCompletion":71,"completion":385,"start":386,"enrollment":387,"conditions":861,"interventions":862},[89],[389,390,391,392],[52,62,394,395,396],{"nctId":864,"briefTitle":865,"status":496,"phases":866,"primaryCompletion":867,"completion":868,"start":869,"enrollment":870,"conditions":871,"interventions":873},"NCT00224874","Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)",[89],"2009-01","2012-06","2005-09",180,[392,872],"Immune System Disorders",[874,629,875,395],"Etanercept","Denileukin Diftitox",{"nctId":59,"briefTitle":60,"status":374,"phases":877,"primaryCompletion":61,"completion":431,"start":432,"enrollment":433,"conditions":878,"interventions":879},[88,89],[389],[62,52,395,394,436,396],{"trials":881,"activeCount":100},[],{"trials":883,"activeCount":100},[],{"trials":885,"activeCount":100},[],{"intervention":416,"totalTrials":843,"cells":887},{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":902,"PHASE4":904,"NA":906},{"trials":889,"activeCount":100},[],{"trials":891,"activeCount":100},[],{"trials":893,"activeCount":843,"soonestReadout":409},[894,898],{"nctId":660,"briefTitle":661,"status":112,"phases":895,"primaryCompletion":663,"completion":664,"start":349,"enrollment":665,"conditions":896,"interventions":897},[88,89],[389,667],[52,416],{"nctId":406,"briefTitle":407,"status":374,"phases":899,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":900,"interventions":901},[88,89],[389],[415,396,416,62,394],{"trials":903,"activeCount":100},[],{"trials":905,"activeCount":100},[],{"trials":907,"activeCount":100},[],{"intervention":415,"totalTrials":843,"cells":909},{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":924,"PHASE4":926,"NA":928},{"trials":911,"activeCount":100},[],{"trials":913,"activeCount":100},[],{"trials":915,"activeCount":843,"soonestReadout":409},[916,920],{"nctId":406,"briefTitle":407,"status":374,"phases":917,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":918,"interventions":919},[88,89],[389],[415,396,416,62,394],{"nctId":438,"briefTitle":439,"status":374,"phases":921,"primaryCompletion":423,"completion":441,"start":442,"enrollment":443,"conditions":922,"interventions":923},[88,89],[403,445],[436,447,396,62,52,448],{"trials":925,"activeCount":100},[],{"trials":927,"activeCount":100},[],{"trials":929,"activeCount":100},[],{"intervention":436,"totalTrials":647,"cells":931},{"EARLY_PHASE1":932,"PHASE1":944,"PHASE2":946,"PHASE3":984,"PHASE4":1003,"NA":1005},{"trials":933,"activeCount":100},[934],{"nctId":935,"briefTitle":936,"status":937,"phases":938,"primaryCompletion":939,"completion":939,"start":940,"enrollment":100,"conditions":941,"interventions":943},"NCT01950585","Hydroxyurea in Pulmonary Arterial Hypertension","WITHDRAWN",[87],"2014-10-23","2013-09-06",[942],"Pulmonary Hypertension",[436],{"trials":945,"activeCount":100},[],{"trials":947,"activeCount":843,"soonestReadout":61},[948,958,968,976,980],{"nctId":949,"briefTitle":950,"status":496,"phases":951,"completion":952,"start":953,"conditions":954,"interventions":956},"NCT00000602","Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)",[89],"1997-03","1994-04",[623,622,955],"Hemoglobinopathies",[957],"hydroxyurea",{"nctId":959,"briefTitle":960,"status":496,"phases":961,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":966,"interventions":967},"NCT00001197","Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia",[89],"2003-12-21","2015-05-18","1984-02-07",41,[403],[436],{"nctId":969,"briefTitle":970,"status":496,"phases":971,"primaryCompletion":972,"completion":972,"start":973,"enrollment":647,"conditions":974,"interventions":975},"NCT02225132","Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease",[88,89],"2018-05-24","2014-08-23",[389],[436],{"nctId":59,"briefTitle":60,"status":374,"phases":977,"primaryCompletion":61,"completion":431,"start":432,"enrollment":433,"conditions":978,"interventions":979},[88,89],[389],[62,52,395,394,436,396],{"nctId":438,"briefTitle":439,"status":374,"phases":981,"primaryCompletion":423,"completion":441,"start":442,"enrollment":443,"conditions":982,"interventions":983},[88,89],[403,445],[436,447,396,62,52,448],{"trials":985,"activeCount":100},[986,994],{"nctId":987,"briefTitle":988,"status":496,"phases":989,"primaryCompletion":990,"completion":990,"start":991,"conditions":992,"interventions":993},"NCT00000586","Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)",[90],"1994-06","1992-01",[623,622,955],[957],{"nctId":995,"briefTitle":996,"status":496,"phases":997,"primaryCompletion":998,"completion":998,"start":999,"enrollment":1000,"conditions":1001,"interventions":1002},"NCT00006400","Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia",[90],"2009-09","2000-08",193,[622,623],[436],{"trials":1004,"activeCount":100},[],{"trials":1006,"activeCount":100},[1007,1016],{"nctId":1008,"briefTitle":1009,"status":496,"phases":1010,"primaryCompletion":1011,"completion":1011,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1015},"NCT00890396","Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)",[],"2011-12","2008-09",163,[623],[436],{"nctId":1017,"briefTitle":1018,"status":496,"phases":1019,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1022,"conditions":1023,"interventions":1024},"NCT01783990","Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol",[],"2016-12-31","2012-10",150,[403],[436],{"intervention":549,"totalTrials":797,"cells":1026},{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1042,"PHASE3":1138,"PHASE4":1140,"NA":1142},{"trials":1028,"activeCount":100},[],{"trials":1030,"activeCount":100},[1031],{"nctId":1032,"briefTitle":1033,"status":496,"phases":1034,"completion":1035,"start":1036,"enrollment":778,"conditions":1037,"interventions":1041},"NCT00001533","Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine",[88],"2000-09","1996-09",[1038,1039,1040,531,722],"Anemia","Leukemia, T-Cell","Lymphocytosis",[476],{"trials":1043,"activeCount":96,"soonestReadout":75},[1044,1048,1058,1062,1070,1074,1078,1089,1100,1104,1116,1120,1124,1128],{"nctId":465,"briefTitle":466,"status":467,"phases":1045,"completion":469,"enrollment":11,"conditions":1046,"interventions":1047},[89],[471,472,473],[475,476,477,478,479,480],{"nctId":1049,"briefTitle":1050,"status":496,"phases":1051,"completion":1052,"start":1053,"conditions":1054,"interventions":1055},"NCT00268515","Aerosol Cyclosporine for Prevention of Lung Rejection",[89],"2003-03","1998-04",[27],[476,1056,581,1057],"tacrolimus","azathioprine",{"nctId":494,"briefTitle":495,"status":496,"phases":1059,"primaryCompletion":498,"completion":499,"start":500,"enrollment":501,"conditions":1060,"interventions":1061},[89],[489],[504,475,476],{"nctId":1063,"briefTitle":1064,"status":496,"phases":1065,"completion":1066,"start":1067,"enrollment":425,"conditions":1068,"interventions":1069},"NCT00005935","Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia",[89],"2002-03","2000-06",[530],[602,549],{"nctId":73,"briefTitle":74,"status":112,"phases":1071,"primaryCompletion":75,"completion":784,"start":785,"enrollment":786,"conditions":1072,"interventions":1073},[89],[381],[76,549,789],{"nctId":536,"briefTitle":537,"status":496,"phases":1075,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":1076,"interventions":1077},[89],[543,544,545,546,547],[534,549,394],{"nctId":1079,"briefTitle":1080,"status":496,"phases":1081,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":630,"conditions":1084,"interventions":1087},"NCT00047060","Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome",[88,89],"2019-01-24","2002-07-30",[1085,1086],"Mycosis Fungoides","Sezary Syndrome",[476,570,1088],"Campath",{"nctId":1090,"briefTitle":1091,"status":496,"phases":1092,"completion":1093,"start":1094,"enrollment":778,"conditions":1095,"interventions":1098},"NCT00001749","Medical Treatment for Diamond Blackfan Anemia",[89],"2005-07","1998-07",[1096,1097],"Fanconi's Anemia","Hematologic Disease",[1099,549],"Antithymocyte globulin",{"nctId":698,"briefTitle":699,"status":496,"phases":1101,"primaryCompletion":701,"completion":702,"start":703,"enrollment":704,"conditions":1102,"interventions":1103},[89],[706,707],[52,549],{"nctId":1105,"briefTitle":1106,"status":496,"phases":1107,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1114},"NCT00003838","Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow",[89],"2018-12-14","2020-06-18","1999-04-15",202,[1113,544,543,547,546],"Myeloproliferative Disorders",[599,549,1115],"G-CSF",{"nctId":714,"briefTitle":715,"status":496,"phases":1117,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":1118,"interventions":1119},[89],[721,722,532,531],[724,724,549,52],{"nctId":608,"briefTitle":609,"status":496,"phases":1121,"primaryCompletion":611,"completion":611,"start":528,"enrollment":612,"conditions":1122,"interventions":1123},[88,89],[530,531,532,381],[394,549],{"nctId":616,"briefTitle":617,"status":496,"phases":1125,"primaryCompletion":619,"completion":619,"start":563,"enrollment":620,"conditions":1126,"interventions":1127},[89],[622,623,624,625],[627,394,628,629,549],{"nctId":1129,"briefTitle":1130,"status":496,"phases":1131,"primaryCompletion":1132,"completion":1133,"start":1134,"enrollment":401,"conditions":1135,"interventions":1136},"NCT00944749","Horse ATG\u002FCsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG\u002FCsA Treatment",[89],"2015-12","2016-12","2009-08-31",[810,811],[1137,549],"h-ATG",{"trials":1139,"activeCount":100},[],{"trials":1141,"activeCount":100},[],{"trials":1143,"activeCount":100},[],{"intervention":534,"totalTrials":363,"cells":1145},{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1202,"PHASE4":1204,"NA":1206},{"trials":1147,"activeCount":100},[],{"trials":1149,"activeCount":100},[],{"trials":1151,"activeCount":96,"soonestReadout":56},[1152,1156,1160,1164,1168,1178,1184],{"nctId":524,"briefTitle":525,"status":496,"phases":1153,"primaryCompletion":527,"completion":527,"start":528,"enrollment":96,"conditions":1154,"interventions":1155},[88,89],[530,531,532,381],[394,534],{"nctId":536,"briefTitle":537,"status":496,"phases":1157,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":1158,"interventions":1159},[89],[543,544,545,546,547],[534,549,394],{"nctId":1079,"briefTitle":1080,"status":496,"phases":1161,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":630,"conditions":1162,"interventions":1163},[88,89],[1085,1086],[476,570,1088],{"nctId":559,"briefTitle":560,"status":467,"phases":1165,"completion":562,"start":563,"conditions":1166,"interventions":1167},[88,89],[565,566],[568,569,475,570],{"nctId":1169,"briefTitle":1170,"status":496,"phases":1171,"primaryCompletion":1172,"completion":1172,"start":638,"enrollment":433,"conditions":1173,"interventions":1175},"NCT02440464","Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)",[89],"2020-10-01",[1174],"Multiple Myeloma",[534,1176,601,1177],"Melphalan","Ixazomib",{"nctId":54,"briefTitle":55,"status":374,"phases":1179,"primaryCompletion":56,"completion":1180,"start":1181,"enrollment":689,"conditions":1182,"interventions":1183},[89],"2034-10-23","2015-12-09",[545,518],[57,534],{"nctId":1185,"briefTitle":1186,"status":496,"phases":1187,"primaryCompletion":1188,"completion":1189,"start":1190,"enrollment":797,"conditions":1191,"interventions":1200},"NCT03204188","Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[89],"2022-07-18","2026-01-09","2017-09-22",[1192,1193,545,1194,1195,1196,1197,1198,1199],"B-Cell Chronic Lymphocytic Leukemia","B-Lymphocytic Leukemia, Chronic","Leukemia, Chronic Lymphatic","Leukemia, Chronic Lymphocytic, B-Cell","Leukemia, Lymphocytic, Chronic","Leukemia, Lymphocytic, Chronic, B-Cell","Lymphocytic Leukemia, Chronic, B Cell","Lymphocytic Leukemia, Chronic, B-Cell",[57,534,1201],"Pembrolizumab",{"trials":1203,"activeCount":100},[],{"trials":1205,"activeCount":100},[],{"trials":1207,"activeCount":100},[],{"intervention":57,"totalTrials":851,"cells":1209},{"EARLY_PHASE1":1210,"PHASE1":1212,"PHASE2":1214,"PHASE3":1235,"PHASE4":1237,"NA":1239},{"trials":1211,"activeCount":100},[],{"trials":1213,"activeCount":100},[],{"trials":1215,"activeCount":96,"soonestReadout":56},[1216,1227,1231],{"nctId":1217,"briefTitle":1218,"status":467,"phases":1219,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":851,"conditions":1222,"interventions":1225},"NCT04209621","Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[89],"2021-01-22","2020-07-31",[1223,1224],"Small Lymphocytic Leukemia (SLL)","Chronic Lymphocytic Leukemia (CLL)",[1226,57],"Duvelisib",{"nctId":54,"briefTitle":55,"status":374,"phases":1228,"primaryCompletion":56,"completion":1180,"start":1181,"enrollment":689,"conditions":1229,"interventions":1230},[89],[545,518],[57,534],{"nctId":1185,"briefTitle":1186,"status":496,"phases":1232,"primaryCompletion":1188,"completion":1189,"start":1190,"enrollment":797,"conditions":1233,"interventions":1234},[89],[1192,1193,545,1194,1195,1196,1197,1198,1199],[57,534,1201],{"trials":1236,"activeCount":100},[],{"trials":1238,"activeCount":100},[],{"trials":1240,"activeCount":100},[],{"intervention":448,"totalTrials":843,"cells":1242},{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1255,"PHASE3":1261,"PHASE4":1263,"NA":1265},{"trials":1244,"activeCount":100},[],{"trials":1246,"activeCount":100},[1247],{"nctId":1248,"briefTitle":1249,"status":496,"phases":1250,"primaryCompletion":1251,"completion":1251,"start":1252,"enrollment":797,"conditions":1253,"interventions":1254},"NCT03226691","Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients",[88],"2019-02-27","2017-07-25",[389],[448],{"trials":1256,"activeCount":96,"soonestReadout":423},[1257],{"nctId":438,"briefTitle":439,"status":374,"phases":1258,"primaryCompletion":423,"completion":441,"start":442,"enrollment":443,"conditions":1259,"interventions":1260},[88,89],[403,445],[436,447,396,62,52,448],{"trials":1262,"activeCount":100},[],{"trials":1264,"activeCount":100},[],{"trials":1266,"activeCount":100},[],{"intervention":1268,"totalTrials":843,"cells":1269},"Danazol",{"EARLY_PHASE1":1270,"PHASE1":1272,"PHASE2":1274,"PHASE3":1296,"PHASE4":1298,"NA":1300},{"trials":1271,"activeCount":100},[],{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":96,"soonestReadout":1289},[1276,1285],{"nctId":1277,"briefTitle":1278,"status":496,"phases":1279,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":1283,"interventions":1284},"NCT01441037","Danazol for Genetic Bone Marrow and Lung Disorders",[88,89],"2016-11-14","2011-07-19",27,[530],[1268],{"nctId":1286,"briefTitle":1287,"status":374,"phases":1288,"primaryCompletion":1289,"completion":1290,"start":1291,"enrollment":1292,"conditions":1293,"interventions":1295},"NCT03312400","Low-Dose Danazol for the Treatment of Telomere Related Diseases",[89],"2027-04-29","2027-10-29","2018-02-08",18,[1294],"Telomere Disease",[1268],{"trials":1297,"activeCount":100},[],{"trials":1299,"activeCount":100},[],{"trials":1301,"activeCount":100},[],{"intervention":81,"totalTrials":843,"cells":1303},{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1305,"activeCount":100},[],{"trials":1307,"activeCount":100},[],{"trials":1309,"activeCount":96,"soonestReadout":80},[1310,1319],{"nctId":78,"briefTitle":79,"status":374,"phases":1311,"primaryCompletion":80,"completion":1312,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1318},[88,89],"2032-06-03","2024-02-20",13,[381,1316,1317],"Single Lineage Cytopenias, T-LGL","Hypoplastic MDS",[81],{"nctId":1320,"briefTitle":1321,"status":496,"phases":1322,"primaryCompletion":1323,"completion":1323,"start":1324,"enrollment":96,"conditions":1325,"interventions":1328},"NCT05998395","JAK\u002FSTAT Inhibition in CNS Kohlmeier-Degos Disease",[88,89],"2025-02-28","2023-09-28",[1326,1327],"Kohlmeier Degos Disease With Neurologic Involvement","Kohlmeier-Degos Disease",[81],{"trials":1330,"activeCount":100},[],{"trials":1332,"activeCount":100},[],{"trials":1334,"activeCount":100},[],{"intervention":1336,"totalTrials":96,"cells":1337},"During Venetoclax",{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1352,"PHASE4":1354,"NA":1356},{"trials":1339,"activeCount":100},[],{"trials":1341,"activeCount":100},[],{"trials":1343,"activeCount":96,"soonestReadout":1348},[1344],{"nctId":1345,"briefTitle":1346,"status":112,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":31,"conditions":1350,"interventions":1351},"NCT03986034","Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",[89],"2026-07-03","2019-06-26",[545],[1336],{"trials":1353,"activeCount":100},[],{"trials":1355,"activeCount":100},[],{"trials":1357,"activeCount":100},[],{"intervention":1359,"totalTrials":96,"cells":1360},"Omidubicel",{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1379,"PHASE4":1381,"NA":1383},{"trials":1362,"activeCount":100},[],{"trials":1364,"activeCount":100},[],{"trials":1366,"activeCount":96,"soonestReadout":1371},[1367],{"nctId":1368,"briefTitle":1369,"status":112,"phases":1370,"primaryCompletion":1371,"completion":1372,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1378},"NCT03173937","Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome",[88,89],"2027-04-28","2032-03-01","2017-06-13",37,[381,1376,1377],"Hypo-Plastic MDS","Myelodysplastic Syndrome (MDS)",[1359],{"trials":1380,"activeCount":100},[],{"trials":1382,"activeCount":100},[],{"trials":1384,"activeCount":100},[],{"intervention":789,"totalTrials":96,"cells":1386},{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1397,"PHASE4":1399,"NA":1401},{"trials":1388,"activeCount":100},[],{"trials":1390,"activeCount":100},[],{"trials":1392,"activeCount":96,"soonestReadout":75},[1393],{"nctId":73,"briefTitle":74,"status":112,"phases":1394,"primaryCompletion":75,"completion":784,"start":785,"enrollment":786,"conditions":1395,"interventions":1396},[89],[381],[76,549,789],{"trials":1398,"activeCount":100},[],{"trials":1400,"activeCount":100},[],{"trials":1402,"activeCount":100},[],{"intervention":1404,"totalTrials":96,"cells":1405},"Baricitinib",{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1425,"PHASE4":1427,"NA":1429},{"trials":1407,"activeCount":100},[],{"trials":1409,"activeCount":100},[],{"trials":1411,"activeCount":96,"soonestReadout":1416},[1412],{"nctId":1413,"briefTitle":1414,"status":112,"phases":1415,"primaryCompletion":1416,"completion":1417,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1424},"NCT06923072","Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement",[89],"2030-12-14","2030-12-15","2026-02-18",12,[1327,1421,1422,1423],"Malignant Atrophic Papulosis","Degos Disease","Papulosis, Malignant Atrophic",[1404],{"trials":1426,"activeCount":100},[],{"trials":1428,"activeCount":100},[],{"trials":1430,"activeCount":100},[],{"intervention":42,"totalTrials":96,"cells":1432},{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1448,"PHASE4":1450,"NA":1452},{"trials":1434,"activeCount":100},[],{"trials":1436,"activeCount":100},[],{"trials":1438,"activeCount":96,"soonestReadout":41},[1439],{"nctId":39,"briefTitle":40,"status":374,"phases":1440,"primaryCompletion":41,"completion":1441,"start":1442,"enrollment":1443,"conditions":1444,"interventions":1447},[89],"2034-09-30","2012-01-05",86,[472,1445,519,1446],"Leukemia, Lymphocytyc","SLL (Small Lymphocytic Lymphoma)",[42],{"trials":1449,"activeCount":100},[],{"trials":1451,"activeCount":100},[],{"trials":1453,"activeCount":100},[],{"intervention":1455,"totalTrials":96,"cells":1456},"control olive oil",{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1474,"PHASE4":1476,"NA":1478},{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":100},[],{"trials":1462,"activeCount":96,"soonestReadout":1467},[1463],{"nctId":1464,"briefTitle":1465,"status":112,"phases":1466,"primaryCompletion":1467,"completion":1467,"start":1468,"enrollment":1469,"conditions":1470,"interventions":1472},"NCT03372733","Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults",[89],"2026-07-31","2018-07-31",110,[1471],"Cardiovascular Disease",[1455,1473],"palmitoleate-rich oil",{"trials":1475,"activeCount":100},[],{"trials":1477,"activeCount":100},[],{"trials":1479,"activeCount":100},[],{"intervention":1473,"totalTrials":96,"cells":1481},{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1486,"PHASE3":1492,"PHASE4":1494,"NA":1496},{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[],{"trials":1487,"activeCount":96,"soonestReadout":1467},[1488],{"nctId":1464,"briefTitle":1465,"status":112,"phases":1489,"primaryCompletion":1467,"completion":1467,"start":1468,"enrollment":1469,"conditions":1490,"interventions":1491},[89],[1471],[1455,1473],{"trials":1493,"activeCount":100},[],{"trials":1495,"activeCount":100},[],{"trials":1497,"activeCount":100},[],{"intervention":1499,"totalTrials":96,"cells":1500},"Mitapivat",{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1516,"PHASE4":1518,"NA":1520},{"trials":1502,"activeCount":100},[],{"trials":1504,"activeCount":100},[],{"trials":1506,"activeCount":96,"soonestReadout":1511},[1507],{"nctId":1508,"briefTitle":1509,"status":374,"phases":1510,"primaryCompletion":1511,"completion":1511,"start":1512,"enrollment":797,"conditions":1513,"interventions":1515},"NCT04610866","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat",[88,89],"2028-02-28","2020-12-09",[389,1514],"Hemolytic Anemia",[1499],{"trials":1517,"activeCount":100},[],{"trials":1519,"activeCount":100},[],{"trials":1521,"activeCount":100},[],{"intervention":1523,"totalTrials":96,"cells":1524},"albuterol inhaler",{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1526,"activeCount":100},[],{"trials":1528,"activeCount":100},[],{"trials":1530,"activeCount":96,"soonestReadout":1535},[1531],{"nctId":1532,"briefTitle":1533,"status":112,"phases":1534,"primaryCompletion":1535,"completion":1535,"start":1536,"enrollment":1537,"conditions":1538,"interventions":1540},"NCT01799538","Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis",[88,89],"2027-11-01","2013-06-10",100,[1539],"Lymphangioleiomyomatosis",[1523,1541],"albuterol nebulizer",{"trials":1543,"activeCount":100},[],{"trials":1545,"activeCount":100},[],{"trials":1547,"activeCount":100},[],{"intervention":1541,"totalTrials":96,"cells":1549},{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1551,"activeCount":100},[],{"trials":1553,"activeCount":100},[],{"trials":1555,"activeCount":96,"soonestReadout":1535},[1556],{"nctId":1532,"briefTitle":1533,"status":112,"phases":1557,"primaryCompletion":1535,"completion":1535,"start":1536,"enrollment":1537,"conditions":1558,"interventions":1559},[88,89],[1539],[1523,1541],{"trials":1561,"activeCount":100},[],{"trials":1563,"activeCount":100},[],{"trials":1565,"activeCount":100},[],{"intervention":47,"totalTrials":96,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1584,"PHASE4":1586,"NA":1588},{"trials":1569,"activeCount":100},[],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":96,"soonestReadout":46},[1574],{"nctId":44,"briefTitle":45,"status":374,"phases":1575,"primaryCompletion":46,"completion":1576,"start":1577,"enrollment":1578,"conditions":1579,"interventions":1580},[88,89],"2029-11-30","2012-07-02",207,[381],[47,1581,1582,1583],"Cohort 2: hATG, CsA, EPAG Day 14 to Month 3","Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6","Extension Cohort",{"trials":1585,"activeCount":100},[],{"trials":1587,"activeCount":100},[],{"trials":1589,"activeCount":100},[],{"intervention":1581,"totalTrials":96,"cells":1591},{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1602,"PHASE4":1604,"NA":1606},{"trials":1593,"activeCount":100},[],{"trials":1595,"activeCount":100},[],{"trials":1597,"activeCount":96,"soonestReadout":46},[1598],{"nctId":44,"briefTitle":45,"status":374,"phases":1599,"primaryCompletion":46,"completion":1576,"start":1577,"enrollment":1578,"conditions":1600,"interventions":1601},[88,89],[381],[47,1581,1582,1583],{"trials":1603,"activeCount":100},[],{"trials":1605,"activeCount":100},[],{"trials":1607,"activeCount":100},[],{"intervention":1582,"totalTrials":96,"cells":1609},{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1620,"PHASE4":1622,"NA":1624},{"trials":1611,"activeCount":100},[],{"trials":1613,"activeCount":100},[],{"trials":1615,"activeCount":96,"soonestReadout":46},[1616],{"nctId":44,"briefTitle":45,"status":374,"phases":1617,"primaryCompletion":46,"completion":1576,"start":1577,"enrollment":1578,"conditions":1618,"interventions":1619},[88,89],[381],[47,1581,1582,1583],{"trials":1621,"activeCount":100},[],{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":100},[],{"intervention":1583,"totalTrials":96,"cells":1627},{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1629,"activeCount":100},[],{"trials":1631,"activeCount":100},[],{"trials":1633,"activeCount":96,"soonestReadout":46},[1634],{"nctId":44,"briefTitle":45,"status":374,"phases":1635,"primaryCompletion":46,"completion":1576,"start":1577,"enrollment":1578,"conditions":1636,"interventions":1637},[88,89],[381],[47,1581,1582,1583],{"trials":1639,"activeCount":100},[],{"trials":1641,"activeCount":100},[],{"trials":1643,"activeCount":100},[],{"intervention":1645,"totalTrials":630,"cells":1646},"fostamatinib",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1672,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1648,"activeCount":100},[],{"trials":1650,"activeCount":843,"soonestReadout":1663},[1651,1659],{"nctId":1652,"briefTitle":1653,"status":345,"phases":1654,"primaryCompletion":1655,"completion":1655,"start":349,"enrollment":620,"conditions":1656,"interventions":1658},"NCT06948097","Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies",[88],"2028-07-14",[1657],"Lung Transplantation",[1645],{"nctId":1660,"briefTitle":1661,"status":112,"phases":1662,"primaryCompletion":1663,"completion":1663,"start":75,"enrollment":778,"conditions":1664,"interventions":1670},"NCT05904093","Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease",[88],"2027-05-14",[389,1665,1666,1667,1668,1669],"Hb-SS Disease","Hemoglobin S","Disease Sickle Cell Anemia","Sickle Cell Disorders","Hemoglobin Beta Thalassemia Disease",[1671],"Fostamatinib",{"trials":1673,"activeCount":100},[1674,1685,1696],{"nctId":1675,"briefTitle":1676,"status":467,"phases":1677,"primaryCompletion":1678,"completion":1678,"start":1679,"enrollment":96,"conditions":1680,"interventions":1684},"NCT05502783","Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias",[89],"2023-06-16","2023-03-10",[1681,1682,1683],"Immune Mediated Anemia","Immune Mediated Thrombocytopenia","Chronic GVHD",[1645],{"nctId":1686,"briefTitle":1687,"status":496,"phases":1688,"primaryCompletion":1689,"completion":1690,"start":1691,"enrollment":1692,"conditions":1693,"interventions":1695},"NCT04579393","Fostamatinib for Hospitalized Adults With COVID-19",[89],"2021-03-30","2021-04-30","2020-10-08",59,[1694],"Coronavirus Disease 2019",[1645],{"nctId":1697,"briefTitle":1698,"status":937,"phases":1699,"primaryCompletion":1700,"completion":1700,"start":1700,"enrollment":100,"conditions":1701,"interventions":1702},"NCT05509582","Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias",[89],"2025-11-07",[1681,1682,1683],[1645],{"trials":1704,"activeCount":100},[],{"trials":1706,"activeCount":100},[],{"trials":1708,"activeCount":100},[],{"intervention":1710,"totalTrials":96,"cells":1711},"ZMA001",{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1727,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1713,"activeCount":100},[],{"trials":1715,"activeCount":96,"soonestReadout":1720},[1716],{"nctId":1717,"briefTitle":1718,"status":112,"phases":1719,"primaryCompletion":1720,"completion":1721,"start":1722,"enrollment":1723,"conditions":1724,"interventions":1726},"NCT05967299","Study of Intravenous ZMA001 in Healthy Subjects",[88],"2027-09-01","2027-11-30","2023-11-27",96,[1725],"Pulmonary Arterial Hypertension PAH",[1710],{"trials":1728,"activeCount":100},[],{"trials":1730,"activeCount":100},[],{"trials":1732,"activeCount":100},[],{"trials":1734,"activeCount":100},[],{"intervention":1736,"totalTrials":96,"cells":1737},"VAS-101",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1750,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1739,"activeCount":100},[],{"trials":1741,"activeCount":96,"soonestReadout":1746},[1742],{"nctId":1743,"briefTitle":1744,"status":345,"phases":1745,"primaryCompletion":1746,"completion":1746,"start":349,"enrollment":778,"conditions":1747,"interventions":1749},"NCT07566494","Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease",[88],"2027-04-27",[1748],"Sickle Cell Disease, Hemolytic Anemia",[1736],{"trials":1751,"activeCount":100},[],{"trials":1753,"activeCount":100},[],{"trials":1755,"activeCount":100},[],{"trials":1757,"activeCount":100},[],{"intervention":1759,"totalTrials":96,"cells":1760},"Fx-5A peptide complex",{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1774,"PHASE3":1776,"PHASE4":1778,"NA":1780},{"trials":1762,"activeCount":100},[],{"trials":1764,"activeCount":96,"soonestReadout":1769},[1765],{"nctId":1766,"briefTitle":1767,"status":112,"phases":1768,"primaryCompletion":1769,"completion":1769,"start":1770,"enrollment":1771,"conditions":1772,"interventions":1773},"NCT04216342","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers",[88],"2026-06-30","2021-09-29",64,[1471],[1759],{"trials":1775,"activeCount":100},[],{"trials":1777,"activeCount":100},[],{"trials":1779,"activeCount":100},[],{"trials":1781,"activeCount":100},[],{"intervention":67,"totalTrials":96,"cells":1783},{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1796,"PHASE3":1798,"PHASE4":1800,"NA":1802},{"trials":1785,"activeCount":100},[],{"trials":1787,"activeCount":96,"soonestReadout":66},[1788],{"nctId":64,"briefTitle":65,"status":374,"phases":1789,"primaryCompletion":66,"completion":1790,"start":1791,"enrollment":1792,"conditions":1793,"interventions":1795},[88],"2029-03-03","2018-07-20",17,[1794],"Kidney Cancer",[67],{"trials":1797,"activeCount":100},[],{"trials":1799,"activeCount":100},[],{"trials":1801,"activeCount":100},[],{"trials":1803,"activeCount":100},[],{"intervention":1805,"totalTrials":96,"cells":1806},"epcoritamab",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1821,"PHASE3":1823,"PHASE4":1825,"NA":1827},{"trials":1808,"activeCount":100},[],{"trials":1810,"activeCount":96,"soonestReadout":1815},[1811],{"nctId":1812,"briefTitle":1813,"status":374,"phases":1814,"primaryCompletion":1815,"completion":1815,"start":1816,"enrollment":630,"conditions":1817,"interventions":1820},"NCT06676033","Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome",[88],"2027-07-01","2025-07-18",[1818,1819],"Leukemia, Chronic Lymphocytic","Richter Syndrome",[1805],{"trials":1822,"activeCount":100},[],{"trials":1824,"activeCount":100},[],{"trials":1826,"activeCount":100},[],{"trials":1828,"activeCount":100},[],{"intervention":1830,"totalTrials":96,"cells":1831},"Pirtobrutinib",{"EARLY_PHASE1":1832,"PHASE1":1844,"PHASE2":1846,"PHASE3":1848,"PHASE4":1850,"NA":1852},{"trials":1833,"activeCount":96,"soonestReadout":1838},[1834],{"nctId":1835,"briefTitle":1836,"status":112,"phases":1837,"primaryCompletion":1838,"completion":1839,"start":1840,"enrollment":620,"conditions":1841,"interventions":1843},"NCT07428707","Immune Profiling of CLL\u002FSLL Treated With First-Line Pirtobrutinib",[87],"2030-02-01","2030-03-01","2026-03-11",[1224,1842],"Small Lymphocytic Lymphoma (SLL)",[1830],{"trials":1845,"activeCount":100},[],{"trials":1847,"activeCount":100},[],{"trials":1849,"activeCount":100},[],{"trials":1851,"activeCount":100},[],{"trials":1853,"activeCount":100},[],{"intervention":1855,"totalTrials":96,"cells":1856},"Biotin-labeled red blood cells",{"EARLY_PHASE1":1857,"PHASE1":1869,"PHASE2":1871,"PHASE3":1873,"PHASE4":1875,"NA":1877},{"trials":1858,"activeCount":96,"soonestReadout":1863},[1859],{"nctId":1860,"briefTitle":1861,"status":112,"phases":1862,"primaryCompletion":1863,"completion":1864,"start":1865,"enrollment":1537,"conditions":1866,"interventions":1868},"NCT06313398","Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling",[87],"2029-05-01","2029-06-15","2024-05-17",[389,390,1867],"Hemoglobinopathy",[1855],{"trials":1870,"activeCount":100},[],{"trials":1872,"activeCount":100},[],{"trials":1874,"activeCount":100},[],{"trials":1876,"activeCount":100},[],{"trials":1878,"activeCount":100},[],{"intervention":1115,"totalTrials":736,"cells":1880},{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1894,"PHASE3":1908,"PHASE4":1910,"NA":1912},{"trials":1882,"activeCount":100},[],{"trials":1884,"activeCount":100},[1885],{"nctId":1886,"briefTitle":1887,"status":496,"phases":1888,"completion":1889,"start":1890,"enrollment":1891,"conditions":1892,"interventions":1893},"NCT00011830","Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission",[88],"2006-02","2001-02",20,[530],[1115],{"trials":1895,"activeCount":100},[1896,1904],{"nctId":1897,"briefTitle":1898,"status":496,"phases":1899,"completion":1900,"start":1890,"enrollment":797,"conditions":1901,"interventions":1903},"NCT00011505","Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia",[89],"2006-04",[1902],"Diamond Blackfan Anemia",[1115],{"nctId":1105,"briefTitle":1106,"status":496,"phases":1905,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1111,"conditions":1906,"interventions":1907},[89],[1113,544,543,547,546],[599,549,1115],{"trials":1909,"activeCount":100},[],{"trials":1911,"activeCount":100},[],{"trials":1913,"activeCount":96},[1914],{"nctId":1915,"briefTitle":1916,"status":112,"phases":1917,"start":1918,"enrollment":116,"conditions":1919,"interventions":1923},"NCT00001529","Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives",[],"1996-03-18",[1920,1921,1922],"Graft-Versus-Host Disease","Graft-versus-leukemia","Donor Apheresis",[1115],{"intervention":1925,"totalTrials":843,"cells":1926},"Rosuvastatin",{"EARLY_PHASE1":1927,"PHASE1":1929,"PHASE2":1931,"PHASE3":1933,"PHASE4":1945,"NA":1958},{"trials":1928,"activeCount":100},[],{"trials":1930,"activeCount":100},[],{"trials":1932,"activeCount":100},[],{"trials":1934,"activeCount":100},[1935],{"nctId":1936,"briefTitle":1937,"status":467,"phases":1938,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":1942,"interventions":1944},"NCT00979121","Statins for Acutely Injured Lungs From Sepsis",[90],"2013-11","2010-01",745,[1943,355],"Sepsis",[1925],{"trials":1946,"activeCount":100},[1947],{"nctId":1948,"briefTitle":1949,"status":467,"phases":1950,"primaryCompletion":1951,"completion":1952,"start":1953,"enrollment":1954,"conditions":1955,"interventions":1956},"NCT02740699","CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction",[91],"2022-01-27","2022-03-11","2016-04-11",79,[1471],[1925,1957],"Atorvastatin",{"trials":1959,"activeCount":100},[],{"intervention":1957,"totalTrials":843,"cells":1961},{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1966,"PHASE3":1977,"PHASE4":1979,"NA":1985},{"trials":1963,"activeCount":100},[],{"trials":1965,"activeCount":100},[],{"trials":1967,"activeCount":100},[1968],{"nctId":1969,"briefTitle":1970,"status":496,"phases":1971,"primaryCompletion":1132,"completion":1132,"start":1972,"enrollment":1973,"conditions":1974,"interventions":1976},"NCT00279708","Atorvastatin to Treat Pulmonary Sarcoidosis",[89],"2006-01",55,[1975],"Sarcoidosis, Pulmonary",[1957],{"trials":1978,"activeCount":100},[],{"trials":1980,"activeCount":100},[1981],{"nctId":1948,"briefTitle":1949,"status":467,"phases":1982,"primaryCompletion":1951,"completion":1952,"start":1953,"enrollment":1954,"conditions":1983,"interventions":1984},[91],[1471],[1925,1957],{"trials":1986,"activeCount":100},[],{"intervention":1988,"totalTrials":96,"cells":1989},"Budesonide + Salmeterol + Azithromycin",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2010},{"trials":1991,"activeCount":100},[],{"trials":1993,"activeCount":100},[],{"trials":1995,"activeCount":100},[],{"trials":1997,"activeCount":100},[],{"trials":1999,"activeCount":100},[2000],{"nctId":2001,"briefTitle":2002,"status":467,"phases":2003,"completion":2004,"start":2005,"enrollment":350,"conditions":2006,"interventions":2007},"NCT00471809","Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)",[91],"2007-03","2006-03",[33],[1988,2008,2009],"Budesonide + Salmeterol + Montelukast","Budesonide + Salmeterol + Placebo",{"trials":2011,"activeCount":100},[],{"intervention":2008,"totalTrials":96,"cells":2013},{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2020,"PHASE4":2022,"NA":2028},{"trials":2015,"activeCount":100},[],{"trials":2017,"activeCount":100},[],{"trials":2019,"activeCount":100},[],{"trials":2021,"activeCount":100},[],{"trials":2023,"activeCount":100},[2024],{"nctId":2001,"briefTitle":2002,"status":467,"phases":2025,"completion":2004,"start":2005,"enrollment":350,"conditions":2026,"interventions":2027},[91],[33],[1988,2008,2009],{"trials":2029,"activeCount":100},[],{"intervention":2009,"totalTrials":96,"cells":2031},{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2036,"PHASE3":2038,"PHASE4":2040,"NA":2046},{"trials":2033,"activeCount":100},[],{"trials":2035,"activeCount":100},[],{"trials":2037,"activeCount":100},[],{"trials":2039,"activeCount":100},[],{"trials":2041,"activeCount":100},[2042],{"nctId":2001,"briefTitle":2002,"status":467,"phases":2043,"completion":2004,"start":2005,"enrollment":350,"conditions":2044,"interventions":2045},[91],[33],[1988,2008,2009],{"trials":2047,"activeCount":100},[],{"intervention":2049,"totalTrials":96,"cells":2050},"Statins, HMG CoA",{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2057,"PHASE4":2059,"NA":2072},{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":100},[],{"trials":2058,"activeCount":100},[],{"trials":2060,"activeCount":100},[2061],{"nctId":2062,"briefTitle":2063,"status":496,"phases":2064,"primaryCompletion":2065,"completion":2066,"start":2067,"enrollment":2068,"conditions":2069,"interventions":2071},"NCT01212900","Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression",[91],"2016-11-30","2017-02-22","2010-09-30",230,[30,2070],"Hypercholesterolemia",[2049],{"trials":2073,"activeCount":100},[],{"intervention":2075,"totalTrials":630,"cells":2076},"aspirin",{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2107,"PHASE4":2137,"NA":2139},{"trials":2078,"activeCount":100},[],{"trials":2080,"activeCount":100},[],{"trials":2082,"activeCount":100},[2083,2094],{"nctId":2084,"briefTitle":2085,"status":496,"phases":2086,"completion":2087,"start":2088,"conditions":2089,"interventions":2092},"NCT00000520","Prevention of Coronary Aneurysms in Kawasaki Syndrome",[89],"1989-11","1985-07",[15,2090,18,2091],"Coronary Aneurysm","Mucocutaneous Lymph Node Syndrome",[2093,2075],"immunoglobulins, intravenous",{"nctId":2095,"briefTitle":2096,"status":496,"phases":2097,"completion":2098,"start":2099,"conditions":2100,"interventions":2105},"NCT00000469","Asymptomatic Carotid Artery Plaque Study (ACAPS)",[89],"1998-08","1988-05",[15,2101,2102,2103,18,2104],"Carotid Stenosis","Cerebral Arteriosclerosis","Cerebrovascular Disorders","Vascular Diseases",[2075,2106],"lovastatin",{"trials":2108,"activeCount":100},[2109,2119,2128],{"nctId":2110,"briefTitle":2111,"status":496,"phases":2112,"completion":2113,"start":2114,"conditions":2115,"interventions":2118},"NCT00000491","Aspirin-Myocardial Infarction Study (AMIS)",[90],"1979-08","1974-10",[15,21,18,2116,2117],"Myocardial Infarction","Myocardial Ischemia",[2075],{"nctId":2120,"briefTitle":2121,"status":496,"phases":2122,"completion":2123,"start":2124,"conditions":2125,"interventions":2126},"NCT00000496","Platelet Drug Trial in Coronary Disease Progression",[90],"1982-12","1979-12",[15,21,18,2117],[2075,2127],"dipyridamole",{"nctId":2129,"briefTitle":2130,"status":496,"phases":2131,"completion":2132,"start":2133,"conditions":2134,"interventions":2136},"NCT00000510","Platelet-Inhibitor Drug Trial in Coronary Angioplasty",[90],"1988-09","1983-09",[2135,15,21,18,2117],"Angina Pectoris",[2075,2127],{"trials":2138,"activeCount":100},[],{"trials":2140,"activeCount":100},[],{"intervention":2142,"totalTrials":736,"cells":2143},"chlorthalidone",{"EARLY_PHASE1":2144,"PHASE1":2146,"PHASE2":2148,"PHASE3":2161,"PHASE4":2194,"NA":2196},{"trials":2145,"activeCount":100},[],{"trials":2147,"activeCount":100},[],{"trials":2149,"activeCount":100},[2150],{"nctId":2151,"briefTitle":2152,"status":496,"phases":2153,"completion":2154,"start":2155,"conditions":2156,"interventions":2157},"NCT00000499","Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)",[89],"1983-05","1980-09",[15,18,24,2104],[2142,2158,2159,2160],"reserpine","hydralazine","metoprolol",{"trials":2162,"activeCount":100},[2163,2172,2186],{"nctId":2164,"briefTitle":2165,"status":496,"phases":2166,"completion":2167,"start":2168,"conditions":2169,"interventions":2170},"NCT00000514","Systolic Hypertension in the Elderly Program (SHEP)",[90],"1996-10","1984-06",[15,2103,18,24],[2142,2171,2158],"atenolol",{"nctId":2173,"briefTitle":2174,"status":496,"phases":2175,"primaryCompletion":1066,"completion":1066,"start":2176,"conditions":2177,"interventions":2180},"NCT00000542","Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)",[90],"1993-08",[15,21,2178,18,2070,24,2116,2117,2179],"Diabetes Mellitus","Heart Failure",[2181,2182,2183,2184,2142,2185],"Inhibitors, ACE","amlodipine","lisinopril","doxazosin","pravastatin",{"nctId":2187,"briefTitle":2188,"status":496,"phases":2189,"completion":2190,"start":2191,"conditions":2192,"interventions":2193},"NCT00000513","Trial of Antihypertensive Intervention Management",[90],"1994-11","1984-04",[15,18,24,2104],[2142,2171],{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[],{"intervention":2199,"totalTrials":736,"cells":2200},"estrogens",{"EARLY_PHASE1":2201,"PHASE1":2203,"PHASE2":2205,"PHASE3":2207,"PHASE4":2253,"NA":2255},{"trials":2202,"activeCount":100},[],{"trials":2204,"activeCount":100},[],{"trials":2206,"activeCount":100},[],{"trials":2208,"activeCount":100},[2209,2221,2231,2240],{"nctId":2210,"briefTitle":2211,"status":496,"phases":2212,"completion":1067,"start":2213,"conditions":2214,"interventions":2217},"NCT00000601","Postmenopausal Hormone Therapy in Unstable Angina",[90],"1995-07",[2215,15,21,18,2216],"Angina, Unstable","Postmenopause",[2218,2199,2219,2220],"estrogen replacement therapy","progesterone","hormone replacement therapy",{"nctId":2222,"briefTitle":2223,"status":496,"phases":2224,"completion":2225,"start":2226,"conditions":2227,"interventions":2229},"NCT00000549","Estrogen Replacement and Atherosclerosis (ERA) in Older Women",[90],"2000-07","1994-08",[15,2228,21,18,2117,2216],"Coronary Arteriosclerosis",[2218,2220,2199,2230],"progestins",{"nctId":2232,"briefTitle":2233,"status":496,"phases":2234,"completion":2235,"start":2236,"conditions":2237,"interventions":2238},"NCT00000605","Estrogen and Graft Atherosclerosis Research Trial (EAGER)",[90],"2002-07","1996-08",[15,2228,21,18,2117,2216],[2220,2199,2239],"medroxyprogesterone",{"nctId":2241,"briefTitle":2242,"status":496,"phases":2243,"primaryCompletion":2244,"conditions":2245,"interventions":2250},"NCT00000611","Women's Health Initiative (WHI)",[90],"2005-03",[2246,2247,15,2248,21,18,2117,2249,2216],"Bone Diseases","Breast Neoplasms","Colonic Neoplasms","Osteoporosis",[2220,2199,2230,2218,2251,2252],"calcium","vitamin D",{"trials":2254,"activeCount":100},[],{"trials":2256,"activeCount":100},[],{"intervention":2219,"totalTrials":736,"cells":2258},{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2277,"PHASE4":2303,"NA":2305},{"trials":2260,"activeCount":100},[],{"trials":2262,"activeCount":100},[],{"trials":2264,"activeCount":100},[2265],{"nctId":2266,"briefTitle":2267,"status":496,"phases":2268,"completion":2269,"start":2270,"enrollment":778,"conditions":2271,"interventions":2274},"NCT00005108","Effects of Hormone Replacement Therapy on Inflammation and Stiffening of Artery Walls",[89],"2002-01","2000-04",[30,2272,2273],"Healthy","Vascular Disease",[2275,2276],"Estradiol","Progesterone",{"trials":2278,"activeCount":100},[2279,2283,2294],{"nctId":2210,"briefTitle":2211,"status":496,"phases":2280,"completion":1067,"start":2213,"conditions":2281,"interventions":2282},[90],[2215,15,21,18,2216],[2218,2199,2219,2220],{"nctId":2284,"briefTitle":2285,"status":496,"phases":2286,"completion":2287,"start":2236,"conditions":2288,"interventions":2289},"NCT00000555","Women's Angiographic Vitamin and Estrogen Trial (WAVE)",[90],"2003-05",[15,2228,21,18,2117,2216],[2218,2290,2219,2220,2291,2292,2293],"estrogens, conjugated","supplementation, food","ascorbic acid","vitamin e",{"nctId":2295,"briefTitle":2296,"status":496,"phases":2297,"completion":2298,"start":2299,"conditions":2300,"interventions":2302},"NCT00000466","Postmenopausal Estrogen\u002FProgestin Interventions (PEPI)",[90],"2000-10","1987-09",[2246,15,21,2178,18,2070,24,2117,2249,2301,2216],"Thrombosis",[2290,2239,2219,2218],{"trials":2304,"activeCount":100},[],{"trials":2306,"activeCount":100},[],{"intervention":599,"totalTrials":736,"cells":2308},{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2313,"PHASE3":2336,"PHASE4":2342,"NA":2344},{"trials":2310,"activeCount":100},[],{"trials":2312,"activeCount":100},[],{"trials":2314,"activeCount":100},[2315,2319,2323],{"nctId":584,"briefTitle":585,"status":496,"phases":2316,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":2317,"interventions":2318},[89],[591,543,592,545,518,593,594,595,596],[598,598,599,599,600,601,602,394],{"nctId":1105,"briefTitle":1106,"status":496,"phases":2320,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1111,"conditions":2321,"interventions":2322},[89],[1113,544,543,547,546],[599,549,1115],{"nctId":2324,"briefTitle":2325,"status":467,"phases":2326,"primaryCompletion":2327,"completion":2328,"start":2329,"enrollment":2330,"conditions":2331,"interventions":2333},"NCT00001880","Stem Cell Transplantation for Metastatic Solid Tumors",[89],"2008-08-14","2020-08-13","1999-03-12",42,[2332],"Neoplasm Metastasis",[2334,2335],"methotrexate","Cyclosporin",{"trials":2337,"activeCount":100},[2338],{"nctId":634,"briefTitle":635,"status":496,"phases":2339,"primaryCompletion":637,"completion":637,"start":638,"enrollment":639,"conditions":2340,"interventions":2341},[90],[591,592],[394,598,599],{"trials":2343,"activeCount":100},[],{"trials":2345,"activeCount":100},[],{"intervention":2347,"totalTrials":736,"cells":2348},"cholestyramine",{"EARLY_PHASE1":2349,"PHASE1":2351,"PHASE2":2353,"PHASE3":2366,"PHASE4":2394,"NA":2396},{"trials":2350,"activeCount":100},[],{"trials":2352,"activeCount":100},[],{"trials":2354,"activeCount":100},[2355],{"nctId":2356,"briefTitle":2357,"status":496,"phases":2358,"completion":2359,"start":2360,"conditions":2361,"interventions":2362},"NCT00000461","Harvard Atherosclerosis Reversibility Project (HARP)",[89],"1992-11","1986-12",[15,21,18,2117],[2185,2363,2347,2364,2365],"niacin","gemfibrozil","fatty acids, omega-3",{"trials":2367,"activeCount":100},[2368,2377,2385],{"nctId":2369,"briefTitle":2370,"status":496,"phases":2371,"completion":2372,"start":2373,"conditions":2374,"interventions":2376},"NCT00000594","NHLBI Type II Coronary Intervention Study",[90],"1976-11","1971-11",[15,21,18,2375,2116,2117],"Hypercholesterolemia, Familial",[2347],{"nctId":2378,"briefTitle":2379,"status":496,"phases":2380,"completion":2381,"start":2382,"conditions":2383,"interventions":2384},"NCT00000488","Lipid Research Clinics Coronary Primary Prevention Trial (CPPT)",[90],"1989-10","1973-06",[15,21,18,2117],[2347],{"nctId":2386,"briefTitle":2387,"status":496,"phases":2388,"completion":2389,"start":2390,"conditions":2391,"interventions":2392},"NCT00000463","Post Coronary Artery Bypass Graft (CABG) Study",[90],"1998-12","1987-04",[15,21,18,2117],[2106,2347,2393],"warfarin",{"trials":2395,"activeCount":100},[],{"trials":2397,"activeCount":100},[],{"intervention":2399,"totalTrials":736,"cells":2400},"Lenalidomide",{"EARLY_PHASE1":2401,"PHASE1":2403,"PHASE2":2419,"PHASE3":2433,"PHASE4":2455,"NA":2457},{"trials":2402,"activeCount":100},[],{"trials":2404,"activeCount":100},[2405],{"nctId":2406,"briefTitle":2407,"status":496,"phases":2408,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":736,"conditions":2412,"interventions":2417},"NCT01629082","Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia",[88],"2015-10-27","2018-06-27","2012-06-06",[2413,2414,2415,531,2416],"Myeldysplastic Syndrome (MDS)","Chronic Myelomonocytic Leukemia","Bone Marrow Diseases","Acute Myeloid Leukemia (AML)",[2418,2399],"Clofarabine",{"trials":2420,"activeCount":100},[2421],{"nctId":2422,"briefTitle":2423,"status":496,"phases":2424,"primaryCompletion":2425,"completion":2426,"start":2427,"enrollment":2428,"conditions":2429,"interventions":2430},"NCT02728102","Dendritic Cell\u002FMyeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)",[89],"2020-06-30","2022-12-09","2016-07",203,[1174],[1176,2431,2432,2399],"Myeloma vaccine","GM-CSF",{"trials":2434,"activeCount":100},[2435,2444],{"nctId":2436,"briefTitle":2437,"status":496,"phases":2438,"primaryCompletion":2439,"completion":2439,"start":2440,"enrollment":2441,"conditions":2442,"interventions":2443},"NCT02322320","Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)",[90],"2019-06-07","2015-03",273,[1174],[2399],{"nctId":2445,"briefTitle":2446,"status":496,"phases":2447,"primaryCompletion":2448,"completion":2449,"start":2450,"enrollment":2451,"conditions":2452,"interventions":2453},"NCT01109004","Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)",[90],"2017-01-15","2018-03-03","2010-05",758,[1174],[2399,2454,2399],"lenalidomide, bortezomib and dexamethasone",{"trials":2456,"activeCount":100},[],{"trials":2458,"activeCount":100},[],{"intervention":598,"totalTrials":851,"cells":2460},{"EARLY_PHASE1":2461,"PHASE1":2463,"PHASE2":2465,"PHASE3":2475,"PHASE4":2481,"NA":2483},{"trials":2462,"activeCount":100},[],{"trials":2464,"activeCount":100},[],{"trials":2466,"activeCount":100},[2467,2471],{"nctId":1049,"briefTitle":1050,"status":496,"phases":2468,"completion":1052,"start":1053,"conditions":2469,"interventions":2470},[89],[27],[476,1056,581,1057],{"nctId":584,"briefTitle":585,"status":496,"phases":2472,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":2473,"interventions":2474},[89],[591,543,592,545,518,593,594,595,596],[598,598,599,599,600,601,602,394],{"trials":2476,"activeCount":100},[2477],{"nctId":634,"briefTitle":635,"status":496,"phases":2478,"primaryCompletion":637,"completion":637,"start":638,"enrollment":639,"conditions":2479,"interventions":2480},[90],[591,592],[394,598,599],{"trials":2482,"activeCount":100},[],{"trials":2484,"activeCount":100},[],{"intervention":2171,"totalTrials":851,"cells":2486},{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2493,"PHASE4":2514,"NA":2516},{"trials":2488,"activeCount":100},[],{"trials":2490,"activeCount":100},[],{"trials":2492,"activeCount":100},[],{"trials":2494,"activeCount":100},[2495,2499,2503],{"nctId":2164,"briefTitle":2165,"status":496,"phases":2496,"completion":2167,"start":2168,"conditions":2497,"interventions":2498},[90],[15,2103,18,24],[2142,2171,2158],{"nctId":2187,"briefTitle":2188,"status":496,"phases":2500,"completion":2190,"start":2191,"conditions":2501,"interventions":2502},[90],[15,18,24,2104],[2142,2171],{"nctId":2504,"briefTitle":2505,"status":496,"phases":2506,"completion":2507,"start":2508,"conditions":2509,"interventions":2510},"NCT00000478","Asymptomatic Cardiac Ischemia Pilot (ACIP) Study",[90],"1997-06","1990-11",[15,21,18,2117],[2171,2511,2512,2513],"nifedipine","diltiazem","isosorbide dinitrate",{"trials":2515,"activeCount":100},[],{"trials":2517,"activeCount":100},[],{"intervention":2185,"totalTrials":851,"cells":2519},{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2530,"PHASE4":2548,"NA":2550},{"trials":2521,"activeCount":100},[],{"trials":2523,"activeCount":100},[],{"trials":2525,"activeCount":100},[2526],{"nctId":2356,"briefTitle":2357,"status":496,"phases":2527,"completion":2359,"start":2360,"conditions":2528,"interventions":2529},[89],[15,21,18,2117],[2185,2363,2347,2364,2365],{"trials":2531,"activeCount":100},[2532,2544],{"nctId":2533,"briefTitle":2534,"status":496,"phases":2535,"completion":2536,"start":2537,"conditions":2538,"interventions":2540},"NCT00000539","Arterial Disease Multifactorial Intervention Trial (ADMIT)",[90],"1999-03","1992-09",[2539,15,18,2104,2178],"Arterial Occlusive Diseases",[2363,2185,2541,2542,2543,2393],"beta-carotene","vitamin E","vitamin C",{"nctId":2173,"briefTitle":2174,"status":496,"phases":2545,"primaryCompletion":1066,"completion":1066,"start":2176,"conditions":2546,"interventions":2547},[90],[15,21,2178,18,2070,24,2116,2117,2179],[2181,2182,2183,2184,2142,2185],{"trials":2549,"activeCount":100},[],{"trials":2551,"activeCount":100},[],{"intervention":2542,"totalTrials":851,"cells":2553},{"EARLY_PHASE1":2554,"PHASE1":2556,"PHASE2":2558,"PHASE3":2572,"PHASE4":2582,"NA":2584},{"trials":2555,"activeCount":100},[],{"trials":2557,"activeCount":100},[],{"trials":2559,"activeCount":100},[2560],{"nctId":2561,"briefTitle":2562,"status":467,"phases":2563,"completion":2564,"start":2565,"conditions":2566,"interventions":2569},"NCT00000600","Vitamin E and C to Slow Progression of Common Carotid Artery Plaque Build-Up",[89],"2000-05","1995-06",[15,2567,2568,2103,18,2104,30],"Carotid Artery Diseases","Intracranial Arteriosclerosis",[2570,2571],"Vitamin E","Vitamin C",{"trials":2573,"activeCount":100},[2574,2578],{"nctId":2533,"briefTitle":2534,"status":496,"phases":2575,"completion":2536,"start":2537,"conditions":2576,"interventions":2577},[90],[2539,15,18,2104,2178],[2363,2185,2541,2542,2543,2393],{"nctId":2284,"briefTitle":2285,"status":496,"phases":2579,"completion":2287,"start":2236,"conditions":2580,"interventions":2581},[90],[15,2228,21,18,2117,2216],[2218,2290,2219,2220,2291,2292,2293],{"trials":2583,"activeCount":100},[],{"trials":2585,"activeCount":100},[],{"intervention":2587,"totalTrials":851,"cells":2588},"Eculizumab",{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2604,"PHASE4":2623,"NA":2625},{"trials":2590,"activeCount":100},[],{"trials":2592,"activeCount":100},[],{"trials":2594,"activeCount":100},[2595],{"nctId":2596,"briefTitle":2597,"status":496,"phases":2598,"primaryCompletion":2599,"completion":2599,"start":2600,"enrollment":647,"conditions":2601,"interventions":2603},"NCT02298933","Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia",[89],"2017-08-08","2014-11-21",[722,2602],"Alloimmune Platelet Refractoriness",[2587],{"trials":2605,"activeCount":100},[2606,2614],{"nctId":2607,"briefTitle":2608,"status":496,"phases":2609,"completion":1889,"start":2610,"enrollment":31,"conditions":2611,"interventions":2613},"NCT00098280","Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria",[90],"2004-12",[2612],"Hemoglobinuria, Paroxysmal",[2587],{"nctId":2615,"briefTitle":2608,"status":496,"phases":2616,"completion":2617,"start":2618,"enrollment":2619,"conditions":2620,"interventions":2622},"NCT00130000",[90],"2007-06-25","2005-08-09",87,[2621],"Paroxysmal Hemoglobinuria, Nocturnal",[2587],{"trials":2624,"activeCount":100},[],{"trials":2626,"activeCount":100},[],{"intervention":2290,"totalTrials":851,"cells":2628},{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2633,"PHASE3":2646,"PHASE4":2656,"NA":2658},{"trials":2630,"activeCount":100},[],{"trials":2632,"activeCount":100},[],{"trials":2634,"activeCount":100},[2635],{"nctId":2636,"briefTitle":2637,"status":496,"phases":2638,"completion":2389,"start":2639,"conditions":2640,"interventions":2645},"NCT00000612","Soy Estrogen Alternative Study (SEA)",[89],"1996-01",[15,2641,18,2642,2643,2644],"Endometrial Hyperplasia","Menopausal Complaints","Uterine Diseases","Menopause",[2290],{"trials":2647,"activeCount":100},[2648,2652],{"nctId":2284,"briefTitle":2285,"status":496,"phases":2649,"completion":2287,"start":2236,"conditions":2650,"interventions":2651},[90],[15,2228,21,18,2117,2216],[2218,2290,2219,2220,2291,2292,2293],{"nctId":2295,"briefTitle":2296,"status":496,"phases":2653,"completion":2298,"start":2299,"conditions":2654,"interventions":2655},[90],[2246,15,21,2178,18,2070,24,2117,2249,2301,2216],[2290,2239,2219,2218],{"trials":2657,"activeCount":100},[],{"trials":2659,"activeCount":100},[],{"intervention":2239,"totalTrials":851,"cells":2661},{"EARLY_PHASE1":2662,"PHASE1":2664,"PHASE2":2666,"PHASE3":2668,"PHASE4":2687,"NA":2689},{"trials":2663,"activeCount":100},[],{"trials":2665,"activeCount":100},[],{"trials":2667,"activeCount":100},[],{"trials":2669,"activeCount":100},[2670,2674,2678],{"nctId":2232,"briefTitle":2233,"status":496,"phases":2671,"completion":2235,"start":2236,"conditions":2672,"interventions":2673},[90],[15,2228,21,18,2117,2216],[2220,2199,2239],{"nctId":2295,"briefTitle":2296,"status":496,"phases":2675,"completion":2298,"start":2299,"conditions":2676,"interventions":2677},[90],[2246,15,21,2178,18,2070,24,2117,2249,2301,2216],[2290,2239,2219,2218],{"nctId":2679,"briefTitle":2680,"status":496,"phases":2681,"completion":2682,"start":2683,"conditions":2684,"interventions":2685},"NCT00000559","Women's Estrogen\u002FProgestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)",[90],"2001-08","1995-03",[15,21,18,2117,2216],[2218,2220,2686,2239],"estradiol",{"trials":2688,"activeCount":100},[],{"trials":2690,"activeCount":100},[],{"intervention":2692,"totalTrials":851,"cells":2693},"moricizine",{"EARLY_PHASE1":2694,"PHASE1":2696,"PHASE2":2698,"PHASE3":2713,"PHASE4":2742,"NA":2744},{"trials":2695,"activeCount":100},[],{"trials":2697,"activeCount":100},[],{"trials":2699,"activeCount":100},[2700],{"nctId":2701,"briefTitle":2702,"status":496,"phases":2703,"completion":2704,"start":2705,"conditions":2706,"interventions":2709},"NCT00000504","Cardiac Arrhythmia Pilot Study (CAPS)",[89],"1985-09","1982-09",[2707,15,18,2708],"Arrhythmia","Ventricular Arrhythmia",[2710,2692,2711,2712],"encainide","flecainide","imipramine",{"trials":2714,"activeCount":100},[2715,2725],{"nctId":2716,"briefTitle":2717,"status":496,"phases":2718,"completion":2719,"start":2720,"conditions":2721,"interventions":2724},"NCT00000526","Cardiac Arrhythmia Suppression Trial (CAST)",[90],"1998-03","1986-08",[15,21,2722,2723,18,2116,2117,2708],"Death, Sudden, Cardiac","Heart Arrest",[2710,2711,2692],{"nctId":2726,"briefTitle":2727,"status":496,"phases":2728,"completion":2729,"start":2683,"conditions":2730,"interventions":2732},"NCT00000556","Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)",[90],"2002-09",[2707,2731,15,18],"Atrial Fibrillation",[2733,2734,2735,2711,2736,2692,2737,2738,2739,2740,2512,2741],"amiodarone","sotalol","propafenone","quinidine","disopyramide","procainamide","adrenergic beta antagonists","verapamil","digoxin",{"trials":2743,"activeCount":100},[],{"trials":2745,"activeCount":100},[],{"intervention":2711,"totalTrials":851,"cells":2747},{"EARLY_PHASE1":2748,"PHASE1":2750,"PHASE2":2752,"PHASE3":2758,"PHASE4":2768,"NA":2770},{"trials":2749,"activeCount":100},[],{"trials":2751,"activeCount":100},[],{"trials":2753,"activeCount":100},[2754],{"nctId":2701,"briefTitle":2702,"status":496,"phases":2755,"completion":2704,"start":2705,"conditions":2756,"interventions":2757},[89],[2707,15,18,2708],[2710,2692,2711,2712],{"trials":2759,"activeCount":100},[2760,2764],{"nctId":2716,"briefTitle":2717,"status":496,"phases":2761,"completion":2719,"start":2720,"conditions":2762,"interventions":2763},[90],[15,21,2722,2723,18,2116,2117,2708],[2710,2711,2692],{"nctId":2726,"briefTitle":2727,"status":496,"phases":2765,"completion":2729,"start":2683,"conditions":2766,"interventions":2767},[90],[2707,2731,15,18],[2733,2734,2735,2711,2736,2692,2737,2738,2739,2740,2512,2741],{"trials":2769,"activeCount":100},[],{"trials":2771,"activeCount":100},[],{"intervention":2773,"totalTrials":851,"cells":2774},"enalapril",{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2781,"PHASE4":2808,"NA":2810},{"trials":2776,"activeCount":100},[],{"trials":2778,"activeCount":100},[],{"trials":2780,"activeCount":100},[],{"trials":2782,"activeCount":100},[2783,2794,2801],{"nctId":2784,"briefTitle":2785,"status":496,"phases":2786,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":2068,"conditions":2789,"interventions":2792},"NCT00113087","Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network",[90],"2008-07","2003-08",[2790,2791],"Heart Defects, Congenital","Heart Failure, Congestive",[2793],"Enalapril",{"nctId":2795,"briefTitle":2796,"status":496,"phases":2797,"completion":1890,"start":953,"conditions":2798,"interventions":2800},"NCT00000547","Enalapril After Anthracycline Cardiotoxicity",[90],[15,18,2179,2799],"Myocardial Diseases",[2773],{"nctId":2802,"briefTitle":2803,"status":496,"phases":2804,"completion":2805,"start":2088,"conditions":2806,"interventions":2807},"NCT00000516","Studies of Left Ventricular Dysfunction (SOLVD)",[90],"1990-05",[15,21,18,2179,24,2117],[2773],{"trials":2809,"activeCount":100},[],{"trials":2811,"activeCount":100},[],{"intervention":2106,"totalTrials":851,"cells":2813},{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2818,"PHASE3":2832,"PHASE4":2838,"NA":2840},{"trials":2815,"activeCount":100},[],{"trials":2817,"activeCount":100},[],{"trials":2819,"activeCount":100},[2820,2828],{"nctId":2821,"briefTitle":2822,"status":496,"phases":2823,"completion":2824,"start":2825,"conditions":2826,"interventions":2827},"NCT00000477","Cholesterol Reduction in Seniors Program (CRISP)",[89],"1992-06","1990-07",[30,15,21,18,2070,2117],[2106],{"nctId":2095,"briefTitle":2096,"status":496,"phases":2829,"completion":2098,"start":2099,"conditions":2830,"interventions":2831},[89],[15,2101,2102,2103,18,2104],[2075,2106],{"trials":2833,"activeCount":100},[2834],{"nctId":2386,"briefTitle":2387,"status":496,"phases":2835,"completion":2389,"start":2390,"conditions":2836,"interventions":2837},[90],[15,21,18,2117],[2106,2347,2393],{"trials":2839,"activeCount":100},[],{"trials":2841,"activeCount":100},[],{"intervention":478,"totalTrials":843,"cells":2843},{"EARLY_PHASE1":2844,"PHASE1":2846,"PHASE2":2848,"PHASE3":2854,"PHASE4":2868,"NA":2870},{"trials":2845,"activeCount":100},[],{"trials":2847,"activeCount":100},[],{"trials":2849,"activeCount":100},[2850],{"nctId":465,"briefTitle":466,"status":467,"phases":2851,"completion":469,"enrollment":11,"conditions":2852,"interventions":2853},[89],[471,472,473],[475,476,477,478,479,480],{"trials":2855,"activeCount":100},[2856],{"nctId":2857,"briefTitle":2858,"status":496,"phases":2859,"completion":2860,"start":2861,"conditions":2862,"interventions":2864},"NCT00000579","Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)",[90],"2004-07","1994-09",[2863,27],"Respiratory Distress Syndrome, Adult",[2865,2866,2867],"Lysofylline","Methylprednisolone","Ketoconazole",{"trials":2869,"activeCount":100},[],{"trials":2871,"activeCount":100},[],{"intervention":2733,"totalTrials":843,"cells":2873},{"EARLY_PHASE1":2874,"PHASE1":2876,"PHASE2":2878,"PHASE3":2880,"PHASE4":2894,"NA":2896},{"trials":2875,"activeCount":100},[],{"trials":2877,"activeCount":100},[],{"trials":2879,"activeCount":100},[],{"trials":2881,"activeCount":100},[2882,2890],{"nctId":2883,"briefTitle":2884,"status":496,"phases":2885,"completion":2886,"start":2887,"conditions":2888,"interventions":2889},"NCT00000609","Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)",[90],"2005-04","1997-05",[2707,15,2722,18,2791,2179],[2733],{"nctId":2726,"briefTitle":2727,"status":496,"phases":2891,"completion":2729,"start":2683,"conditions":2892,"interventions":2893},[90],[2707,2731,15,18],[2733,2734,2735,2711,2736,2692,2737,2738,2739,2740,2512,2741],{"trials":2895,"activeCount":100},[],{"trials":2897,"activeCount":100},[],{"intervention":2158,"totalTrials":843,"cells":2899},{"EARLY_PHASE1":2900,"PHASE1":2902,"PHASE2":2904,"PHASE3":2910,"PHASE4":2916,"NA":2918},{"trials":2901,"activeCount":100},[],{"trials":2903,"activeCount":100},[],{"trials":2905,"activeCount":100},[2906],{"nctId":2151,"briefTitle":2152,"status":496,"phases":2907,"completion":2154,"start":2155,"conditions":2908,"interventions":2909},[89],[15,18,24,2104],[2142,2158,2159,2160],{"trials":2911,"activeCount":100},[2912],{"nctId":2164,"briefTitle":2165,"status":496,"phases":2913,"completion":2167,"start":2168,"conditions":2914,"interventions":2915},[90],[15,2103,18,24],[2142,2171,2158],{"trials":2917,"activeCount":100},[],{"trials":2919,"activeCount":100},[],{"intervention":2543,"totalTrials":843,"cells":2921},{"EARLY_PHASE1":2922,"PHASE1":2924,"PHASE2":2926,"PHASE3":2932,"PHASE4":2938,"NA":2940},{"trials":2923,"activeCount":100},[],{"trials":2925,"activeCount":100},[],{"trials":2927,"activeCount":100},[2928],{"nctId":2561,"briefTitle":2562,"status":467,"phases":2929,"completion":2564,"start":2565,"conditions":2930,"interventions":2931},[89],[15,2567,2568,2103,18,2104,30],[2570,2571],{"trials":2933,"activeCount":100},[2934],{"nctId":2533,"briefTitle":2534,"status":496,"phases":2935,"completion":2536,"start":2537,"conditions":2936,"interventions":2937},[90],[2539,15,18,2104,2178],[2363,2185,2541,2542,2543,2393],{"trials":2939,"activeCount":100},[],{"trials":2941,"activeCount":100},[],{"intervention":2275,"totalTrials":843,"cells":2943},{"EARLY_PHASE1":2944,"PHASE1":2946,"PHASE2":2948,"PHASE3":2954,"PHASE4":2960,"NA":2962},{"trials":2945,"activeCount":100},[],{"trials":2947,"activeCount":100},[],{"trials":2949,"activeCount":100},[2950],{"nctId":2266,"briefTitle":2267,"status":496,"phases":2951,"completion":2269,"start":2270,"enrollment":778,"conditions":2952,"interventions":2953},[89],[30,2272,2273],[2275,2276],{"trials":2955,"activeCount":100},[2956],{"nctId":2679,"briefTitle":2680,"status":496,"phases":2957,"completion":2682,"start":2683,"conditions":2958,"interventions":2959},[90],[15,21,18,2117,2216],[2218,2220,2686,2239],{"trials":2961,"activeCount":100},[],{"trials":2963,"activeCount":100},[],{"intervention":2365,"totalTrials":843,"cells":2965},{"EARLY_PHASE1":2966,"PHASE1":2968,"PHASE2":2970,"PHASE3":2976,"PHASE4":2985,"NA":2987},{"trials":2967,"activeCount":100},[],{"trials":2969,"activeCount":100},[],{"trials":2971,"activeCount":100},[2972],{"nctId":2356,"briefTitle":2357,"status":496,"phases":2973,"completion":2359,"start":2360,"conditions":2974,"interventions":2975},[89],[15,21,18,2117],[2185,2363,2347,2364,2365],{"trials":2977,"activeCount":100},[2978],{"nctId":2979,"briefTitle":2980,"status":496,"phases":2981,"completion":990,"start":2982,"conditions":2983,"interventions":2984},"NCT00000473","Do Fish Oils Prevent Restenosis Post-Coronary Angioplasty?",[90],"1989-07",[15,21,18,2117],[2365],{"trials":2986,"activeCount":100},[],{"trials":2988,"activeCount":100},[],{"intervention":2734,"totalTrials":843,"cells":2990},{"EARLY_PHASE1":2991,"PHASE1":2993,"PHASE2":2995,"PHASE3":2997,"PHASE4":3013,"NA":3015},{"trials":2992,"activeCount":100},[],{"trials":2994,"activeCount":100},[],{"trials":2996,"activeCount":100},[],{"trials":2998,"activeCount":100},[2999,3009],{"nctId":3000,"briefTitle":3001,"status":496,"phases":3002,"completion":3003,"start":2537,"conditions":3004,"interventions":3007},"NCT00000531","Antiarrhythmics Versus Implantable Defibrillators (AVID)",[90],"2002-08",[2707,15,2722,18,3005,3006],"Tachycardia, Ventricular","Ventricular Fibrillation",[3008,2734],"amiodarone amiodarone",{"nctId":2726,"briefTitle":2727,"status":496,"phases":3010,"completion":2729,"start":2683,"conditions":3011,"interventions":3012},[90],[2707,2731,15,18],[2733,2734,2735,2711,2736,2692,2737,2738,2739,2740,2512,2741],{"trials":3014,"activeCount":100},[],{"trials":3016,"activeCount":100},[],{"intervention":2230,"totalTrials":843,"cells":3018},{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3023,"PHASE3":3025,"PHASE4":3035,"NA":3037},{"trials":3020,"activeCount":100},[],{"trials":3022,"activeCount":100},[],{"trials":3024,"activeCount":100},[],{"trials":3026,"activeCount":100},[3027,3031],{"nctId":2222,"briefTitle":2223,"status":496,"phases":3028,"completion":2225,"start":2226,"conditions":3029,"interventions":3030},[90],[15,2228,21,18,2117,2216],[2218,2220,2199,2230],{"nctId":2241,"briefTitle":2242,"status":496,"phases":3032,"primaryCompletion":2244,"conditions":3033,"interventions":3034},[90],[2246,2247,15,2248,21,18,2117,2249,2216],[2220,2199,2230,2218,2251,2252],{"trials":3036,"activeCount":100},[],{"trials":3038,"activeCount":100},[],{"intervention":3040,"totalTrials":843,"cells":3041},"immunoglobulins",{"EARLY_PHASE1":3042,"PHASE1":3044,"PHASE2":3046,"PHASE3":3048,"PHASE4":3071,"NA":3073},{"trials":3043,"activeCount":100},[],{"trials":3045,"activeCount":100},[],{"trials":3047,"activeCount":100},[],{"trials":3049,"activeCount":100},[3050,3061],{"nctId":3051,"briefTitle":3052,"status":496,"phases":3053,"completion":3054,"start":3055,"conditions":3056,"interventions":3060},"NCT00000590","Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)",[90],"1996-12","1991-09",[3057,3058,3059],"Acquired Immunodeficiency Syndrome","Disease Transmission, Vertical","HIV Infections",[3040],{"nctId":3062,"briefTitle":3063,"status":496,"phases":3064,"completion":3065,"start":3066,"conditions":3067,"interventions":3070},"NCT00000584","Transfusion-Transmitted Cytomegalovirus Prevention in Neonates",[90],"1988-06","1983-07",[3068,3069],"Blood Transfusion","Cytomegalovirus Infections",[3040],{"trials":3072,"activeCount":100},[],{"trials":3074,"activeCount":100},[],{"intervention":3076,"totalTrials":843,"cells":3077},"tissue plasminogen activator",{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3082,"PHASE3":3084,"PHASE4":3102,"NA":3104},{"trials":3079,"activeCount":100},[],{"trials":3081,"activeCount":100},[],{"trials":3083,"activeCount":100},[],{"trials":3085,"activeCount":100},[3086,3094],{"nctId":3087,"briefTitle":3088,"status":496,"phases":3089,"completion":2565,"start":3090,"conditions":3091,"interventions":3092},"NCT00000472","Thrombolysis in Myocardial Ischemia Trial (TIMI III)",[90],"1989-04",[2135,15,21,18,2116,2117],[3076,3093],"heparin",{"nctId":3095,"briefTitle":3096,"status":496,"phases":3097,"completion":3098,"start":3099,"conditions":3100,"interventions":3101},"NCT00000505","Thrombolysis in Myocardial Infarction (TIMI)",[90],"1990-12","1983-04",[15,21,18,2116,2117],[3076],{"trials":3103,"activeCount":100},[],{"trials":3105,"activeCount":100},[],{"intervention":3107,"totalTrials":843,"cells":3108},"nitroglycerin",{"EARLY_PHASE1":3109,"PHASE1":3111,"PHASE2":3113,"PHASE3":3123,"PHASE4":3134,"NA":3136},{"trials":3110,"activeCount":100},[],{"trials":3112,"activeCount":100},[],{"trials":3114,"activeCount":100},[3115],{"nctId":3116,"briefTitle":3117,"status":496,"phases":3118,"completion":869,"start":3119,"enrollment":620,"conditions":3120,"interventions":3122},"NCT00090558","Effect of Nitric Oxide Donor on Endothelial Progenitor Cells in Patients With Coronary Artery Disease",[89],"2004-08",[3121],"Coronary Artery Disease",[3107],{"trials":3124,"activeCount":100},[3125],{"nctId":3126,"briefTitle":3127,"status":496,"phases":3128,"completion":3129,"start":3130,"conditions":3131,"interventions":3132},"NCT00000503","Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries",[90],"1987-10","1982-08",[15,21,18,2116,2117],[3107,3133],"streptokinase",{"trials":3135,"activeCount":100},[],{"trials":3137,"activeCount":100},[],{"intervention":3139,"totalTrials":843,"cells":3140},"Angiotensin II type 1 receptor antagonists",{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3145,"PHASE3":3147,"PHASE4":3164,"NA":3166},{"trials":3142,"activeCount":100},[],{"trials":3144,"activeCount":100},[],{"trials":3146,"activeCount":100},[],{"trials":3148,"activeCount":100},[3149,3157],{"nctId":3150,"briefTitle":3151,"status":496,"phases":3152,"completion":1035,"start":3153,"enrollment":3154,"conditions":3155,"interventions":3156},"NCT00001629","The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function",[90],"1997-07",49,[30,2791,24,2116],[3139],{"nctId":3158,"briefTitle":3159,"status":496,"phases":3160,"completion":1035,"start":3153,"enrollment":3161,"conditions":3162,"interventions":3163},"NCT00001628","The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function",[90],36,[30,2791,24,2116],[3139],{"trials":3165,"activeCount":100},[],{"trials":3167,"activeCount":100},[],{"intervention":2511,"totalTrials":843,"cells":3169},{"EARLY_PHASE1":3170,"PHASE1":3172,"PHASE2":3174,"PHASE3":3176,"PHASE4":3190,"NA":3192},{"trials":3171,"activeCount":100},[],{"trials":3173,"activeCount":100},[],{"trials":3175,"activeCount":100},[],{"trials":3177,"activeCount":100},[3178,3186],{"nctId":3179,"briefTitle":3180,"status":496,"phases":3181,"completion":3182,"start":2537,"conditions":3183,"interventions":3185},"NCT00000530","Raynaud's Treatment Study (RTS)",[90],"1998-06",[15,18,3184,2104],"Raynaud's Disease",[2511],{"nctId":2504,"briefTitle":2505,"status":496,"phases":3187,"completion":2507,"start":2508,"conditions":3188,"interventions":3189},[90],[15,21,18,2117],[2171,2511,2512,2513],{"trials":3191,"activeCount":100},[],{"trials":3193,"activeCount":100},[],{"intervention":3195,"totalTrials":843,"cells":3196},"antihypertensive agents",{"EARLY_PHASE1":3197,"PHASE1":3199,"PHASE2":3201,"PHASE3":3203,"PHASE4":3222,"NA":3224},{"trials":3198,"activeCount":100},[],{"trials":3200,"activeCount":100},[],{"trials":3202,"activeCount":100},[],{"trials":3204,"activeCount":100},[3205,3214],{"nctId":3206,"briefTitle":3207,"status":496,"phases":3208,"completion":3209,"start":3210,"conditions":3211,"interventions":3212},"NCT00000485","Hypertension Detection and Follow-up Program (HDFP)",[90],"1982-05","1971-05",[15,18,24,2104],[3213,3195],"diuretics",{"nctId":3215,"briefTitle":3216,"status":496,"phases":3217,"completion":3218,"start":3219,"conditions":3220,"interventions":3221},"NCT00000498","Control of Hypertension by Non-Pharmacologic Means",[90],"1983-03","1980-04",[15,18,24,2104],[3195],{"trials":3223,"activeCount":100},[],{"trials":3225,"activeCount":100},[],{"intervention":2093,"totalTrials":843,"cells":3227},{"EARLY_PHASE1":3228,"PHASE1":3230,"PHASE2":3232,"PHASE3":3238,"PHASE4":3251,"NA":3253},{"trials":3229,"activeCount":100},[],{"trials":3231,"activeCount":100},[],{"trials":3233,"activeCount":100},[3234],{"nctId":2084,"briefTitle":2085,"status":496,"phases":3235,"completion":2087,"start":2088,"conditions":3236,"interventions":3237},[89],[15,2090,18,2091],[2093,2075],{"trials":3239,"activeCount":100},[3240],{"nctId":3241,"briefTitle":3242,"status":496,"phases":3243,"completion":3244,"start":3245,"conditions":3246,"interventions":3250},"NCT00000580","Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin",[90],"1986-06","1975-11",[3247,3248,3249],"Hepatitis B","Hepatitis, Viral, Human","Liver Diseases",[2093],{"trials":3252,"activeCount":100},[],{"trials":3254,"activeCount":100},[],{"intervention":3256,"totalTrials":843,"cells":3257},"SCH-58235",{"EARLY_PHASE1":3258,"PHASE1":3260,"PHASE2":3262,"PHASE3":3273,"PHASE4":3284,"NA":3286},{"trials":3259,"activeCount":100},[],{"trials":3261,"activeCount":100},[],{"trials":3263,"activeCount":100},[3264],{"nctId":3265,"briefTitle":3266,"status":496,"phases":3267,"completion":3268,"start":3269,"enrollment":630,"conditions":3270,"interventions":3272},"NCT00045812","SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia",[89],"2004-04","2001-03",[3271],"Lipoidosis",[3256],{"trials":3274,"activeCount":100},[3275],{"nctId":3276,"briefTitle":3277,"status":496,"phases":3278,"completion":3279,"start":2610,"enrollment":851,"conditions":3280,"interventions":3282},"NCT00099996","Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia",[90],"2005-12",[18,3281],"Metabolism, Inborn Errors",[3256,3283],"Ezetimibe",{"trials":3285,"activeCount":100},[],{"trials":3287,"activeCount":100},[],{"intervention":3289,"totalTrials":843,"cells":3290},"propranolol",{"EARLY_PHASE1":3291,"PHASE1":3293,"PHASE2":3295,"PHASE3":3297,"PHASE4":3315,"NA":3317},{"trials":3292,"activeCount":100},[],{"trials":3294,"activeCount":100},[],{"trials":3296,"activeCount":100},[],{"trials":3298,"activeCount":100},[3299,3307],{"nctId":3300,"briefTitle":3301,"status":496,"phases":3302,"completion":3303,"start":3304,"conditions":3305,"interventions":3306},"NCT00000492","Beta-Blocker Heart Attack Trial (BHAT)",[90],"1981-10","1977-09",[2707,15,21,2722,18,2116,2117,3006],[3289],{"nctId":3308,"briefTitle":3309,"status":496,"phases":3310,"completion":3311,"start":3304,"conditions":3312,"interventions":3313},"NCT00000493","Multicenter Investigation of Limitation of Infarct Size (MILIS)",[90],"1985-12",[15,21,18,2116,2117],[3289,3314],"hyaluronidase",{"trials":3316,"activeCount":100},[],{"trials":3318,"activeCount":100},[],{"intervention":2127,"totalTrials":843,"cells":3320},{"EARLY_PHASE1":3321,"PHASE1":3323,"PHASE2":3325,"PHASE3":3327,"PHASE4":3337,"NA":3339},{"trials":3322,"activeCount":100},[],{"trials":3324,"activeCount":100},[],{"trials":3326,"activeCount":100},[],{"trials":3328,"activeCount":100},[3329,3333],{"nctId":2120,"briefTitle":2121,"status":496,"phases":3330,"completion":2123,"start":2124,"conditions":3331,"interventions":3332},[90],[15,21,18,2117],[2075,2127],{"nctId":2129,"briefTitle":2130,"status":496,"phases":3334,"completion":2132,"start":2133,"conditions":3335,"interventions":3336},[90],[2135,15,21,18,2117],[2075,2127],{"trials":3338,"activeCount":100},[],{"trials":3340,"activeCount":100},[],{"intervention":2739,"totalTrials":843,"cells":3342},{"EARLY_PHASE1":3343,"PHASE1":3345,"PHASE2":3347,"PHASE3":3349,"PHASE4":3362,"NA":3364},{"trials":3344,"activeCount":100},[],{"trials":3346,"activeCount":100},[],{"trials":3348,"activeCount":100},[],{"trials":3350,"activeCount":100},[3351,3358],{"nctId":3352,"briefTitle":3353,"status":496,"phases":3354,"completion":3355,"start":990,"conditions":3356,"interventions":3357},"NCT00000560","Beta-Blocker Evaluation in Survival Trial (BEST)",[90],"1999-09",[15,18,2791,2179],[2739],{"nctId":2726,"briefTitle":2727,"status":496,"phases":3359,"completion":2729,"start":2683,"conditions":3360,"interventions":3361},[90],[2707,2731,15,18],[2733,2734,2735,2711,2736,2692,2737,2738,2739,2740,2512,2741],{"trials":3363,"activeCount":100},[],{"trials":3365,"activeCount":100},[],{"intervention":874,"totalTrials":843,"cells":3367},{"EARLY_PHASE1":3368,"PHASE1":3370,"PHASE2":3372,"PHASE3":3378,"PHASE4":3391,"NA":3393},{"trials":3369,"activeCount":100},[],{"trials":3371,"activeCount":100},[],{"trials":3373,"activeCount":100},[3374],{"nctId":864,"briefTitle":865,"status":496,"phases":3375,"primaryCompletion":867,"completion":868,"start":869,"enrollment":870,"conditions":3376,"interventions":3377},[89],[392,872],[874,629,875,395],{"trials":3379,"activeCount":100},[3380],{"nctId":3381,"briefTitle":3382,"status":496,"phases":3383,"primaryCompletion":3384,"completion":3385,"start":3386,"enrollment":1374,"conditions":3387,"interventions":3390},"NCT00421174","Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)",[90],"2010-06","2013-07","2007-08",[3388,3389],"Pneumonia","Idiopathic Pneumonia Syndrome",[874],{"trials":3392,"activeCount":100},[],{"trials":3394,"activeCount":100},[],{"intervention":2251,"totalTrials":843,"cells":3396},{"EARLY_PHASE1":3397,"PHASE1":3399,"PHASE2":3401,"PHASE3":3412,"PHASE4":3418,"NA":3420},{"trials":3398,"activeCount":100},[],{"trials":3400,"activeCount":100},[],{"trials":3402,"activeCount":100},[3403],{"nctId":3404,"briefTitle":3405,"status":496,"phases":3406,"completion":3407,"start":2176,"conditions":3408,"interventions":3411},"NCT00000543","Oral Calcium in Pregnant Women With Hypertension",[89],"1999-07",[15,18,24,3409,3410,2104],"Pre-Eclampsia","Pregnancy Toxemias",[2251],{"trials":3413,"activeCount":100},[3414],{"nctId":2241,"briefTitle":2242,"status":496,"phases":3415,"primaryCompletion":2244,"conditions":3416,"interventions":3417},[90],[2246,2247,15,2248,21,18,2117,2249,2216],[2220,2199,2230,2218,2251,2252],{"trials":3419,"activeCount":100},[],{"trials":3421,"activeCount":100},[],{"intervention":2710,"totalTrials":843,"cells":3423},{"EARLY_PHASE1":3424,"PHASE1":3426,"PHASE2":3428,"PHASE3":3434,"PHASE4":3440,"NA":3442},{"trials":3425,"activeCount":100},[],{"trials":3427,"activeCount":100},[],{"trials":3429,"activeCount":100},[3430],{"nctId":2701,"briefTitle":2702,"status":496,"phases":3431,"completion":2704,"start":2705,"conditions":3432,"interventions":3433},[89],[2707,15,18,2708],[2710,2692,2711,2712],{"trials":3435,"activeCount":100},[3436],{"nctId":2716,"briefTitle":2717,"status":496,"phases":3437,"completion":2719,"start":2720,"conditions":3438,"interventions":3439},[90],[15,21,2722,2723,18,2116,2117,2708],[2710,2711,2692],{"trials":3441,"activeCount":100},[],{"trials":3443,"activeCount":100},[],{"intervention":3445,"totalTrials":843,"cells":3446},"beclomethasone",{"EARLY_PHASE1":3447,"PHASE1":3449,"PHASE2":3451,"PHASE3":3453,"PHASE4":3472,"NA":3474},{"trials":3448,"activeCount":100},[],{"trials":3450,"activeCount":100},[],{"trials":3452,"activeCount":100},[],{"trials":3454,"activeCount":100},[3455,3465],{"nctId":3456,"briefTitle":3457,"status":496,"phases":3458,"completion":3459,"start":3460,"conditions":3461,"interventions":3464},"NCT00000576","Inhaled Beclomethasone to Prevent Chronic Lung Disease",[90],"1999-04","1993-06",[3462,3463,27],"Bronchopulmonary Dysplasia","Hyaline Membrane Disease",[3445],{"nctId":3466,"briefTitle":3467,"status":496,"phases":3468,"completion":2298,"start":953,"conditions":3469,"interventions":3470},"NCT00000578","NHLBI\u002FNICHD Collaborative Studies of Asthma in Pregnancy",[90],[33,27],[3471,3445],"theophylline",{"trials":3473,"activeCount":100},[],{"trials":3475,"activeCount":100},[],{"intervention":2512,"totalTrials":843,"cells":3477},{"EARLY_PHASE1":3478,"PHASE1":3480,"PHASE2":3482,"PHASE3":3484,"PHASE4":3494,"NA":3496},{"trials":3479,"activeCount":100},[],{"trials":3481,"activeCount":100},[],{"trials":3483,"activeCount":100},[],{"trials":3485,"activeCount":100},[3486,3490],{"nctId":2726,"briefTitle":2727,"status":496,"phases":3487,"completion":2729,"start":2683,"conditions":3488,"interventions":3489},[90],[2707,2731,15,18],[2733,2734,2735,2711,2736,2692,2737,2738,2739,2740,2512,2741],{"nctId":2504,"briefTitle":2505,"status":496,"phases":3491,"completion":2507,"start":2508,"conditions":3492,"interventions":3493},[90],[15,21,18,2117],[2171,2511,2512,2513],{"trials":3495,"activeCount":100},[],{"trials":3497,"activeCount":100},[],{"intervention":2541,"totalTrials":96,"cells":3499},{"EARLY_PHASE1":3500,"PHASE1":3502,"PHASE2":3504,"PHASE3":3506,"PHASE4":3512,"NA":3514},{"trials":3501,"activeCount":100},[],{"trials":3503,"activeCount":100},[],{"trials":3505,"activeCount":100},[],{"trials":3507,"activeCount":100},[3508],{"nctId":2533,"briefTitle":2534,"status":496,"phases":3509,"completion":2536,"start":2537,"conditions":3510,"interventions":3511},[90],[2539,15,18,2104,2178],[2363,2185,2541,2542,2543,2393],{"trials":3513,"activeCount":100},[],{"trials":3515,"activeCount":100},[],{"intervention":3517,"totalTrials":96,"cells":3518},"anti-arrhythmia agents",{"EARLY_PHASE1":3519,"PHASE1":3521,"PHASE2":3523,"PHASE3":3525,"PHASE4":3533,"NA":3535},{"trials":3520,"activeCount":100},[],{"trials":3522,"activeCount":100},[],{"trials":3524,"activeCount":100},[],{"trials":3526,"activeCount":100},[3527],{"nctId":3528,"briefTitle":3529,"status":496,"phases":3530,"completion":1036,"start":3055,"conditions":3531,"interventions":3532},"NCT00000480","Multicenter Unsustained Tachycardia Trial (MUSTT)",[90],[2707,15,21,2722,18,2117,3005],[3517],{"trials":3534,"activeCount":100},[],{"trials":3536,"activeCount":100},[],{"intervention":2181,"totalTrials":96,"cells":3538},{"EARLY_PHASE1":3539,"PHASE1":3541,"PHASE2":3543,"PHASE3":3545,"PHASE4":3551,"NA":3553},{"trials":3540,"activeCount":100},[],{"trials":3542,"activeCount":100},[],{"trials":3544,"activeCount":100},[],{"trials":3546,"activeCount":100},[3547],{"nctId":2173,"briefTitle":2174,"status":496,"phases":3548,"primaryCompletion":1066,"completion":1066,"start":2176,"conditions":3549,"interventions":3550},[90],[15,21,2178,18,2070,24,2116,2117,2179],[2181,2182,2183,2184,2142,2185],{"trials":3552,"activeCount":100},[],{"trials":3554,"activeCount":100},[],{"intervention":2182,"totalTrials":96,"cells":3556},{"EARLY_PHASE1":3557,"PHASE1":3559,"PHASE2":3561,"PHASE3":3563,"PHASE4":3569,"NA":3571},{"trials":3558,"activeCount":100},[],{"trials":3560,"activeCount":100},[],{"trials":3562,"activeCount":100},[],{"trials":3564,"activeCount":100},[3565],{"nctId":2173,"briefTitle":2174,"status":496,"phases":3566,"primaryCompletion":1066,"completion":1066,"start":2176,"conditions":3567,"interventions":3568},[90],[15,21,2178,18,2070,24,2116,2117,2179],[2181,2182,2183,2184,2142,2185],{"trials":3570,"activeCount":100},[],{"trials":3572,"activeCount":100},[],{"intervention":2183,"totalTrials":96,"cells":3574},{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3581,"PHASE4":3587,"NA":3589},{"trials":3576,"activeCount":100},[],{"trials":3578,"activeCount":100},[],{"trials":3580,"activeCount":100},[],{"trials":3582,"activeCount":100},[3583],{"nctId":2173,"briefTitle":2174,"status":496,"phases":3584,"primaryCompletion":1066,"completion":1066,"start":2176,"conditions":3585,"interventions":3586},[90],[15,21,2178,18,2070,24,2116,2117,2179],[2181,2182,2183,2184,2142,2185],{"trials":3588,"activeCount":100},[],{"trials":3590,"activeCount":100},[],{"intervention":2184,"totalTrials":96,"cells":3592},{"EARLY_PHASE1":3593,"PHASE1":3595,"PHASE2":3597,"PHASE3":3599,"PHASE4":3605,"NA":3607},{"trials":3594,"activeCount":100},[],{"trials":3596,"activeCount":100},[],{"trials":3598,"activeCount":100},[],{"trials":3600,"activeCount":100},[3601],{"nctId":2173,"briefTitle":2174,"status":496,"phases":3602,"primaryCompletion":1066,"completion":1066,"start":2176,"conditions":3603,"interventions":3604},[90],[15,21,2178,18,2070,24,2116,2117,2179],[2181,2182,2183,2184,2142,2185],{"trials":3606,"activeCount":100},[],{"trials":3608,"activeCount":100},[],{"intervention":3008,"totalTrials":96,"cells":3610},{"EARLY_PHASE1":3611,"PHASE1":3613,"PHASE2":3615,"PHASE3":3617,"PHASE4":3623,"NA":3625},{"trials":3612,"activeCount":100},[],{"trials":3614,"activeCount":100},[],{"trials":3616,"activeCount":100},[],{"trials":3618,"activeCount":100},[3619],{"nctId":3000,"briefTitle":3001,"status":496,"phases":3620,"completion":3003,"start":2537,"conditions":3621,"interventions":3622},[90],[2707,15,2722,18,3005,3006],[3008,2734],{"trials":3624,"activeCount":100},[],{"trials":3626,"activeCount":100},[],{"intervention":3628,"totalTrials":96,"cells":3629},"Hypoglycemic Agents",{"EARLY_PHASE1":3630,"PHASE1":3632,"PHASE2":3634,"PHASE3":3636,"PHASE4":3653,"NA":3655},{"trials":3631,"activeCount":100},[],{"trials":3633,"activeCount":100},[],{"trials":3635,"activeCount":100},[],{"trials":3637,"activeCount":100},[3638],{"nctId":3639,"briefTitle":3640,"status":496,"phases":3641,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":3644,"conditions":3645,"interventions":3647},"NCT00542178","Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)",[90],"2009-12","2003-10",3472,[3646],"Diabetic Retinopathy",[3628,3648,3649,3650,3651,3652],"Standard glycemia control","Intensive BP treatment","Standard BP control","Fenofibrate","Simvastatin",{"trials":3654,"activeCount":100},[],{"trials":3656,"activeCount":100},[],{"intervention":3648,"totalTrials":96,"cells":3658},{"EARLY_PHASE1":3659,"PHASE1":3661,"PHASE2":3663,"PHASE3":3665,"PHASE4":3671,"NA":3673},{"trials":3660,"activeCount":100},[],{"trials":3662,"activeCount":100},[],{"trials":3664,"activeCount":100},[],{"trials":3666,"activeCount":100},[3667],{"nctId":3639,"briefTitle":3640,"status":496,"phases":3668,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":3644,"conditions":3669,"interventions":3670},[90],[3646],[3628,3648,3649,3650,3651,3652],{"trials":3672,"activeCount":100},[],{"trials":3674,"activeCount":100},[],{"intervention":3649,"totalTrials":96,"cells":3676},{"EARLY_PHASE1":3677,"PHASE1":3679,"PHASE2":3681,"PHASE3":3683,"PHASE4":3689,"NA":3691},{"trials":3678,"activeCount":100},[],{"trials":3680,"activeCount":100},[],{"trials":3682,"activeCount":100},[],{"trials":3684,"activeCount":100},[3685],{"nctId":3639,"briefTitle":3640,"status":496,"phases":3686,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":3644,"conditions":3687,"interventions":3688},[90],[3646],[3628,3648,3649,3650,3651,3652],{"trials":3690,"activeCount":100},[],{"trials":3692,"activeCount":100},[],{"intervention":3650,"totalTrials":96,"cells":3694},{"EARLY_PHASE1":3695,"PHASE1":3697,"PHASE2":3699,"PHASE3":3701,"PHASE4":3707,"NA":3709},{"trials":3696,"activeCount":100},[],{"trials":3698,"activeCount":100},[],{"trials":3700,"activeCount":100},[],{"trials":3702,"activeCount":100},[3703],{"nctId":3639,"briefTitle":3640,"status":496,"phases":3704,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":3644,"conditions":3705,"interventions":3706},[90],[3646],[3628,3648,3649,3650,3651,3652],{"trials":3708,"activeCount":100},[],{"trials":3710,"activeCount":100},[],{"intervention":3651,"totalTrials":96,"cells":3712},{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3717,"PHASE3":3719,"PHASE4":3725,"NA":3727},{"trials":3714,"activeCount":100},[],{"trials":3716,"activeCount":100},[],{"trials":3718,"activeCount":100},[],{"trials":3720,"activeCount":100},[3721],{"nctId":3639,"briefTitle":3640,"status":496,"phases":3722,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":3644,"conditions":3723,"interventions":3724},[90],[3646],[3628,3648,3649,3650,3651,3652],{"trials":3726,"activeCount":100},[],{"trials":3728,"activeCount":100},[],{"intervention":3652,"totalTrials":96,"cells":3730},{"EARLY_PHASE1":3731,"PHASE1":3733,"PHASE2":3735,"PHASE3":3737,"PHASE4":3743,"NA":3745},{"trials":3732,"activeCount":100},[],{"trials":3734,"activeCount":100},[],{"trials":3736,"activeCount":100},[],{"trials":3738,"activeCount":100},[3739],{"nctId":3639,"briefTitle":3640,"status":496,"phases":3740,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":3644,"conditions":3741,"interventions":3742},[90],[3646],[3628,3648,3649,3650,3651,3652],{"trials":3744,"activeCount":100},[],{"trials":3746,"activeCount":100},[],{"intervention":3748,"totalTrials":96,"cells":3749},"penicillin",{"EARLY_PHASE1":3750,"PHASE1":3752,"PHASE2":3754,"PHASE3":3756,"PHASE4":3767,"NA":3769},{"trials":3751,"activeCount":100},[],{"trials":3753,"activeCount":100},[],{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[3758],{"nctId":3759,"briefTitle":3760,"status":496,"phases":3761,"completion":3762,"start":3763,"conditions":3764,"interventions":3766},"NCT00000585","Penicillin Prophylaxis in Sickle Cell Disease (PROPS)",[90],"1994-10","1983-08",[623,622,955,3765,3388],"Infection (S. Pneumoniae)",[3748],{"trials":3768,"activeCount":100},[],{"trials":3770,"activeCount":100},[],{"intervention":3772,"totalTrials":96,"cells":3773},"long-acting beta2-agonist",{"EARLY_PHASE1":3774,"PHASE1":3776,"PHASE2":3778,"PHASE3":3780,"PHASE4":3790,"NA":3792},{"trials":3775,"activeCount":100},[],{"trials":3777,"activeCount":100},[],{"trials":3779,"activeCount":100},[],{"trials":3781,"activeCount":100},[3782],{"nctId":3783,"briefTitle":3784,"status":496,"phases":3785,"completion":3786,"start":3003,"conditions":3787,"interventions":3788},"NCT00272506","Pediatric Asthma Controller Trial (PACT)",[90],"2004-09",[33,27],[3789,3772],"inhaled corticosteroid",{"trials":3791,"activeCount":100},[],{"trials":3793,"activeCount":100},[],{"intervention":2865,"totalTrials":96,"cells":3795},{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3800,"PHASE3":3802,"PHASE4":3808,"NA":3810},{"trials":3797,"activeCount":100},[],{"trials":3799,"activeCount":100},[],{"trials":3801,"activeCount":100},[],{"trials":3803,"activeCount":100},[3804],{"nctId":2857,"briefTitle":2858,"status":496,"phases":3805,"completion":2860,"start":2861,"conditions":3806,"interventions":3807},[90],[2863,27],[2865,2866,2867],{"trials":3809,"activeCount":100},[],{"trials":3811,"activeCount":100},[],{"intervention":2867,"totalTrials":96,"cells":3813},{"EARLY_PHASE1":3814,"PHASE1":3816,"PHASE2":3818,"PHASE3":3820,"PHASE4":3826,"NA":3828},{"trials":3815,"activeCount":100},[],{"trials":3817,"activeCount":100},[],{"trials":3819,"activeCount":100},[],{"trials":3821,"activeCount":100},[3822],{"nctId":2857,"briefTitle":2858,"status":496,"phases":3823,"completion":2860,"start":2861,"conditions":3824,"interventions":3825},[90],[2863,27],[2865,2866,2867],{"trials":3827,"activeCount":100},[],{"trials":3829,"activeCount":100},[],{"intervention":3831,"totalTrials":96,"cells":3832},"azithromycin",{"EARLY_PHASE1":3833,"PHASE1":3835,"PHASE2":3837,"PHASE3":3839,"PHASE4":3849,"NA":3851},{"trials":3834,"activeCount":100},[],{"trials":3836,"activeCount":100},[],{"trials":3838,"activeCount":100},[],{"trials":3840,"activeCount":100},[3841],{"nctId":3842,"briefTitle":3843,"status":496,"phases":3844,"completion":3845,"start":3846,"conditions":3847,"interventions":3848},"NCT00000617","Azithromycin and Coronary Events Study (ACES)",[90],"2005-11","1998-09",[21,18,2116,15],[3831],{"trials":3850,"activeCount":100},[],{"trials":3852,"activeCount":100},[],{"intervention":3854,"totalTrials":96,"cells":3855},"hepatitis B vaccines",{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3860,"PHASE3":3862,"PHASE4":3872,"NA":3874},{"trials":3857,"activeCount":100},[],{"trials":3859,"activeCount":100},[],{"trials":3861,"activeCount":100},[],{"trials":3863,"activeCount":100},[3864],{"nctId":3865,"briefTitle":3866,"status":496,"phases":3867,"completion":3868,"start":3869,"conditions":3870,"interventions":3871},"NCT00000583","Hepatitis B Vaccine Clinical Trial",[90],"1980-06","1978-11",[3247,3248,3249],[3854],{"trials":3873,"activeCount":100},[],{"trials":3875,"activeCount":100},[],{"intervention":3877,"totalTrials":96,"cells":3878},"factor ix",{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3883,"PHASE3":3885,"PHASE4":3898,"NA":3900},{"trials":3880,"activeCount":100},[],{"trials":3882,"activeCount":100},[],{"trials":3884,"activeCount":100},[],{"trials":3886,"activeCount":100},[3887],{"nctId":3888,"briefTitle":3889,"status":496,"phases":3890,"completion":3891,"start":3892,"conditions":3893,"interventions":3897},"NCT00000582","Cooperative Study of Factor VIII Inhibitors",[90],"1979-07","1978-07",[3894,622,3895,3896],"Blood Coagulation Disorders","Hemophilia A","Hemorrhagic Disorders",[3877],{"trials":3899,"activeCount":100},[],{"trials":3901,"activeCount":100},[],{"intervention":3903,"totalTrials":96,"cells":3904},"clofibrate clofibrate",{"EARLY_PHASE1":3905,"PHASE1":3907,"PHASE2":3909,"PHASE3":3911,"PHASE4":3923,"NA":3925},{"trials":3906,"activeCount":100},[],{"trials":3908,"activeCount":100},[],{"trials":3910,"activeCount":100},[],{"trials":3912,"activeCount":100},[3913],{"nctId":3914,"briefTitle":3915,"status":496,"phases":3916,"completion":3917,"start":3918,"conditions":3919,"interventions":3920},"NCT00000482","Coronary Drug Project",[90],"1985-03","1965-04",[15,21,18,2116,2117],[3921,3903,3922,2363],"estrogen","dextrothyroxine sodium",{"trials":3924,"activeCount":100},[],{"trials":3926,"activeCount":100},[],{"intervention":3928,"totalTrials":96,"cells":3929},"Supplemental oxygen therapy",{"EARLY_PHASE1":3930,"PHASE1":3932,"PHASE2":3934,"PHASE3":3936,"PHASE4":3946,"NA":3948},{"trials":3931,"activeCount":100},[],{"trials":3933,"activeCount":100},[],{"trials":3935,"activeCount":100},[],{"trials":3937,"activeCount":100},[3938],{"nctId":3939,"briefTitle":3940,"status":496,"phases":3941,"primaryCompletion":638,"completion":638,"start":867,"enrollment":3942,"conditions":3943,"interventions":3945},"NCT00692198","Long-term Oxygen Treatment Trial",[90],738,[3944],"Chronic Obstructive Pulmonary Disease",[3928],{"trials":3947,"activeCount":100},[],{"trials":3949,"activeCount":100},[],{"intervention":3213,"totalTrials":96,"cells":3951},{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3956,"PHASE3":3958,"PHASE4":3964,"NA":3966},{"trials":3953,"activeCount":100},[],{"trials":3955,"activeCount":100},[],{"trials":3957,"activeCount":100},[],{"trials":3959,"activeCount":100},[3960],{"nctId":3206,"briefTitle":3207,"status":496,"phases":3961,"completion":3209,"start":3210,"conditions":3962,"interventions":3963},[90],[15,18,24,2104],[3213,3195],{"trials":3965,"activeCount":100},[],{"trials":3967,"activeCount":100},[],{"intervention":3969,"totalTrials":96,"cells":3970},"colestipol",{"EARLY_PHASE1":3971,"PHASE1":3973,"PHASE2":3975,"PHASE3":3977,"PHASE4":3985,"NA":3987},{"trials":3972,"activeCount":100},[],{"trials":3974,"activeCount":100},[],{"trials":3976,"activeCount":100},[],{"trials":3978,"activeCount":100},[3979],{"nctId":3980,"briefTitle":3981,"status":496,"phases":3982,"completion":2190,"start":3868,"conditions":3983,"interventions":3984},"NCT00000599","Cholesterol-Lowering Atherosclerosis Study (CLAS)",[90],[2539,15,2567,2102,2103,2228,21,18,2117,30],[3969,2363],{"trials":3986,"activeCount":100},[],{"trials":3988,"activeCount":100},[],{"intervention":3990,"totalTrials":96,"cells":3991},"Albuterol Sulfate",{"EARLY_PHASE1":3992,"PHASE1":3994,"PHASE2":3996,"PHASE3":3998,"PHASE4":4008,"NA":4010},{"trials":3993,"activeCount":100},[],{"trials":3995,"activeCount":100},[],{"trials":3997,"activeCount":100},[],{"trials":3999,"activeCount":100},[4000],{"nctId":4001,"briefTitle":4002,"status":467,"phases":4003,"primaryCompletion":1012,"completion":4004,"start":3386,"enrollment":4005,"conditions":4006,"interventions":4007},"NCT00434993","Drug Study of Albuterol to Treat Acute Lung Injury",[89,90],"2008-11",282,[2863],[3990],{"trials":4009,"activeCount":100},[],{"trials":4011,"activeCount":100},[],{"intervention":4013,"totalTrials":96,"cells":4014},"chlorothiazide",{"EARLY_PHASE1":4015,"PHASE1":4017,"PHASE2":4019,"PHASE3":4021,"PHASE4":4032,"NA":4034},{"trials":4016,"activeCount":100},[],{"trials":4018,"activeCount":100},[],{"trials":4020,"activeCount":100},[],{"trials":4022,"activeCount":100},[4023],{"nctId":4024,"briefTitle":4025,"status":496,"phases":4026,"completion":4027,"start":4028,"conditions":4029,"interventions":4030},"NCT00000484","Treatment of Hypertension",[90],"1979-01","1966-04",[15,18,24,2104],[4013,4031],"Rauwolfia alkaloids",{"trials":4033,"activeCount":100},[],{"trials":4035,"activeCount":100},[],{"intervention":4031,"totalTrials":96,"cells":4037},{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4042,"PHASE3":4044,"PHASE4":4050,"NA":4052},{"trials":4039,"activeCount":100},[],{"trials":4041,"activeCount":100},[],{"trials":4043,"activeCount":100},[],{"trials":4045,"activeCount":100},[4046],{"nctId":4024,"briefTitle":4025,"status":496,"phases":4047,"completion":4027,"start":4028,"conditions":4048,"interventions":4049},[90],[15,18,24,2104],[4013,4031],{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[],{"intervention":3133,"totalTrials":96,"cells":4055},{"EARLY_PHASE1":4056,"PHASE1":4058,"PHASE2":4060,"PHASE3":4062,"PHASE4":4068,"NA":4070},{"trials":4057,"activeCount":100},[],{"trials":4059,"activeCount":100},[],{"trials":4061,"activeCount":100},[],{"trials":4063,"activeCount":100},[4064],{"nctId":3126,"briefTitle":3127,"status":496,"phases":4065,"completion":3129,"start":3130,"conditions":4066,"interventions":4067},[90],[15,21,18,2116,2117],[3107,3133],{"trials":4069,"activeCount":100},[],{"trials":4071,"activeCount":100},[],{"intervention":4073,"totalTrials":96,"cells":4074},"antilymphocyte serum",{"EARLY_PHASE1":4075,"PHASE1":4077,"PHASE2":4079,"PHASE3":4081,"PHASE4":4093,"NA":4095},{"trials":4076,"activeCount":100},[],{"trials":4078,"activeCount":100},[],{"trials":4080,"activeCount":100},[],{"trials":4082,"activeCount":100},[4083],{"nctId":4084,"briefTitle":4085,"status":496,"phases":4086,"completion":4087,"start":4088,"conditions":4089,"interventions":4091},"NCT00000597","Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders",[90],"1988-12","1982-03",[810,622,532,4090],"Blood Disease",[4073,4092],"nandrolone",{"trials":4094,"activeCount":100},[],{"trials":4096,"activeCount":100},[],{"intervention":4092,"totalTrials":96,"cells":4098},{"EARLY_PHASE1":4099,"PHASE1":4101,"PHASE2":4103,"PHASE3":4105,"PHASE4":4111,"NA":4113},{"trials":4100,"activeCount":100},[],{"trials":4102,"activeCount":100},[],{"trials":4104,"activeCount":100},[],{"trials":4106,"activeCount":100},[4107],{"nctId":4084,"briefTitle":4085,"status":496,"phases":4108,"completion":4087,"start":4088,"conditions":4109,"interventions":4110},[90],[810,622,532,4090],[4073,4092],{"trials":4112,"activeCount":100},[],{"trials":4114,"activeCount":100},[],{"intervention":4116,"totalTrials":96,"cells":4117},"magnesium",{"EARLY_PHASE1":4118,"PHASE1":4120,"PHASE2":4122,"PHASE3":4124,"PHASE4":4133,"NA":4135},{"trials":4119,"activeCount":100},[],{"trials":4121,"activeCount":100},[],{"trials":4123,"activeCount":100},[],{"trials":4125,"activeCount":100},[4126],{"nctId":4127,"briefTitle":4128,"status":496,"phases":4129,"completion":4130,"start":1053,"conditions":4131,"interventions":4132},"NCT00000610","Magnesium in Coronaries (MAGIC)",[90],"2003-11",[15,21,18,2116,2117],[4116],{"trials":4134,"activeCount":100},[],{"trials":4136,"activeCount":100},[],{"intervention":2291,"totalTrials":96,"cells":4138},{"EARLY_PHASE1":4139,"PHASE1":4141,"PHASE2":4143,"PHASE3":4145,"PHASE4":4151,"NA":4153},{"trials":4140,"activeCount":100},[],{"trials":4142,"activeCount":100},[],{"trials":4144,"activeCount":100},[],{"trials":4146,"activeCount":100},[4147],{"nctId":2284,"briefTitle":2285,"status":496,"phases":4148,"completion":2287,"start":2236,"conditions":4149,"interventions":4150},[90],[15,2228,21,18,2117,2216],[2218,2290,2219,2220,2291,2292,2293],{"trials":4152,"activeCount":100},[],{"trials":4154,"activeCount":100},[],{"intervention":2292,"totalTrials":96,"cells":4156},{"EARLY_PHASE1":4157,"PHASE1":4159,"PHASE2":4161,"PHASE3":4163,"PHASE4":4169,"NA":4171},{"trials":4158,"activeCount":100},[],{"trials":4160,"activeCount":100},[],{"trials":4162,"activeCount":100},[],{"trials":4164,"activeCount":100},[4165],{"nctId":2284,"briefTitle":2285,"status":496,"phases":4166,"completion":2287,"start":2236,"conditions":4167,"interventions":4168},[90],[15,2228,21,18,2117,2216],[2218,2290,2219,2220,2291,2292,2293],{"trials":4170,"activeCount":100},[],{"trials":4172,"activeCount":100},[],{"intervention":4174,"totalTrials":96,"cells":4175},"ipratropium",{"EARLY_PHASE1":4176,"PHASE1":4178,"PHASE2":4180,"PHASE3":4182,"PHASE4":4193,"NA":4195},{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":100},[],{"trials":4181,"activeCount":100},[],{"trials":4183,"activeCount":100},[4184],{"nctId":4185,"briefTitle":4186,"status":496,"phases":4187,"completion":4188,"start":4189,"conditions":4190,"interventions":4192},"NCT00000568","Lung Health Study (LHS) I and III",[90],"2005-01","1984-09",[27,4191,3944],"Lung Diseases, Obstructive",[4174],{"trials":4194,"activeCount":100},[],{"trials":4196,"activeCount":100},[],{"intervention":4198,"totalTrials":96,"cells":4199},"Anti-hyperglycemic Agents",{"EARLY_PHASE1":4200,"PHASE1":4202,"PHASE2":4204,"PHASE3":4206,"PHASE4":4220,"NA":4222},{"trials":4201,"activeCount":100},[],{"trials":4203,"activeCount":100},[],{"trials":4205,"activeCount":100},[],{"trials":4207,"activeCount":100},[4208],{"nctId":4209,"briefTitle":4210,"status":496,"phases":4211,"primaryCompletion":4212,"completion":4213,"start":3355,"enrollment":4214,"conditions":4215,"interventions":4217},"NCT00000620","Action to Control Cardiovascular Risk in Diabetes (ACCORD)",[90],"2009-06","2012-12",10251,[30,15,2070,24,4216,2178,21],"Diabetes Mellitus, Type 2",[4198,4218,4219],"Anti-hypertensive Agents","Blinded fenofibrate or placebo plus simvastatin",{"trials":4221,"activeCount":100},[],{"trials":4223,"activeCount":100},[],{"intervention":4218,"totalTrials":96,"cells":4225},{"EARLY_PHASE1":4226,"PHASE1":4228,"PHASE2":4230,"PHASE3":4232,"PHASE4":4238,"NA":4240},{"trials":4227,"activeCount":100},[],{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":100},[],{"trials":4233,"activeCount":100},[4234],{"nctId":4209,"briefTitle":4210,"status":496,"phases":4235,"primaryCompletion":4212,"completion":4213,"start":3355,"enrollment":4214,"conditions":4236,"interventions":4237},[90],[30,15,2070,24,4216,2178,21],[4198,4218,4219],{"trials":4239,"activeCount":100},[],{"trials":4241,"activeCount":100},[],{"intervention":4219,"totalTrials":96,"cells":4243},{"EARLY_PHASE1":4244,"PHASE1":4246,"PHASE2":4248,"PHASE3":4250,"PHASE4":4256,"NA":4258},{"trials":4245,"activeCount":100},[],{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[],{"trials":4251,"activeCount":100},[4252],{"nctId":4209,"briefTitle":4210,"status":496,"phases":4253,"primaryCompletion":4212,"completion":4213,"start":3355,"enrollment":4214,"conditions":4254,"interventions":4255},[90],[30,15,2070,24,4216,2178,21],[4198,4218,4219],{"trials":4257,"activeCount":100},[],{"trials":4259,"activeCount":100},[],{"intervention":4261,"totalTrials":96,"cells":4262},"FDG",{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4267,"PHASE3":4269,"PHASE4":4281,"NA":4283},{"trials":4264,"activeCount":100},[],{"trials":4266,"activeCount":100},[],{"trials":4268,"activeCount":100},[],{"trials":4270,"activeCount":100},[4271],{"nctId":4272,"briefTitle":4273,"status":496,"phases":4274,"completion":4275,"start":4276,"enrollment":4277,"conditions":4278,"interventions":4279},"NCT00001895","Electromechanical Mapping to Evaluate Heart Muscle",[90],"2001-12","1999-08",71,[2117],[4261,4280],"NH",{"trials":4282,"activeCount":100},[],{"trials":4284,"activeCount":100},[],{"intervention":4280,"totalTrials":96,"cells":4286},{"EARLY_PHASE1":4287,"PHASE1":4289,"PHASE2":4291,"PHASE3":4293,"PHASE4":4299,"NA":4301},{"trials":4288,"activeCount":100},[],{"trials":4290,"activeCount":100},[],{"trials":4292,"activeCount":100},[],{"trials":4294,"activeCount":100},[4295],{"nctId":4272,"briefTitle":4273,"status":496,"phases":4296,"completion":4275,"start":4276,"enrollment":4277,"conditions":4297,"interventions":4298},[90],[2117],[4261,4280],{"trials":4300,"activeCount":100},[],{"trials":4302,"activeCount":100},[],{"intervention":4304,"totalTrials":96,"cells":4305},"digitalis",{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4310,"PHASE3":4312,"PHASE4":4322,"NA":4324},{"trials":4307,"activeCount":100},[],{"trials":4309,"activeCount":100},[],{"trials":4311,"activeCount":100},[],{"trials":4313,"activeCount":100},[4314],{"nctId":4315,"briefTitle":4316,"status":496,"phases":4317,"completion":3182,"start":4318,"conditions":4319,"interventions":4321},"NCT00000476","Digitalis Investigation Group (DIG)",[90],"1990-06",[2707,15,18,2791,4320,2179],"Sinus Arrhythmia",[4304],{"trials":4323,"activeCount":100},[],{"trials":4325,"activeCount":100},[],{"intervention":4327,"totalTrials":96,"cells":4328},"Mythylprednisolone",{"EARLY_PHASE1":4329,"PHASE1":4331,"PHASE2":4333,"PHASE3":4335,"PHASE4":4345,"NA":4347},{"trials":4330,"activeCount":100},[],{"trials":4332,"activeCount":100},[],{"trials":4334,"activeCount":100},[],{"trials":4336,"activeCount":100},[4337],{"nctId":4338,"briefTitle":4339,"status":496,"phases":4340,"completion":869,"start":952,"enrollment":4341,"conditions":4342,"interventions":4344},"NCT00295269","Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome",[90],200,[4343,27],"Acute Respiratory Distress Syndrome",[4327],{"trials":4346,"activeCount":100},[],{"trials":4348,"activeCount":100},[],{"intervention":4350,"totalTrials":96,"cells":4351},"indomethacin",{"EARLY_PHASE1":4352,"PHASE1":4354,"PHASE2":4356,"PHASE3":4358,"PHASE4":4369,"NA":4371},{"trials":4353,"activeCount":100},[],{"trials":4355,"activeCount":100},[],{"trials":4357,"activeCount":100},[],{"trials":4359,"activeCount":100},[4360],{"nctId":4361,"briefTitle":4362,"status":496,"phases":4363,"completion":4088,"start":4364,"conditions":4365,"interventions":4368},"NCT00000494","Management of Patent Ductus in Premature Infants",[90],"1978-09",[15,4366,4367,18],"Defect, Congenital Heart","Ductus Arteriosus, Patent",[4350],{"trials":4370,"activeCount":100},[],{"trials":4372,"activeCount":100},[],{"intervention":3314,"totalTrials":96,"cells":4374},{"EARLY_PHASE1":4375,"PHASE1":4377,"PHASE2":4379,"PHASE3":4381,"PHASE4":4387,"NA":4389},{"trials":4376,"activeCount":100},[],{"trials":4378,"activeCount":100},[],{"trials":4380,"activeCount":100},[],{"trials":4382,"activeCount":100},[4383],{"nctId":3308,"briefTitle":3309,"status":496,"phases":4384,"completion":3311,"start":3304,"conditions":4385,"interventions":4386},[90],[15,21,18,2116,2117],[3289,3314],{"trials":4388,"activeCount":100},[],{"trials":4390,"activeCount":100},[],{"intervention":2252,"totalTrials":96,"cells":4392},{"EARLY_PHASE1":4393,"PHASE1":4395,"PHASE2":4397,"PHASE3":4399,"PHASE4":4405,"NA":4407},{"trials":4394,"activeCount":100},[],{"trials":4396,"activeCount":100},[],{"trials":4398,"activeCount":100},[],{"trials":4400,"activeCount":100},[4401],{"nctId":2241,"briefTitle":2242,"status":496,"phases":4402,"primaryCompletion":2244,"conditions":4403,"interventions":4404},[90],[2246,2247,15,2248,21,18,2117,2249,2216],[2220,2199,2230,2218,2251,2252],{"trials":4406,"activeCount":100},[],{"trials":4408,"activeCount":100},[],{"intervention":4410,"totalTrials":96,"cells":4411},"pulmonary surfactant",{"EARLY_PHASE1":4412,"PHASE1":4414,"PHASE2":4416,"PHASE3":4418,"PHASE4":4428,"NA":4430},{"trials":4413,"activeCount":100},[],{"trials":4415,"activeCount":100},[],{"trials":4417,"activeCount":100},[],{"trials":4419,"activeCount":100},[4420],{"nctId":4421,"briefTitle":4422,"status":496,"phases":4423,"completion":4318,"start":4424,"conditions":4425,"interventions":4427},"NCT00000570","Human Surfactant Treatment of Respiratory Distress Syndrome Bicenter Trial",[90],"1986-01",[27,4426],"Respiratory Distress Syndrome",[4410],{"trials":4429,"activeCount":100},[],{"trials":4431,"activeCount":100},[],{"intervention":2735,"totalTrials":96,"cells":4433},{"EARLY_PHASE1":4434,"PHASE1":4436,"PHASE2":4438,"PHASE3":4440,"PHASE4":4446,"NA":4448},{"trials":4435,"activeCount":100},[],{"trials":4437,"activeCount":100},[],{"trials":4439,"activeCount":100},[],{"trials":4441,"activeCount":100},[4442],{"nctId":2726,"briefTitle":2727,"status":496,"phases":4443,"completion":2729,"start":2683,"conditions":4444,"interventions":4445},[90],[2707,2731,15,18],[2733,2734,2735,2711,2736,2692,2737,2738,2739,2740,2512,2741],{"trials":4447,"activeCount":100},[],{"trials":4449,"activeCount":100},[],{"intervention":2736,"totalTrials":96,"cells":4451},{"EARLY_PHASE1":4452,"PHASE1":4454,"PHASE2":4456,"PHASE3":4458,"PHASE4":4464,"NA":4466},{"trials":4453,"activeCount":100},[],{"trials":4455,"activeCount":100},[],{"trials":4457,"activeCount":100},[],{"trials":4459,"activeCount":100},[4460],{"nctId":2726,"briefTitle":2727,"status":496,"phases":4461,"completion":2729,"start":2683,"conditions":4462,"interventions":4463},[90],[2707,2731,15,18],[2733,2734,2735,2711,2736,2692,2737,2738,2739,2740,2512,2741],{"trials":4465,"activeCount":100},[],{"trials":4467,"activeCount":100},[],{"intervention":2737,"totalTrials":96,"cells":4469},{"EARLY_PHASE1":4470,"PHASE1":4472,"PHASE2":4474,"PHASE3":4476,"PHASE4":4482,"NA":4484},{"trials":4471,"activeCount":100},[],{"trials":4473,"activeCount":100},[],{"trials":4475,"activeCount":100},[],{"trials":4477,"activeCount":100},[4478],{"nctId":2726,"briefTitle":2727,"status":496,"phases":4479,"completion":2729,"start":2683,"conditions":4480,"interventions":4481},[90],[2707,2731,15,18],[2733,2734,2735,2711,2736,2692,2737,2738,2739,2740,2512,2741],{"trials":4483,"activeCount":100},[],{"trials":4485,"activeCount":100},[],{"intervention":2738,"totalTrials":96,"cells":4487},{"EARLY_PHASE1":4488,"PHASE1":4490,"PHASE2":4492,"PHASE3":4494,"PHASE4":4500,"NA":4502},{"trials":4489,"activeCount":100},[],{"trials":4491,"activeCount":100},[],{"trials":4493,"activeCount":100},[],{"trials":4495,"activeCount":100},[4496],{"nctId":2726,"briefTitle":2727,"status":496,"phases":4497,"completion":2729,"start":2683,"conditions":4498,"interventions":4499},[90],[2707,2731,15,18],[2733,2734,2735,2711,2736,2692,2737,2738,2739,2740,2512,2741],{"trials":4501,"activeCount":100},[],{"trials":4503,"activeCount":100},[],{"intervention":2740,"totalTrials":96,"cells":4505},{"EARLY_PHASE1":4506,"PHASE1":4508,"PHASE2":4510,"PHASE3":4512,"PHASE4":4518,"NA":4520},{"trials":4507,"activeCount":100},[],{"trials":4509,"activeCount":100},[],{"trials":4511,"activeCount":100},[],{"trials":4513,"activeCount":100},[4514],{"nctId":2726,"briefTitle":2727,"status":496,"phases":4515,"completion":2729,"start":2683,"conditions":4516,"interventions":4517},[90],[2707,2731,15,18],[2733,2734,2735,2711,2736,2692,2737,2738,2739,2740,2512,2741],{"trials":4519,"activeCount":100},[],{"trials":4521,"activeCount":100},[],{"intervention":2741,"totalTrials":96,"cells":4523},{"EARLY_PHASE1":4524,"PHASE1":4526,"PHASE2":4528,"PHASE3":4530,"PHASE4":4536,"NA":4538},{"trials":4525,"activeCount":100},[],{"trials":4527,"activeCount":100},[],{"trials":4529,"activeCount":100},[],{"trials":4531,"activeCount":100},[4532],{"nctId":2726,"briefTitle":2727,"status":496,"phases":4533,"completion":2729,"start":2683,"conditions":4534,"interventions":4535},[90],[2707,2731,15,18],[2733,2734,2735,2711,2736,2692,2737,2738,2739,2740,2512,2741],{"trials":4537,"activeCount":100},[],{"trials":4539,"activeCount":100},[],{"intervention":3471,"totalTrials":96,"cells":4541},{"EARLY_PHASE1":4542,"PHASE1":4544,"PHASE2":4546,"PHASE3":4548,"PHASE4":4554,"NA":4556},{"trials":4543,"activeCount":100},[],{"trials":4545,"activeCount":100},[],{"trials":4547,"activeCount":100},[],{"trials":4549,"activeCount":100},[4550],{"nctId":3466,"briefTitle":3467,"status":496,"phases":4551,"completion":2298,"start":953,"conditions":4552,"interventions":4553},[90],[33,27],[3471,3445],{"trials":4555,"activeCount":100},[],{"trials":4557,"activeCount":100},[],{"intervention":3283,"totalTrials":96,"cells":4559},{"EARLY_PHASE1":4560,"PHASE1":4562,"PHASE2":4564,"PHASE3":4566,"PHASE4":4572,"NA":4574},{"trials":4561,"activeCount":100},[],{"trials":4563,"activeCount":100},[],{"trials":4565,"activeCount":100},[],{"trials":4567,"activeCount":100},[4568],{"nctId":3276,"briefTitle":3277,"status":496,"phases":4569,"completion":3279,"start":2610,"enrollment":851,"conditions":4570,"interventions":4571},[90],[18,3281],[3256,3283],{"trials":4573,"activeCount":100},[],{"trials":4575,"activeCount":100},[],{"intervention":2454,"totalTrials":96,"cells":4577},{"EARLY_PHASE1":4578,"PHASE1":4580,"PHASE2":4582,"PHASE3":4584,"PHASE4":4590,"NA":4592},{"trials":4579,"activeCount":100},[],{"trials":4581,"activeCount":100},[],{"trials":4583,"activeCount":100},[],{"trials":4585,"activeCount":100},[4586],{"nctId":2445,"briefTitle":2446,"status":496,"phases":4587,"primaryCompletion":2448,"completion":2449,"start":2450,"enrollment":2451,"conditions":4588,"interventions":4589},[90],[1174],[2399,2454,2399],{"trials":4591,"activeCount":100},[],{"trials":4593,"activeCount":100},[],{"intervention":4595,"totalTrials":96,"cells":4596},"angiotensin-converting enzyme inhibitors",{"EARLY_PHASE1":4597,"PHASE1":4599,"PHASE2":4601,"PHASE3":4603,"PHASE4":4613,"NA":4615},{"trials":4598,"activeCount":100},[],{"trials":4600,"activeCount":100},[],{"trials":4602,"activeCount":100},[],{"trials":4604,"activeCount":100},[4605],{"nctId":4606,"briefTitle":4607,"status":496,"phases":4608,"primaryCompletion":4609,"completion":4609,"start":4610,"conditions":4611,"interventions":4612},"NCT00000558","Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)",[90],"2005-06","1995-11",[15,21,18,2116,2117],[4595],{"trials":4614,"activeCount":100},[],{"trials":4616,"activeCount":100},[],{"intervention":2513,"totalTrials":96,"cells":4618},{"EARLY_PHASE1":4619,"PHASE1":4621,"PHASE2":4623,"PHASE3":4625,"PHASE4":4631,"NA":4633},{"trials":4620,"activeCount":100},[],{"trials":4622,"activeCount":100},[],{"trials":4624,"activeCount":100},[],{"trials":4626,"activeCount":100},[4627],{"nctId":2504,"briefTitle":2505,"status":496,"phases":4628,"completion":2507,"start":2508,"conditions":4629,"interventions":4630},[90],[15,21,18,2117],[2171,2511,2512,2513],{"trials":4632,"activeCount":100},[],{"trials":4634,"activeCount":100},[],{"intervention":4636,"totalTrials":96,"cells":4637},"Autologous transplantation using rituxan\u002FBEAM",{"EARLY_PHASE1":4638,"PHASE1":4640,"PHASE2":4642,"PHASE3":4644,"PHASE4":4657,"NA":4659},{"trials":4639,"activeCount":100},[],{"trials":4641,"activeCount":100},[],{"trials":4643,"activeCount":100},[],{"trials":4645,"activeCount":100},[4646],{"nctId":4647,"briefTitle":4648,"status":496,"phases":4649,"primaryCompletion":4650,"completion":4650,"start":3279,"enrollment":4651,"conditions":4652,"interventions":4655},"NCT00329030","Rituxan\u002FBEAM vs Bexxar\u002FBEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)",[90],"2013-08",224,[593,4653,4654],"Lymphoma, Large-Cell, Immunoblastic","Lymphoma, Non-Hodgkin",[4636,4656],"Autologous transplantation using Bexxar\u002FBEAM",{"trials":4658,"activeCount":100},[],{"trials":4660,"activeCount":100},[],{"intervention":4656,"totalTrials":96,"cells":4662},{"EARLY_PHASE1":4663,"PHASE1":4665,"PHASE2":4667,"PHASE3":4669,"PHASE4":4675,"NA":4677},{"trials":4664,"activeCount":100},[],{"trials":4666,"activeCount":100},[],{"trials":4668,"activeCount":100},[],{"trials":4670,"activeCount":100},[4671],{"nctId":4647,"briefTitle":4648,"status":496,"phases":4672,"primaryCompletion":4650,"completion":4650,"start":3279,"enrollment":4651,"conditions":4673,"interventions":4674},[90],[593,4653,4654],[4636,4656],{"trials":4676,"activeCount":100},[],{"trials":4678,"activeCount":100},[],{"intervention":4680,"totalTrials":736,"cells":4681},"Acetylcholine",{"EARLY_PHASE1":4682,"PHASE1":4684,"PHASE2":4708,"PHASE3":4730,"PHASE4":4732,"NA":4734},{"trials":4683,"activeCount":100},[],{"trials":4685,"activeCount":100},[4686,4696],{"nctId":4687,"briefTitle":4688,"status":467,"phases":4689,"primaryCompletion":4690,"completion":4690,"start":4691,"enrollment":1891,"conditions":4692,"interventions":4694},"NCT00327080","Sildenafil to Treat HIV-Associated Pulmonary Hypertension",[88],"2009-03-18","2006-05-12",[4693],"HIV",[4695,4680],"L-NMMA",{"nctId":4697,"briefTitle":4698,"status":496,"phases":4699,"primaryCompletion":4700,"completion":4700,"start":4701,"enrollment":4702,"conditions":4703,"interventions":4706},"NCT00250185","The Role of Nitrite in Preconditioning Mediated Tolerance to Ischemic Stress",[88],"2007-06-09","2005-11-01",135,[4704,4705],"Ischemic Stress","Transient Non-Lethal Ischemia",[4707,4680],"Sodium Nitrate",{"trials":4709,"activeCount":100},[4710,4720],{"nctId":4711,"briefTitle":4712,"status":496,"phases":4713,"primaryCompletion":4714,"completion":4714,"start":4715,"enrollment":412,"conditions":4716,"interventions":4719},"NCT00453531","Model System for Transient Forearm Blood Vessel Dysfunction",[88,89],"2009-02-11","2007-03-26",[4717,4718],"Limb Ischemia","Ischemic Preconditioning",[4680],{"nctId":4721,"briefTitle":4722,"status":496,"phases":4723,"primaryCompletion":4724,"completion":4725,"start":4726,"enrollment":620,"conditions":4727,"interventions":4728},"NCT00508989","Niacin to Improve Blood Flow in People With Sickle Cell Disease",[89],"2010-12-31","2015-12-24","2007-07-24",[389],[4729,4695,4680],"Niacin-ER",{"trials":4731,"activeCount":100},[],{"trials":4733,"activeCount":100},[],{"trials":4735,"activeCount":100},[],{"intervention":602,"totalTrials":736,"cells":4737},{"EARLY_PHASE1":4738,"PHASE1":4740,"PHASE2":4742,"PHASE3":4760,"PHASE4":4762,"NA":4764},{"trials":4739,"activeCount":100},[],{"trials":4741,"activeCount":100},[],{"trials":4743,"activeCount":100},[4744,4748,4752,4756],{"nctId":1063,"briefTitle":1064,"status":496,"phases":4745,"completion":1066,"start":1067,"enrollment":425,"conditions":4746,"interventions":4747},[89],[530],[602,549],{"nctId":864,"briefTitle":865,"status":496,"phases":4749,"primaryCompletion":867,"completion":868,"start":869,"enrollment":870,"conditions":4750,"interventions":4751},[89],[392,872],[874,629,875,395],{"nctId":584,"briefTitle":585,"status":496,"phases":4753,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":4754,"interventions":4755},[89],[591,543,592,545,518,593,594,595,596],[598,598,599,599,600,601,602,394],{"nctId":616,"briefTitle":617,"status":496,"phases":4757,"primaryCompletion":619,"completion":619,"start":563,"enrollment":620,"conditions":4758,"interventions":4759},[89],[622,623,624,625],[627,394,628,629,549],{"trials":4761,"activeCount":100},[],{"trials":4763,"activeCount":100},[],{"trials":4765,"activeCount":100},[],{"intervention":601,"totalTrials":851,"cells":4767},{"EARLY_PHASE1":4768,"PHASE1":4770,"PHASE2":4786,"PHASE3":4796,"PHASE4":4798,"NA":4800},{"trials":4769,"activeCount":100},[],{"trials":4771,"activeCount":100},[4772],{"nctId":4773,"briefTitle":4774,"status":496,"phases":4775,"primaryCompletion":4776,"completion":4776,"start":4777,"enrollment":4778,"conditions":4779,"interventions":4784},"NCT00720785","Natural Killer Cells and Bortezomib to Treat Cancer",[88],"2021-04-06","2008-08-01",35,[4780,4781,4782,1174,4783],"Chronic Myeloid Leukemia (CML)","Pancreatic Ca","Colon\u002FRectal Ca","Carcinoma, Non-Small -Cell Lung",[601,4785],"NK cells",{"trials":4787,"activeCount":100},[4788,4792],{"nctId":584,"briefTitle":585,"status":496,"phases":4789,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":4790,"interventions":4791},[89],[591,543,592,545,518,593,594,595,596],[598,598,599,599,600,601,602,394],{"nctId":1169,"briefTitle":1170,"status":496,"phases":4793,"primaryCompletion":1172,"completion":1172,"start":638,"enrollment":433,"conditions":4794,"interventions":4795},[89],[1174],[534,1176,601,1177],{"trials":4797,"activeCount":100},[],{"trials":4799,"activeCount":100},[],{"trials":4801,"activeCount":100},[],{"intervention":4695,"totalTrials":851,"cells":4803},{"EARLY_PHASE1":4804,"PHASE1":4806,"PHASE2":4821,"PHASE3":4827,"PHASE4":4829,"NA":4831},{"trials":4805,"activeCount":100},[],{"trials":4807,"activeCount":100},[4808,4812],{"nctId":4687,"briefTitle":4688,"status":467,"phases":4809,"primaryCompletion":4690,"completion":4690,"start":4691,"enrollment":1891,"conditions":4810,"interventions":4811},[88],[4693],[4695,4680],{"nctId":4813,"briefTitle":4814,"status":496,"phases":4815,"primaryCompletion":4816,"completion":4816,"start":4817,"enrollment":1292,"conditions":4818,"interventions":4819},"NCT00095472","Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease",[88],"2007-08-24","2004-11-01",[403],[4695,4820],"Sodium Nitrite",{"trials":4822,"activeCount":100},[4823],{"nctId":4721,"briefTitle":4722,"status":496,"phases":4824,"primaryCompletion":4724,"completion":4725,"start":4726,"enrollment":620,"conditions":4825,"interventions":4826},[89],[389],[4729,4695,4680],{"trials":4828,"activeCount":100},[],{"trials":4830,"activeCount":100},[],{"trials":4832,"activeCount":100},[],{"intervention":4834,"totalTrials":843,"cells":4835},"Rituximab",{"EARLY_PHASE1":4836,"PHASE1":4838,"PHASE2":4849,"PHASE3":4859,"PHASE4":4861,"NA":4863},{"trials":4837,"activeCount":100},[],{"trials":4839,"activeCount":100},[4840],{"nctId":4841,"briefTitle":4842,"status":496,"phases":4843,"primaryCompletion":4844,"completion":4844,"start":4845,"enrollment":736,"conditions":4846,"interventions":4848},"NCT00366418","Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia",[88],"2009-06-11","2006-08-10",[4847],"Refractory Chronic Lymphocytic Leukemia",[4834],{"trials":4850,"activeCount":100},[4851],{"nctId":4852,"briefTitle":4853,"status":496,"phases":4854,"primaryCompletion":3384,"completion":3384,"start":869,"enrollment":4855,"conditions":4856,"interventions":4858},"NCT00229619","Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia",[89],11,[810,4857,799],"Red-Cell Aplasia, Pure",[4834],{"trials":4860,"activeCount":100},[],{"trials":4862,"activeCount":100},[],{"trials":4864,"activeCount":100},[],{"intervention":477,"totalTrials":843,"cells":4866},{"EARLY_PHASE1":4867,"PHASE1":4869,"PHASE2":4871,"PHASE3":4881,"PHASE4":4883,"NA":4885},{"trials":4868,"activeCount":100},[],{"trials":4870,"activeCount":100},[],{"trials":4872,"activeCount":100},[4873,4877],{"nctId":465,"briefTitle":466,"status":467,"phases":4874,"completion":469,"enrollment":11,"conditions":4875,"interventions":4876},[89],[471,472,473],[475,476,477,478,479,480],{"nctId":510,"briefTitle":511,"status":496,"phases":4878,"primaryCompletion":513,"completion":514,"start":515,"enrollment":516,"conditions":4879,"interventions":4880},[89],[518,519],[521,522,394],{"trials":4882,"activeCount":100},[],{"trials":4884,"activeCount":100},[],{"trials":4886,"activeCount":100},[],{"intervention":581,"totalTrials":843,"cells":4888},{"EARLY_PHASE1":4889,"PHASE1":4891,"PHASE2":4893,"PHASE3":4903,"PHASE4":4905,"NA":4907},{"trials":4890,"activeCount":100},[],{"trials":4892,"activeCount":100},[],{"trials":4894,"activeCount":100},[4895,4899],{"nctId":1049,"briefTitle":1050,"status":496,"phases":4896,"completion":1052,"start":1053,"conditions":4897,"interventions":4898},[89],[27],[476,1056,581,1057],{"nctId":572,"briefTitle":573,"status":496,"phases":4900,"completion":575,"start":576,"conditions":4901,"interventions":4902},[89],[27,578,579],[581,475,582],{"trials":4904,"activeCount":100},[],{"trials":4906,"activeCount":100},[],{"trials":4908,"activeCount":100},[],{"intervention":2432,"totalTrials":843,"cells":4910},{"EARLY_PHASE1":4911,"PHASE1":4913,"PHASE2":4915,"PHASE3":4932,"PHASE4":4934,"NA":4936},{"trials":4912,"activeCount":100},[],{"trials":4914,"activeCount":100},[],{"trials":4916,"activeCount":100},[4917,4928],{"nctId":4918,"briefTitle":4919,"status":496,"phases":4920,"primaryCompletion":4921,"completion":4921,"start":4922,"enrollment":647,"conditions":4923,"interventions":4924},"NCT00488592","Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers",[89],"2010-04","2007-06",[1377,2416,4780],[4925,4926,2432,4927],"WT1:126-134","PR1:169-177 Peptide","Montanide adjuvant",{"nctId":2422,"briefTitle":2423,"status":496,"phases":4929,"primaryCompletion":2425,"completion":2426,"start":2427,"enrollment":2428,"conditions":4930,"interventions":4931},[89],[1174],[1176,2431,2432,2399],{"trials":4933,"activeCount":100},[],{"trials":4935,"activeCount":100},[],{"trials":4937,"activeCount":100},[],{"intervention":4939,"totalTrials":843,"cells":4940},"Cyclosporine Inhalation Solution",{"EARLY_PHASE1":4941,"PHASE1":4943,"PHASE2":4945,"PHASE3":4970,"PHASE4":4972,"NA":4974},{"trials":4942,"activeCount":100},[],{"trials":4944,"activeCount":100},[],{"trials":4946,"activeCount":100},[4947,4959],{"nctId":4948,"briefTitle":4949,"status":496,"phases":4950,"primaryCompletion":4951,"completion":4951,"start":4952,"enrollment":778,"conditions":4953,"interventions":4958},"NCT01287078","Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome",[89],"2018-08-08","2011-01-29",[4954,4955,392,4956,4957],"Constrictive Bronchiolitis","Bronchiolitis Obliterans","Bronchiolitis, Exudative","Bronchiolitis, Proliferative",[4939],{"nctId":4960,"briefTitle":4961,"status":496,"phases":4962,"primaryCompletion":4963,"completion":4964,"start":4965,"enrollment":363,"conditions":4966,"interventions":4969},"NCT01273207","Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans",[89],"2019-05-10","2019-05-23","2012-03-02",[4955,4967,4968,4956,4957,1920],"Constructive Bronchiolitis","Graft Versus Host Disease",[4939],{"trials":4971,"activeCount":100},[],{"trials":4973,"activeCount":100},[],{"trials":4975,"activeCount":100},[],{"intervention":4977,"totalTrials":843,"cells":4978},"Cyclosporine A",{"EARLY_PHASE1":4979,"PHASE1":4981,"PHASE2":4983,"PHASE3":5006,"PHASE4":5008,"NA":5010},{"trials":4980,"activeCount":100},[],{"trials":4982,"activeCount":100},[],{"trials":4984,"activeCount":100},[4985,4994],{"nctId":4986,"briefTitle":4987,"status":496,"phases":4988,"completion":1890,"start":4989,"enrollment":516,"conditions":4990,"interventions":4993},"NCT00001965","Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)",[89],"1999-12",[4991,4992],"Cardiomyopathy, Hypertrophic","Heart Hypertrophy",[4977],{"nctId":4995,"briefTitle":4996,"status":496,"phases":4997,"primaryCompletion":4998,"completion":4999,"start":5000,"enrollment":5001,"conditions":5002,"interventions":5003},"NCT00001964","Combination Therapy of Severe Aplastic Anemia",[89],"2003-12-09","2015-05-12","2000-03-17",104,[381],[4977,5004,5005],"ATG","MMF",{"trials":5007,"activeCount":100},[],{"trials":5009,"activeCount":100},[],{"trials":5011,"activeCount":100},[],{"intervention":504,"totalTrials":843,"cells":5013},{"EARLY_PHASE1":5014,"PHASE1":5016,"PHASE2":5018,"PHASE3":5028,"PHASE4":5030,"NA":5032},{"trials":5015,"activeCount":100},[],{"trials":5017,"activeCount":100},[],{"trials":5019,"activeCount":100},[5020,5024],{"nctId":494,"briefTitle":495,"status":496,"phases":5021,"primaryCompletion":498,"completion":499,"start":500,"enrollment":501,"conditions":5022,"interventions":5023},[89],[489],[504,475,476],{"nctId":1090,"briefTitle":1091,"status":496,"phases":5025,"completion":1093,"start":1094,"enrollment":778,"conditions":5026,"interventions":5027},[89],[1096,1097],[1099,549],{"trials":5029,"activeCount":100},[],{"trials":5031,"activeCount":100},[],{"trials":5033,"activeCount":100},[],{"intervention":5035,"totalTrials":843,"cells":5036},"Imatinib",{"EARLY_PHASE1":5037,"PHASE1":5039,"PHASE2":5049,"PHASE3":5060,"PHASE4":5062,"NA":5064},{"trials":5038,"activeCount":100},[],{"trials":5040,"activeCount":100},[5041],{"nctId":5042,"briefTitle":5043,"status":937,"phases":5044,"primaryCompletion":5045,"completion":5045,"start":4965,"enrollment":100,"conditions":5046,"interventions":5047},"NCT01568645","Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease",[88],"2012-12-11",[942],[5048,5035],"Carvedilol",{"trials":5050,"activeCount":100},[5051],{"nctId":5052,"briefTitle":5053,"status":496,"phases":5054,"primaryCompletion":5055,"completion":5056,"start":5057,"enrollment":363,"conditions":5058,"interventions":5059},"NCT00079313","Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia",[89],"2006-12-30","2010-10-25","2004-01-14",[2414,543],[5035],{"trials":5061,"activeCount":100},[],{"trials":5063,"activeCount":100},[],{"trials":5065,"activeCount":100},[],{"intervention":5067,"totalTrials":843,"cells":5068},"AMD3100",{"EARLY_PHASE1":5069,"PHASE1":5071,"PHASE2":5083,"PHASE3":5094,"PHASE4":5096,"NA":5098},{"trials":5070,"activeCount":100},[],{"trials":5072,"activeCount":100},[5073],{"nctId":5074,"briefTitle":5075,"status":496,"phases":5076,"primaryCompletion":5077,"completion":5077,"start":5078,"enrollment":5079,"conditions":5080,"interventions":5082},"NCT00322127","An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers",[88],"2015-01-23","2006-06-14",44,[5081],"Healthy Volunteers",[5067],{"trials":5084,"activeCount":100},[5085],{"nctId":5086,"briefTitle":5087,"status":496,"phases":5088,"primaryCompletion":5089,"completion":5089,"start":5090,"enrollment":5091,"conditions":5092,"interventions":5093},"NCT00075335","AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation",[89],"2012-08","2004-01",8,[2272],[5067],{"trials":5095,"activeCount":100},[],{"trials":5097,"activeCount":100},[],{"trials":5099,"activeCount":100},[],{"intervention":5101,"totalTrials":843,"cells":5102},"Daclizumab",{"EARLY_PHASE1":5103,"PHASE1":5105,"PHASE2":5107,"PHASE3":5127,"PHASE4":5129,"NA":5131},{"trials":5104,"activeCount":100},[],{"trials":5106,"activeCount":100},[],{"trials":5108,"activeCount":100},[5109,5117],{"nctId":5110,"briefTitle":5111,"status":496,"phases":5112,"completion":5113,"start":4130,"enrollment":5114,"conditions":5115,"interventions":5116},"NCT00072969","A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)",[89],"2005-08",132,[676],[5101],{"nctId":5118,"briefTitle":5119,"status":467,"phases":5120,"primaryCompletion":5121,"completion":5122,"start":5123,"enrollment":1537,"conditions":5124,"interventions":5126},"NCT00001962","A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure",[89],"2009-08","2010-09","1999-11",[530,5125,1902],"Pure Red Cell Aplasia",[5101],{"trials":5128,"activeCount":100},[],{"trials":5130,"activeCount":100},[],{"trials":5132,"activeCount":100},[],{"intervention":1201,"totalTrials":843,"cells":5134},{"EARLY_PHASE1":5135,"PHASE1":5137,"PHASE2":5139,"PHASE3":5155,"PHASE4":5157,"NA":5159},{"trials":5136,"activeCount":100},[],{"trials":5138,"activeCount":100},[],{"trials":5140,"activeCount":100},[5141,5151],{"nctId":5142,"briefTitle":5143,"status":496,"phases":5144,"primaryCompletion":5145,"completion":5145,"start":5146,"enrollment":647,"conditions":5147,"interventions":5149},"NCT02996474","Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia",[88,89],"2019-04-02","2016-12-16",[5148],"Relapsed Acute Myeloid Leukemia",[1201,5150],"Decitabine",{"nctId":1185,"briefTitle":1186,"status":496,"phases":5152,"primaryCompletion":1188,"completion":1189,"start":1190,"enrollment":797,"conditions":5153,"interventions":5154},[89],[1192,1193,545,1194,1195,1196,1197,1198,1199],[57,534,1201],{"trials":5156,"activeCount":100},[],{"trials":5158,"activeCount":100},[],{"trials":5160,"activeCount":100},[],{"intervention":5150,"totalTrials":843,"cells":5162},{"EARLY_PHASE1":5163,"PHASE1":5165,"PHASE2":5167,"PHASE3":5181,"PHASE4":5183,"NA":5185},{"trials":5164,"activeCount":100},[],{"trials":5166,"activeCount":100},[],{"trials":5168,"activeCount":100},[5169,5173],{"nctId":5142,"briefTitle":5143,"status":496,"phases":5170,"primaryCompletion":5145,"completion":5145,"start":5146,"enrollment":647,"conditions":5171,"interventions":5172},[88,89],[5148],[1201,5150],{"nctId":5174,"briefTitle":5175,"status":496,"phases":5176,"primaryCompletion":1132,"completion":5177,"start":5178,"enrollment":647,"conditions":5179,"interventions":5180},"NCT01375608","Decitabine for High-Risk Sickle Cell Disease",[89],"2016-02","2011-06",[531,389],[5150],{"trials":5182,"activeCount":100},[],{"trials":5184,"activeCount":100},[],{"trials":5186,"activeCount":100},[],{"intervention":5188,"totalTrials":843,"cells":5189},"Sildenafil",{"EARLY_PHASE1":5190,"PHASE1":5192,"PHASE2":5194,"PHASE3":5213,"PHASE4":5215,"NA":5217},{"trials":5191,"activeCount":100},[],{"trials":5193,"activeCount":100},[],{"trials":5195,"activeCount":100},[5196,5205],{"nctId":5197,"briefTitle":5198,"status":496,"phases":5199,"completion":5200,"start":5201,"enrollment":1891,"conditions":5202,"interventions":5204},"NCT00352482","Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension",[89],"2007-07","2004-11",[578,5203],"Hypertension, Pulmonary",[5188],{"nctId":5206,"briefTitle":5207,"status":467,"phases":5208,"primaryCompletion":998,"completion":5209,"start":4922,"enrollment":5210,"conditions":5211,"interventions":5212},"NCT00492531","Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease",[89],"2009-10",74,[389,942],[5188],{"trials":5214,"activeCount":100},[],{"trials":5216,"activeCount":100},[],{"trials":5218,"activeCount":100},[],{"intervention":569,"totalTrials":843,"cells":5220},{"EARLY_PHASE1":5221,"PHASE1":5223,"PHASE2":5225,"PHASE3":5235,"PHASE4":5237,"NA":5239},{"trials":5222,"activeCount":100},[],{"trials":5224,"activeCount":100},[],{"trials":5226,"activeCount":100},[5227,5231],{"nctId":559,"briefTitle":560,"status":467,"phases":5228,"completion":562,"start":563,"conditions":5229,"interventions":5230},[88,89],[565,566],[568,569,475,570],{"nctId":714,"briefTitle":715,"status":496,"phases":5232,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":5233,"interventions":5234},[89],[721,722,532,531],[724,724,549,52],{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[],{"trials":5240,"activeCount":100},[],{"intervention":1176,"totalTrials":843,"cells":5242},{"EARLY_PHASE1":5243,"PHASE1":5245,"PHASE2":5247,"PHASE3":5257,"PHASE4":5259,"NA":5261},{"trials":5244,"activeCount":100},[],{"trials":5246,"activeCount":100},[],{"trials":5248,"activeCount":100},[5249,5253],{"nctId":2422,"briefTitle":2423,"status":496,"phases":5250,"primaryCompletion":2425,"completion":2426,"start":2427,"enrollment":2428,"conditions":5251,"interventions":5252},[89],[1174],[1176,2431,2432,2399],{"nctId":1169,"briefTitle":1170,"status":496,"phases":5254,"primaryCompletion":1172,"completion":1172,"start":638,"enrollment":433,"conditions":5255,"interventions":5256},[89],[1174],[534,1176,601,1177],{"trials":5258,"activeCount":100},[],{"trials":5260,"activeCount":100},[],{"trials":5262,"activeCount":100},[],{"intervention":5264,"totalTrials":96,"cells":5265},"Roflumilast",{"EARLY_PHASE1":5266,"PHASE1":5268,"PHASE2":5270,"PHASE3":5280,"PHASE4":5282,"NA":5284},{"trials":5267,"activeCount":100},[],{"trials":5269,"activeCount":100},[],{"trials":5271,"activeCount":100},[5272],{"nctId":5273,"briefTitle":5274,"status":496,"phases":5275,"primaryCompletion":1252,"completion":1252,"start":5276,"enrollment":5277,"conditions":5278,"interventions":5279},"NCT01862029","Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals",[88,89],"2013-05-22",24,[35],[5264],{"trials":5281,"activeCount":100},[],{"trials":5283,"activeCount":100},[],{"trials":5285,"activeCount":100},[],{"intervention":479,"totalTrials":96,"cells":5287},{"EARLY_PHASE1":5288,"PHASE1":5290,"PHASE2":5292,"PHASE3":5298,"PHASE4":5300,"NA":5302},{"trials":5289,"activeCount":100},[],{"trials":5291,"activeCount":100},[],{"trials":5293,"activeCount":100},[5294],{"nctId":465,"briefTitle":466,"status":467,"phases":5295,"completion":469,"enrollment":11,"conditions":5296,"interventions":5297},[89],[471,472,473],[475,476,477,478,479,480],{"trials":5299,"activeCount":100},[],{"trials":5301,"activeCount":100},[],{"trials":5303,"activeCount":100},[],{"intervention":480,"totalTrials":96,"cells":5305},{"EARLY_PHASE1":5306,"PHASE1":5308,"PHASE2":5310,"PHASE3":5316,"PHASE4":5318,"NA":5320},{"trials":5307,"activeCount":100},[],{"trials":5309,"activeCount":100},[],{"trials":5311,"activeCount":100},[5312],{"nctId":465,"briefTitle":466,"status":467,"phases":5313,"completion":469,"enrollment":11,"conditions":5314,"interventions":5315},[89],[471,472,473],[475,476,477,478,479,480],{"trials":5317,"activeCount":100},[],{"trials":5319,"activeCount":100},[],{"trials":5321,"activeCount":100},[],{"intervention":1057,"totalTrials":96,"cells":5323},{"EARLY_PHASE1":5324,"PHASE1":5326,"PHASE2":5328,"PHASE3":5334,"PHASE4":5336,"NA":5338},{"trials":5325,"activeCount":100},[],{"trials":5327,"activeCount":100},[],{"trials":5329,"activeCount":100},[5330],{"nctId":1049,"briefTitle":1050,"status":496,"phases":5331,"completion":1052,"start":1053,"conditions":5332,"interventions":5333},[89],[27],[476,1056,581,1057],{"trials":5335,"activeCount":100},[],{"trials":5337,"activeCount":100},[],{"trials":5339,"activeCount":100},[],{"intervention":5341,"totalTrials":96,"cells":5342},"AMD 3100",{"EARLY_PHASE1":5343,"PHASE1":5345,"PHASE2":5347,"PHASE3":5359,"PHASE4":5361,"NA":5363},{"trials":5344,"activeCount":100},[],{"trials":5346,"activeCount":100},[],{"trials":5348,"activeCount":100},[5349],{"nctId":5350,"briefTitle":5351,"status":496,"phases":5352,"primaryCompletion":5353,"completion":5353,"start":5354,"enrollment":5355,"conditions":5356,"interventions":5357},"NCT00082329","G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers",[89],"2012-10-25","2004-06-18",9,[2272],[5341,5358],"Granulocyte colony-stimulating factor",{"trials":5360,"activeCount":100},[],{"trials":5362,"activeCount":100},[],{"trials":5364,"activeCount":100},[],{"intervention":5358,"totalTrials":96,"cells":5366},{"EARLY_PHASE1":5367,"PHASE1":5369,"PHASE2":5371,"PHASE3":5377,"PHASE4":5379,"NA":5381},{"trials":5368,"activeCount":100},[],{"trials":5370,"activeCount":100},[],{"trials":5372,"activeCount":100},[5373],{"nctId":5350,"briefTitle":5351,"status":496,"phases":5374,"primaryCompletion":5353,"completion":5353,"start":5354,"enrollment":5355,"conditions":5375,"interventions":5376},[89],[2272],[5341,5358],{"trials":5378,"activeCount":100},[],{"trials":5380,"activeCount":100},[],{"trials":5382,"activeCount":100},[],{"intervention":5384,"totalTrials":96,"cells":5385},"Pioglitazone Hydrochloride",{"EARLY_PHASE1":5386,"PHASE1":5388,"PHASE2":5390,"PHASE3":5403,"PHASE4":5405,"NA":5407},{"trials":5387,"activeCount":100},[],{"trials":5389,"activeCount":100},[],{"trials":5391,"activeCount":100},[5392],{"nctId":5393,"briefTitle":5394,"status":937,"phases":5395,"primaryCompletion":5396,"completion":5396,"start":5397,"enrollment":100,"conditions":5398,"interventions":5402},"NCT00604578","Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma",[89],"2009-10-30","2008-01-04",[33,5399,5400,5401],"Airway Inflammation","Airflow Obstruction","Airway Hyperactivity",[5384],{"trials":5404,"activeCount":100},[],{"trials":5406,"activeCount":100},[],{"trials":5408,"activeCount":100},[],{"intervention":4925,"totalTrials":96,"cells":5410},{"EARLY_PHASE1":5411,"PHASE1":5413,"PHASE2":5415,"PHASE3":5421,"PHASE4":5423,"NA":5425},{"trials":5412,"activeCount":100},[],{"trials":5414,"activeCount":100},[],{"trials":5416,"activeCount":100},[5417],{"nctId":4918,"briefTitle":4919,"status":496,"phases":5418,"primaryCompletion":4921,"completion":4921,"start":4922,"enrollment":647,"conditions":5419,"interventions":5420},[89],[1377,2416,4780],[4925,4926,2432,4927],{"trials":5422,"activeCount":100},[],{"trials":5424,"activeCount":100},[],{"trials":5426,"activeCount":100},[],{"intervention":4926,"totalTrials":96,"cells":5428},{"EARLY_PHASE1":5429,"PHASE1":5431,"PHASE2":5433,"PHASE3":5439,"PHASE4":5441,"NA":5443},{"trials":5430,"activeCount":100},[],{"trials":5432,"activeCount":100},[],{"trials":5434,"activeCount":100},[5435],{"nctId":4918,"briefTitle":4919,"status":496,"phases":5436,"primaryCompletion":4921,"completion":4921,"start":4922,"enrollment":647,"conditions":5437,"interventions":5438},[89],[1377,2416,4780],[4925,4926,2432,4927],{"trials":5440,"activeCount":100},[],{"trials":5442,"activeCount":100},[],{"trials":5444,"activeCount":100},[],{"intervention":4927,"totalTrials":96,"cells":5446},{"EARLY_PHASE1":5447,"PHASE1":5449,"PHASE2":5451,"PHASE3":5457,"PHASE4":5459,"NA":5461},{"trials":5448,"activeCount":100},[],{"trials":5450,"activeCount":100},[],{"trials":5452,"activeCount":100},[5453],{"nctId":4918,"briefTitle":4919,"status":496,"phases":5454,"primaryCompletion":4921,"completion":4921,"start":4922,"enrollment":647,"conditions":5455,"interventions":5456},[89],[1377,2416,4780],[4925,4926,2432,4927],{"trials":5458,"activeCount":100},[],{"trials":5460,"activeCount":100},[],{"trials":5462,"activeCount":100},[],{"intervention":5464,"totalTrials":96,"cells":5465},"Miltenyi system",{"EARLY_PHASE1":5466,"PHASE1":5468,"PHASE2":5470,"PHASE3":5485,"PHASE4":5487,"NA":5489},{"trials":5467,"activeCount":100},[],{"trials":5469,"activeCount":100},[],{"trials":5471,"activeCount":100},[5472],{"nctId":5473,"briefTitle":5474,"status":496,"phases":5475,"primaryCompletion":5476,"completion":5476,"start":5477,"enrollment":5478,"conditions":5479,"interventions":5484},"NCT00467961","Stem Cell Transplantation for Patients With Cancers of the Blood",[89],"2012-11","2007-04",61,[5480,519,5481,5482,5483],"CML (Chronic Myelogenous Leukemia)","AML (Acute Myelogenous Leukemia)","Acute Lymphocytic Leukemia","MDS (Myelodysplastic Syndrome)",[5464],{"trials":5486,"activeCount":100},[],{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[],{"intervention":1226,"totalTrials":96,"cells":5492},{"EARLY_PHASE1":5493,"PHASE1":5495,"PHASE2":5497,"PHASE3":5503,"PHASE4":5505,"NA":5507},{"trials":5494,"activeCount":100},[],{"trials":5496,"activeCount":100},[],{"trials":5498,"activeCount":100},[5499],{"nctId":1217,"briefTitle":1218,"status":467,"phases":5500,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":851,"conditions":5501,"interventions":5502},[89],[1223,1224],[1226,57],{"trials":5504,"activeCount":100},[],{"trials":5506,"activeCount":100},[],{"trials":5508,"activeCount":100},[],{"intervention":5510,"totalTrials":96,"cells":5511},"fenfluramine",{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5516,"PHASE3":5526,"PHASE4":5528,"NA":5530},{"trials":5513,"activeCount":100},[],{"trials":5515,"activeCount":100},[],{"trials":5517,"activeCount":100},[5518],{"nctId":5519,"briefTitle":5520,"status":496,"phases":5521,"completion":5522,"start":2154,"conditions":5523,"interventions":5524},"NCT00000506","Cardiovascular System in Obesity: Effect of Treatment",[89],"1988-04",[18,35,2104],[5510,5525],"phentermine",{"trials":5527,"activeCount":100},[],{"trials":5529,"activeCount":100},[],{"trials":5531,"activeCount":100},[],{"intervention":5525,"totalTrials":96,"cells":5533},{"EARLY_PHASE1":5534,"PHASE1":5536,"PHASE2":5538,"PHASE3":5544,"PHASE4":5546,"NA":5548},{"trials":5535,"activeCount":100},[],{"trials":5537,"activeCount":100},[],{"trials":5539,"activeCount":100},[5540],{"nctId":5519,"briefTitle":5520,"status":496,"phases":5541,"completion":5522,"start":2154,"conditions":5542,"interventions":5543},[89],[18,35,2104],[5510,5525],{"trials":5545,"activeCount":100},[],{"trials":5547,"activeCount":100},[],{"trials":5549,"activeCount":100},[],{"intervention":5551,"totalTrials":96,"cells":5552},"L-NMMA and Sodium Nitrite",{"EARLY_PHASE1":5553,"PHASE1":5555,"PHASE2":5557,"PHASE3":5567,"PHASE4":5569,"NA":5571},{"trials":5554,"activeCount":100},[],{"trials":5556,"activeCount":100},[],{"trials":5558,"activeCount":100},[5559],{"nctId":5560,"briefTitle":5561,"status":496,"phases":5562,"completion":4130,"start":562,"enrollment":2330,"conditions":5563,"interventions":5566},"NCT00048477","Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers",[89],[5564,5565,2272],"Nitric Oxide","Endothelium-Derived Relaxing Factor",[5551],{"trials":5568,"activeCount":100},[],{"trials":5570,"activeCount":100},[],{"trials":5572,"activeCount":100},[],{"intervention":5574,"totalTrials":96,"cells":5575},"Sirolimus 2mg",{"EARLY_PHASE1":5576,"PHASE1":5578,"PHASE2":5580,"PHASE3":5591,"PHASE4":5593,"NA":5595},{"trials":5577,"activeCount":100},[],{"trials":5579,"activeCount":100},[],{"trials":5581,"activeCount":100},[5582],{"nctId":5583,"briefTitle":5584,"status":496,"phases":5585,"primaryCompletion":5586,"completion":5587,"start":5588,"enrollment":501,"conditions":5589,"interventions":5590},"NCT03304678","Discovery of Sirolimus Sensitive Biomarkers in Blood",[89],"2025-03-09","2025-03-14","2017-12-04",[1539],[5574],{"trials":5592,"activeCount":100},[],{"trials":5594,"activeCount":100},[],{"trials":5596,"activeCount":100},[],{"intervention":5598,"totalTrials":96,"cells":5599},"Avandia",{"EARLY_PHASE1":5600,"PHASE1":5602,"PHASE2":5604,"PHASE3":5617,"PHASE4":5619,"NA":5621},{"trials":5601,"activeCount":100},[],{"trials":5603,"activeCount":100},[],{"trials":5605,"activeCount":100},[5606],{"nctId":5607,"briefTitle":5608,"status":496,"phases":5609,"completion":5610,"start":5611,"enrollment":5612,"conditions":5613,"interventions":5615},"NCT00064727","Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes",[89],"2007-04-11","2003-07-09",50,[5614],"Congestive Heart Failure",[5598,5616],"Avanclia",{"trials":5618,"activeCount":100},[],{"trials":5620,"activeCount":100},[],{"trials":5622,"activeCount":100},[],{"intervention":5616,"totalTrials":96,"cells":5624},{"EARLY_PHASE1":5625,"PHASE1":5627,"PHASE2":5629,"PHASE3":5635,"PHASE4":5637,"NA":5639},{"trials":5626,"activeCount":100},[],{"trials":5628,"activeCount":100},[],{"trials":5630,"activeCount":100},[5631],{"nctId":5607,"briefTitle":5608,"status":496,"phases":5632,"completion":5610,"start":5611,"enrollment":5612,"conditions":5633,"interventions":5634},[89],[5614],[5598,5616],{"trials":5636,"activeCount":100},[],{"trials":5638,"activeCount":100},[],{"trials":5640,"activeCount":100},[],{"intervention":5642,"totalTrials":96,"cells":5643},"ATG+Rapamune+cyclosporine",{"EARLY_PHASE1":5644,"PHASE1":5646,"PHASE2":5648,"PHASE3":5661,"PHASE4":5663,"NA":5665},{"trials":5645,"activeCount":100},[],{"trials":5647,"activeCount":100},[],{"trials":5649,"activeCount":100},[5650],{"nctId":5651,"briefTitle":5652,"status":496,"phases":5653,"primaryCompletion":5654,"completion":5655,"start":5656,"enrollment":5657,"conditions":5658,"interventions":5659},"NCT00061360","Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia",[89],"2006-02-15","2015-09-08","2003-06-26",77,[381],[5642,5660],"ATG+cyclosporine",{"trials":5662,"activeCount":100},[],{"trials":5664,"activeCount":100},[],{"trials":5666,"activeCount":100},[],{"intervention":5660,"totalTrials":96,"cells":5668},{"EARLY_PHASE1":5669,"PHASE1":5671,"PHASE2":5673,"PHASE3":5679,"PHASE4":5681,"NA":5683},{"trials":5670,"activeCount":100},[],{"trials":5672,"activeCount":100},[],{"trials":5674,"activeCount":100},[5675],{"nctId":5651,"briefTitle":5652,"status":496,"phases":5676,"primaryCompletion":5654,"completion":5655,"start":5656,"enrollment":5657,"conditions":5677,"interventions":5678},[89],[381],[5642,5660],{"trials":5680,"activeCount":100},[],{"trials":5682,"activeCount":100},[],{"trials":5684,"activeCount":100},[],{"intervention":4729,"totalTrials":96,"cells":5686},{"EARLY_PHASE1":5687,"PHASE1":5689,"PHASE2":5691,"PHASE3":5697,"PHASE4":5699,"NA":5701},{"trials":5688,"activeCount":100},[],{"trials":5690,"activeCount":100},[],{"trials":5692,"activeCount":100},[5693],{"nctId":4721,"briefTitle":4722,"status":496,"phases":5694,"primaryCompletion":4724,"completion":4725,"start":4726,"enrollment":620,"conditions":5695,"interventions":5696},[89],[389],[4729,4695,4680],{"trials":5698,"activeCount":100},[],{"trials":5700,"activeCount":100},[],{"trials":5702,"activeCount":100},[],{"intervention":5704,"totalTrials":96,"cells":5705},"Alpha cyclodextrin",{"EARLY_PHASE1":5706,"PHASE1":5708,"PHASE2":5710,"PHASE3":5721,"PHASE4":5723,"NA":5725},{"trials":5707,"activeCount":100},[],{"trials":5709,"activeCount":100},[],{"trials":5711,"activeCount":100},[5712],{"nctId":5713,"briefTitle":5714,"status":496,"phases":5715,"primaryCompletion":5716,"completion":5716,"start":5717,"enrollment":5718,"conditions":5719,"interventions":5720},"NCT01131299","Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol",[89],"2015-02","2010-03",103,[1471],[5704],{"trials":5722,"activeCount":100},[],{"trials":5724,"activeCount":100},[],{"trials":5726,"activeCount":100},[],{"intervention":5728,"totalTrials":96,"cells":5729},"Isoquercetin",{"EARLY_PHASE1":5730,"PHASE1":5732,"PHASE2":5734,"PHASE3":5746,"PHASE4":5748,"NA":5750},{"trials":5731,"activeCount":100},[],{"trials":5733,"activeCount":100},[],{"trials":5735,"activeCount":100},[5736],{"nctId":5737,"briefTitle":5738,"status":496,"phases":5739,"primaryCompletion":5740,"completion":5741,"start":5742,"enrollment":5743,"conditions":5744,"interventions":5745},"NCT04514510","Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease",[89],"2022-06-13","2022-07-07","2020-11-02",46,[389],[5728],{"trials":5747,"activeCount":100},[],{"trials":5749,"activeCount":100},[],{"trials":5751,"activeCount":100},[],{"intervention":5753,"totalTrials":96,"cells":5754},"RFT5-SMPT-dgA",{"EARLY_PHASE1":5755,"PHASE1":5757,"PHASE2":5759,"PHASE3":5775,"PHASE4":5777,"NA":5779},{"trials":5756,"activeCount":100},[],{"trials":5758,"activeCount":100},[],{"trials":5760,"activeCount":100},[5761],{"nctId":5762,"briefTitle":5763,"status":496,"phases":5764,"primaryCompletion":5765,"completion":5765,"start":5766,"enrollment":401,"conditions":5767,"interventions":5773},"NCT00025662","Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS",[89],"2008-02","2001-05",[392,676,472,5768,5769,5770,118,5771,4654,5772],"Leukemia, Myeloid","Leukemia, Myelomonocytic, Chronic","Leukemia, Lymphocytic","Lymphoma, Mantle-cell","Hodgkin Disease",[5753,5774],"Isolex system",{"trials":5776,"activeCount":100},[],{"trials":5778,"activeCount":100},[],{"trials":5780,"activeCount":100},[],{"intervention":5774,"totalTrials":96,"cells":5782},{"EARLY_PHASE1":5783,"PHASE1":5785,"PHASE2":5787,"PHASE3":5793,"PHASE4":5795,"NA":5797},{"trials":5784,"activeCount":100},[],{"trials":5786,"activeCount":100},[],{"trials":5788,"activeCount":100},[5789],{"nctId":5762,"briefTitle":5763,"status":496,"phases":5790,"primaryCompletion":5765,"completion":5765,"start":5766,"enrollment":401,"conditions":5791,"interventions":5792},[89],[392,676,472,5768,5769,5770,118,5771,4654,5772],[5753,5774],{"trials":5794,"activeCount":100},[],{"trials":5796,"activeCount":100},[],{"trials":5798,"activeCount":100},[],{"intervention":5800,"totalTrials":96,"cells":5801},"Metoclopramide",{"EARLY_PHASE1":5802,"PHASE1":5804,"PHASE2":5806,"PHASE3":5816,"PHASE4":5818,"NA":5820},{"trials":5803,"activeCount":100},[],{"trials":5805,"activeCount":100},[],{"trials":5807,"activeCount":100},[5808],{"nctId":5809,"briefTitle":5810,"status":937,"phases":5811,"completion":5812,"start":5813,"enrollment":100,"conditions":5814,"interventions":5815},"NCT00120653","Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS)",[89],"2008-06-17","2005-07-14",[676],[5800],{"trials":5817,"activeCount":100},[],{"trials":5819,"activeCount":100},[],{"trials":5821,"activeCount":100},[],{"intervention":5823,"totalTrials":96,"cells":5824},"Ramipril",{"EARLY_PHASE1":5825,"PHASE1":5827,"PHASE2":5829,"PHASE3":5839,"PHASE4":5841,"NA":5843},{"trials":5826,"activeCount":100},[],{"trials":5828,"activeCount":100},[],{"trials":5830,"activeCount":100},[5831],{"nctId":5832,"briefTitle":5833,"status":496,"phases":5834,"completion":5835,"start":1067,"enrollment":778,"conditions":5836,"interventions":5838},"NCT00005928","Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation",[89],"2002-02",[30,21,5837],"Vasculitis",[5823],{"trials":5840,"activeCount":100},[],{"trials":5842,"activeCount":100},[],{"trials":5844,"activeCount":100},[],{"intervention":522,"totalTrials":96,"cells":5846},{"EARLY_PHASE1":5847,"PHASE1":5849,"PHASE2":5851,"PHASE3":5857,"PHASE4":5859,"NA":5861},{"trials":5848,"activeCount":100},[],{"trials":5850,"activeCount":100},[],{"trials":5852,"activeCount":100},[5853],{"nctId":510,"briefTitle":511,"status":496,"phases":5854,"primaryCompletion":513,"completion":514,"start":515,"enrollment":516,"conditions":5855,"interventions":5856},[89],[518,519],[521,522,394],{"trials":5858,"activeCount":100},[],{"trials":5860,"activeCount":100},[],{"trials":5862,"activeCount":100},[],{"intervention":2159,"totalTrials":96,"cells":5864},{"EARLY_PHASE1":5865,"PHASE1":5867,"PHASE2":5869,"PHASE3":5875,"PHASE4":5877,"NA":5879},{"trials":5866,"activeCount":100},[],{"trials":5868,"activeCount":100},[],{"trials":5870,"activeCount":100},[5871],{"nctId":2151,"briefTitle":2152,"status":496,"phases":5872,"completion":2154,"start":2155,"conditions":5873,"interventions":5874},[89],[15,18,24,2104],[2142,2158,2159,2160],{"trials":5876,"activeCount":100},[],{"trials":5878,"activeCount":100},[],{"trials":5880,"activeCount":100},[],{"intervention":2160,"totalTrials":96,"cells":5882},{"EARLY_PHASE1":5883,"PHASE1":5885,"PHASE2":5887,"PHASE3":5893,"PHASE4":5895,"NA":5897},{"trials":5884,"activeCount":100},[],{"trials":5886,"activeCount":100},[],{"trials":5888,"activeCount":100},[5889],{"nctId":2151,"briefTitle":2152,"status":496,"phases":5890,"completion":2154,"start":2155,"conditions":5891,"interventions":5892},[89],[15,18,24,2104],[2142,2158,2159,2160],{"trials":5894,"activeCount":100},[],{"trials":5896,"activeCount":100},[],{"trials":5898,"activeCount":100},[],{"intervention":5900,"totalTrials":96,"cells":5901},"Pioglitazone",{"EARLY_PHASE1":5902,"PHASE1":5904,"PHASE2":5906,"PHASE3":5917,"PHASE4":5919,"NA":5921},{"trials":5903,"activeCount":100},[],{"trials":5905,"activeCount":100},[],{"trials":5907,"activeCount":100},[5908],{"nctId":5909,"briefTitle":5910,"status":496,"phases":5911,"primaryCompletion":5912,"completion":5912,"start":5913,"enrollment":797,"conditions":5914,"interventions":5916},"NCT00994175","A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma",[89],"2016-06-24","2009-09-23",[5915,5399,5400],"Severe, Refractory Asthma",[5900],{"trials":5918,"activeCount":100},[],{"trials":5920,"activeCount":100},[],{"trials":5922,"activeCount":100},[],{"intervention":5924,"totalTrials":96,"cells":5925},"Nitric Oxide and INOpulse Delivery System",{"EARLY_PHASE1":5926,"PHASE1":5928,"PHASE2":5930,"PHASE3":5940,"PHASE4":5942,"NA":5944},{"trials":5927,"activeCount":100},[],{"trials":5929,"activeCount":100},[],{"trials":5931,"activeCount":100},[5932],{"nctId":5933,"briefTitle":5934,"status":496,"phases":5935,"completion":5936,"start":5937,"enrollment":778,"conditions":5938,"interventions":5939},"NCT00014040","Nitric Oxide Inhalation Therapy to Relieve Chest Pain in Patients With Coronary Artery Disease",[89],"2003-04","2001-04",[21,2117],[5924],{"trials":5941,"activeCount":100},[],{"trials":5943,"activeCount":100},[],{"trials":5945,"activeCount":100},[],{"intervention":5947,"totalTrials":96,"cells":5948},"HEPLISAV-B",{"EARLY_PHASE1":5949,"PHASE1":5951,"PHASE2":5953,"PHASE3":5966,"PHASE4":5968,"NA":5970},{"trials":5950,"activeCount":100},[],{"trials":5952,"activeCount":100},[],{"trials":5954,"activeCount":100},[5955],{"nctId":5956,"briefTitle":5957,"status":496,"phases":5958,"primaryCompletion":5959,"completion":5959,"start":5960,"enrollment":5961,"conditions":5962,"interventions":5965},"NCT03685708","HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)",[89],"2020-12-16","2018-12-07",78,[5963,5964],"Hepatitis","Safety and Tolerability",[5947],{"trials":5967,"activeCount":100},[],{"trials":5969,"activeCount":100},[],{"trials":5971,"activeCount":100},[],{"intervention":5004,"totalTrials":96,"cells":5973},{"EARLY_PHASE1":5974,"PHASE1":5976,"PHASE2":5978,"PHASE3":5984,"PHASE4":5986,"NA":5988},{"trials":5975,"activeCount":100},[],{"trials":5977,"activeCount":100},[],{"trials":5979,"activeCount":100},[5980],{"nctId":4995,"briefTitle":4996,"status":496,"phases":5981,"primaryCompletion":4998,"completion":4999,"start":5000,"enrollment":5001,"conditions":5982,"interventions":5983},[89],[381],[4977,5004,5005],{"trials":5985,"activeCount":100},[],{"trials":5987,"activeCount":100},[],{"trials":5989,"activeCount":100},[],{"intervention":5005,"totalTrials":96,"cells":5991},{"EARLY_PHASE1":5992,"PHASE1":5994,"PHASE2":5996,"PHASE3":6002,"PHASE4":6004,"NA":6006},{"trials":5993,"activeCount":100},[],{"trials":5995,"activeCount":100},[],{"trials":5997,"activeCount":100},[5998],{"nctId":4995,"briefTitle":4996,"status":496,"phases":5999,"primaryCompletion":4998,"completion":4999,"start":5000,"enrollment":5001,"conditions":6000,"interventions":6001},[89],[381],[4977,5004,5005],{"trials":6003,"activeCount":100},[],{"trials":6005,"activeCount":100},[],{"trials":6007,"activeCount":100},[],{"intervention":6009,"totalTrials":96,"cells":6010},"MSC",{"EARLY_PHASE1":6011,"PHASE1":6013,"PHASE2":6015,"PHASE3":6025,"PHASE4":6027,"NA":6029},{"trials":6012,"activeCount":100},[],{"trials":6014,"activeCount":100},[],{"trials":6016,"activeCount":100},[6017],{"nctId":6018,"briefTitle":6019,"status":467,"phases":6020,"primaryCompletion":6021,"completion":6021,"start":6022,"enrollment":96,"conditions":6023,"interventions":6024},"NCT02379442","Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids",[88,89],"2017-12-13","2015-02-23",[1920],[6009],{"trials":6026,"activeCount":100},[],{"trials":6028,"activeCount":100},[],{"trials":6030,"activeCount":100},[],{"intervention":6032,"totalTrials":96,"cells":6033},"Etidronate",{"EARLY_PHASE1":6034,"PHASE1":6036,"PHASE2":6038,"PHASE3":6050,"PHASE4":6052,"NA":6054},{"trials":6035,"activeCount":100},[],{"trials":6037,"activeCount":100},[],{"trials":6039,"activeCount":100},[6040],{"nctId":6041,"briefTitle":6042,"status":496,"phases":6043,"primaryCompletion":6044,"completion":6044,"start":6045,"enrollment":363,"conditions":6046,"interventions":6049},"NCT01585402","Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)",[89],"2021-08-06","2012-08-20",[6047,6048],"Arterial Calcification","CD73 Deficiency",[6032],{"trials":6051,"activeCount":100},[],{"trials":6053,"activeCount":100},[],{"trials":6055,"activeCount":100},[],{"intervention":6057,"totalTrials":96,"cells":6058},"sargramostim",{"EARLY_PHASE1":6059,"PHASE1":6061,"PHASE2":6063,"PHASE3":6073,"PHASE4":6075,"NA":6077},{"trials":6060,"activeCount":100},[],{"trials":6062,"activeCount":100},[],{"trials":6064,"activeCount":100},[6065],{"nctId":6066,"briefTitle":6067,"status":496,"phases":6068,"completion":2682,"start":2298,"conditions":6069,"interventions":6070},"NCT00006240","Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia",[89],[472],[6057,6071,6072],"dexamethasone","oral sodium phenylbutyrate",{"trials":6074,"activeCount":100},[],{"trials":6076,"activeCount":100},[],{"trials":6078,"activeCount":100},[],{"intervention":6072,"totalTrials":96,"cells":6080},{"EARLY_PHASE1":6081,"PHASE1":6083,"PHASE2":6085,"PHASE3":6091,"PHASE4":6093,"NA":6095},{"trials":6082,"activeCount":100},[],{"trials":6084,"activeCount":100},[],{"trials":6086,"activeCount":100},[6087],{"nctId":6066,"briefTitle":6067,"status":496,"phases":6088,"completion":2682,"start":2298,"conditions":6089,"interventions":6090},[89],[472],[6057,6071,6072],{"trials":6092,"activeCount":100},[],{"trials":6094,"activeCount":100},[],{"trials":6096,"activeCount":100},[],{"intervention":875,"totalTrials":96,"cells":6098},{"EARLY_PHASE1":6099,"PHASE1":6101,"PHASE2":6103,"PHASE3":6109,"PHASE4":6111,"NA":6113},{"trials":6100,"activeCount":100},[],{"trials":6102,"activeCount":100},[],{"trials":6104,"activeCount":100},[6105],{"nctId":864,"briefTitle":865,"status":496,"phases":6106,"primaryCompletion":867,"completion":868,"start":869,"enrollment":870,"conditions":6107,"interventions":6108},[89],[392,872],[874,629,875,395],{"trials":6110,"activeCount":100},[],{"trials":6112,"activeCount":100},[],{"trials":6114,"activeCount":100},[],{"intervention":1088,"totalTrials":96,"cells":6116},{"EARLY_PHASE1":6117,"PHASE1":6119,"PHASE2":6121,"PHASE3":6127,"PHASE4":6129,"NA":6131},{"trials":6118,"activeCount":100},[],{"trials":6120,"activeCount":100},[],{"trials":6122,"activeCount":100},[6123],{"nctId":1079,"briefTitle":1080,"status":496,"phases":6124,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":630,"conditions":6125,"interventions":6126},[88,89],[1085,1086],[476,570,1088],{"trials":6128,"activeCount":100},[],{"trials":6130,"activeCount":100},[],{"trials":6132,"activeCount":100},[],{"intervention":6134,"totalTrials":96,"cells":6135},"Dapagliflozin",{"EARLY_PHASE1":6136,"PHASE1":6138,"PHASE2":6140,"PHASE3":6151,"PHASE4":6153,"NA":6155},{"trials":6137,"activeCount":100},[],{"trials":6139,"activeCount":100},[],{"trials":6141,"activeCount":100},[6142],{"nctId":6143,"briefTitle":6144,"status":937,"phases":6145,"primaryCompletion":6146,"completion":6146,"start":6146,"enrollment":100,"conditions":6147,"interventions":6150},"NCT05330013","The Effect of Inflammation in Heart Failure",[89],"2022-06-23",[6148,2179,6149],"Myocardial Dysfunction","Inflammation",[6134],{"trials":6152,"activeCount":100},[],{"trials":6154,"activeCount":100},[],{"trials":6156,"activeCount":100},[],{"intervention":6158,"totalTrials":96,"cells":6159},"Rilonacept",{"EARLY_PHASE1":6160,"PHASE1":6162,"PHASE2":6164,"PHASE3":6175,"PHASE4":6177,"NA":6179},{"trials":6161,"activeCount":100},[],{"trials":6163,"activeCount":100},[],{"trials":6165,"activeCount":100},[6166],{"nctId":6167,"briefTitle":6168,"status":496,"phases":6169,"primaryCompletion":6170,"completion":6170,"start":6171,"enrollment":647,"conditions":6172,"interventions":6174},"NCT00417417","Rilonacept to Improve Artery Function in Patients With Atherosclerosis",[89],"2008-04","2006-12",[3121,30,6149,6173],"Endothelial Dysfunction",[6158],{"trials":6176,"activeCount":100},[],{"trials":6178,"activeCount":100},[],{"trials":6180,"activeCount":100},[],{"intervention":568,"totalTrials":96,"cells":6182},{"EARLY_PHASE1":6183,"PHASE1":6185,"PHASE2":6187,"PHASE3":6193,"PHASE4":6195,"NA":6197},{"trials":6184,"activeCount":100},[],{"trials":6186,"activeCount":100},[],{"trials":6188,"activeCount":100},[6189],{"nctId":559,"briefTitle":560,"status":467,"phases":6190,"completion":562,"start":563,"conditions":6191,"interventions":6192},[88,89],[565,566],[568,569,475,570],{"trials":6194,"activeCount":100},[],{"trials":6196,"activeCount":100},[],{"trials":6198,"activeCount":100},[],{"intervention":2712,"totalTrials":96,"cells":6200},{"EARLY_PHASE1":6201,"PHASE1":6203,"PHASE2":6205,"PHASE3":6211,"PHASE4":6213,"NA":6215},{"trials":6202,"activeCount":100},[],{"trials":6204,"activeCount":100},[],{"trials":6206,"activeCount":100},[6207],{"nctId":2701,"briefTitle":2702,"status":496,"phases":6208,"completion":2704,"start":2705,"conditions":6209,"interventions":6210},[89],[2707,15,18,2708],[2710,2692,2711,2712],{"trials":6212,"activeCount":100},[],{"trials":6214,"activeCount":100},[],{"trials":6216,"activeCount":100},[],{"intervention":582,"totalTrials":96,"cells":6218},{"EARLY_PHASE1":6219,"PHASE1":6221,"PHASE2":6223,"PHASE3":6229,"PHASE4":6231,"NA":6233},{"trials":6220,"activeCount":100},[],{"trials":6222,"activeCount":100},[],{"trials":6224,"activeCount":100},[6225],{"nctId":572,"briefTitle":573,"status":496,"phases":6226,"completion":575,"start":576,"conditions":6227,"interventions":6228},[89],[27,578,579],[581,475,582],{"trials":6230,"activeCount":100},[],{"trials":6232,"activeCount":100},[],{"trials":6234,"activeCount":100},[],{"intervention":6236,"totalTrials":96,"cells":6237},"Pirfenidone",{"EARLY_PHASE1":6238,"PHASE1":6240,"PHASE2":6242,"PHASE3":6251,"PHASE4":6253,"NA":6255},{"trials":6239,"activeCount":100},[],{"trials":6241,"activeCount":100},[],{"trials":6243,"activeCount":100},[6244],{"nctId":6245,"briefTitle":6246,"status":496,"phases":6247,"completion":5936,"start":1890,"enrollment":5612,"conditions":6248,"interventions":6250},"NCT00011076","Pirfenidone to Treat Hypertrophic Cardiomyopathy",[89],[6249],"Hypertrophic Cardiomyopathy",[6236],{"trials":6252,"activeCount":100},[],{"trials":6254,"activeCount":100},[],{"trials":6256,"activeCount":100},[],{"intervention":6258,"totalTrials":96,"cells":6259},"CD34+ selection with CliniMACS device",{"EARLY_PHASE1":6260,"PHASE1":6262,"PHASE2":6264,"PHASE3":6274,"PHASE4":6276,"NA":6278},{"trials":6261,"activeCount":100},[],{"trials":6263,"activeCount":100},[],{"trials":6265,"activeCount":100},[6266],{"nctId":6267,"briefTitle":6268,"status":496,"phases":6269,"primaryCompletion":6270,"completion":6270,"start":4609,"enrollment":704,"conditions":6271,"interventions":6273},"NCT00201240","Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)",[89],"2013-12",[6272],"Leukemia, Myelocytic, Acute",[6258],{"trials":6275,"activeCount":100},[],{"trials":6277,"activeCount":100},[],{"trials":6279,"activeCount":100},[],{"intervention":6281,"totalTrials":96,"cells":6282},"Estrogen therapy",{"EARLY_PHASE1":6283,"PHASE1":6285,"PHASE2":6287,"PHASE3":6298,"PHASE4":6300,"NA":6302},{"trials":6284,"activeCount":100},[],{"trials":6286,"activeCount":100},[],{"trials":6288,"activeCount":100},[6289],{"nctId":6290,"briefTitle":6291,"status":496,"phases":6292,"completion":3269,"start":6293,"enrollment":786,"conditions":6294,"interventions":6297},"NCT00001890","Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections",[89],"1999-05",[30,6295,3069,6296,2216],"Chlamydia Infections","Pneumonia, Bacterial",[6281],{"trials":6299,"activeCount":100},[],{"trials":6301,"activeCount":100},[],{"trials":6303,"activeCount":100},[],{"intervention":6305,"totalTrials":96,"cells":6306},"Bitopertin",{"EARLY_PHASE1":6307,"PHASE1":6309,"PHASE2":6311,"PHASE3":6322,"PHASE4":6324,"NA":6326},{"trials":6308,"activeCount":100},[],{"trials":6310,"activeCount":100},[],{"trials":6312,"activeCount":100},[6313],{"nctId":6314,"briefTitle":6315,"status":496,"phases":6316,"primaryCompletion":6317,"completion":6317,"start":6318,"enrollment":797,"conditions":6319,"interventions":6321},"NCT05828108","Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia",[88,89],"2025-08-28","2023-07-25",[6320],"Steroid-refractory Diamond-Blackfan Anemia (DBA)",[6305],{"trials":6323,"activeCount":100},[],{"trials":6325,"activeCount":100},[],{"trials":6327,"activeCount":100},[],{"intervention":6329,"totalTrials":96,"cells":6330},"ALVAC-CMV",{"EARLY_PHASE1":6331,"PHASE1":6333,"PHASE2":6335,"PHASE3":6346,"PHASE4":6348,"NA":6350},{"trials":6332,"activeCount":100},[],{"trials":6334,"activeCount":100},[],{"trials":6336,"activeCount":100},[6337],{"nctId":6338,"briefTitle":6339,"status":496,"phases":6340,"primaryCompletion":6341,"completion":6341,"start":6342,"enrollment":6343,"conditions":6344,"interventions":6345},"NCT00353977","Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors",[89],"2008-03","2004-05",38,[3069],[6329],{"trials":6347,"activeCount":100},[],{"trials":6349,"activeCount":100},[],{"trials":6351,"activeCount":100},[],{"intervention":600,"totalTrials":96,"cells":6353},{"EARLY_PHASE1":6354,"PHASE1":6356,"PHASE2":6358,"PHASE3":6364,"PHASE4":6366,"NA":6368},{"trials":6355,"activeCount":100},[],{"trials":6357,"activeCount":100},[],{"trials":6359,"activeCount":100},[6360],{"nctId":584,"briefTitle":585,"status":496,"phases":6361,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":6362,"interventions":6363},[89],[591,543,592,545,518,593,594,595,596],[598,598,599,599,600,601,602,394],{"trials":6365,"activeCount":100},[],{"trials":6367,"activeCount":100},[],{"trials":6369,"activeCount":100},[],{"intervention":2431,"totalTrials":96,"cells":6371},{"EARLY_PHASE1":6372,"PHASE1":6374,"PHASE2":6376,"PHASE3":6382,"PHASE4":6384,"NA":6386},{"trials":6373,"activeCount":100},[],{"trials":6375,"activeCount":100},[],{"trials":6377,"activeCount":100},[6378],{"nctId":2422,"briefTitle":2423,"status":496,"phases":6379,"primaryCompletion":2425,"completion":2426,"start":2427,"enrollment":2428,"conditions":6380,"interventions":6381},[89],[1174],[1176,2431,2432,2399],{"trials":6383,"activeCount":100},[],{"trials":6385,"activeCount":100},[],{"trials":6387,"activeCount":100},[],{"intervention":6389,"totalTrials":96,"cells":6390},"Stemgen",{"EARLY_PHASE1":6391,"PHASE1":6393,"PHASE2":6395,"PHASE3":6403,"PHASE4":6405,"NA":6407},{"trials":6392,"activeCount":100},[],{"trials":6394,"activeCount":100},[],{"trials":6396,"activeCount":100},[6397],{"nctId":6398,"briefTitle":6399,"status":496,"phases":6400,"completion":3003,"start":3846,"enrollment":516,"conditions":6401,"interventions":6402},"NCT00001750","Comparing Treatments for Multiple Myeloma",[89],[1174],[6389],{"trials":6404,"activeCount":100},[],{"trials":6406,"activeCount":100},[],{"trials":6408,"activeCount":100},[],{"intervention":6410,"totalTrials":96,"cells":6411},"potassium",{"EARLY_PHASE1":6412,"PHASE1":6414,"PHASE2":6416,"PHASE3":6425,"PHASE4":6427,"NA":6429},{"trials":6413,"activeCount":100},[],{"trials":6415,"activeCount":100},[],{"trials":6417,"activeCount":100},[6418],{"nctId":6419,"briefTitle":6420,"status":496,"phases":6421,"completion":2720,"start":6422,"conditions":6423,"interventions":6424},"NCT00000501","Hypertension Prevention Trial (HPT) Feasibility Study",[89],"1981-09",[15,18,24,35,2104],[6410],{"trials":6426,"activeCount":100},[],{"trials":6428,"activeCount":100},[],{"trials":6430,"activeCount":100},[],{"intervention":6432,"totalTrials":96,"cells":6433},"Pentoxifylline",{"EARLY_PHASE1":6434,"PHASE1":6436,"PHASE2":6438,"PHASE3":6448,"PHASE4":6450,"NA":6452},{"trials":6435,"activeCount":100},[],{"trials":6437,"activeCount":100},[],{"trials":6439,"activeCount":100},[6440],{"nctId":6441,"briefTitle":6442,"status":496,"phases":6443,"completion":6342,"start":6444,"enrollment":1537,"conditions":6445,"interventions":6447},"NCT00001877","Treatment of Pulmonary Sarcoidosis With Pentoxifylline",[89],"1999-02",[6446],"Pulmonary Sarcoidosis",[6432],{"trials":6449,"activeCount":100},[],{"trials":6451,"activeCount":100},[],{"trials":6453,"activeCount":100},[],{"intervention":6455,"totalTrials":96,"cells":6456},"deferoxamine",{"EARLY_PHASE1":6457,"PHASE1":6459,"PHASE2":6461,"PHASE3":6473,"PHASE4":6475,"NA":6477},{"trials":6458,"activeCount":100},[],{"trials":6460,"activeCount":100},[],{"trials":6462,"activeCount":100},[6463],{"nctId":6464,"briefTitle":6465,"status":496,"phases":6466,"completion":2861,"start":6467,"conditions":6468,"interventions":6472},"NCT00000595","Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis",[89],"1978-01",[6469,624,622,955,390,6470,6471],"Anemia (Iron-Loading)","Iron Overload","Hemochromatosis",[6455],{"trials":6474,"activeCount":100},[],{"trials":6476,"activeCount":100},[],{"trials":6478,"activeCount":100},[],{"intervention":6480,"totalTrials":96,"cells":6481},"Modified bone marrow stem cell transplantation",{"EARLY_PHASE1":6482,"PHASE1":6484,"PHASE2":6486,"PHASE3":6496,"PHASE4":6498,"NA":6500},{"trials":6483,"activeCount":100},[],{"trials":6485,"activeCount":100},[],{"trials":6487,"activeCount":100},[6488],{"nctId":6489,"briefTitle":6490,"status":496,"phases":6491,"completion":562,"start":6492,"enrollment":5612,"conditions":6493,"interventions":6495},"NCT00001144","Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia",[89],"1999-10",[6494,392],"Chronic Myeloid Leukemia",[6480],{"trials":6497,"activeCount":100},[],{"trials":6499,"activeCount":100},[],{"trials":6501,"activeCount":100},[],{"intervention":6503,"totalTrials":96,"cells":6504},"WT1 Peptide Vaccine",{"EARLY_PHASE1":6505,"PHASE1":6507,"PHASE2":6509,"PHASE3":6519,"PHASE4":6521,"NA":6523},{"trials":6506,"activeCount":100},[],{"trials":6508,"activeCount":100},[],{"trials":6510,"activeCount":100},[6511],{"nctId":6512,"briefTitle":6513,"status":496,"phases":6514,"primaryCompletion":6515,"completion":6515,"start":6516,"enrollment":736,"conditions":6517,"interventions":6518},"NCT00433745","Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy",[89],"2009-11","2007-02",[547,2416,4780],[6503],{"trials":6520,"activeCount":100},[],{"trials":6522,"activeCount":100},[],{"trials":6524,"activeCount":100},[],{"intervention":6526,"totalTrials":96,"cells":6527},"TNFR:Fc",{"EARLY_PHASE1":6528,"PHASE1":6530,"PHASE2":6532,"PHASE3":6542,"PHASE4":6544,"NA":6546},{"trials":6529,"activeCount":100},[],{"trials":6531,"activeCount":100},[],{"trials":6533,"activeCount":100},[6534],{"nctId":6535,"briefTitle":6536,"status":496,"phases":6537,"primaryCompletion":6538,"start":6539,"enrollment":1022,"conditions":6540,"interventions":6541},"NCT00001893","Study of TNFR:Fc (Enbrel) in the Treatment of Asthma",[89],"2002-12-31","1999-08-17",[33],[6526],{"trials":6543,"activeCount":100},[],{"trials":6545,"activeCount":100},[],{"trials":6547,"activeCount":100},[],{"intervention":6549,"totalTrials":96,"cells":6550},"Fosinopril",{"EARLY_PHASE1":6551,"PHASE1":6553,"PHASE2":6555,"PHASE3":6563,"PHASE4":6565,"NA":6567},{"trials":6552,"activeCount":100},[],{"trials":6554,"activeCount":100},[],{"trials":6556,"activeCount":100},[6557],{"nctId":6558,"briefTitle":6559,"status":496,"phases":6560,"primaryCompletion":469,"completion":469,"start":5835,"conditions":6561,"interventions":6562},"NCT00051389","ACE Inhibition and Novel Cardiovascular Risk Factors",[89],[15,18,24],[6549],{"trials":6564,"activeCount":100},[],{"trials":6566,"activeCount":100},[],{"trials":6568,"activeCount":100},[],{"intervention":6570,"totalTrials":96,"cells":6571},"genistein",{"EARLY_PHASE1":6572,"PHASE1":6574,"PHASE2":6576,"PHASE3":6586,"PHASE4":6588,"NA":6590},{"trials":6573,"activeCount":100},[],{"trials":6575,"activeCount":100},[],{"trials":6577,"activeCount":100},[6578],{"nctId":6579,"briefTitle":6580,"status":496,"phases":6581,"completion":2610,"start":6582,"conditions":6583,"interventions":6585},"NCT00000613","CVD Risk and Health in Postmenopausal Phytoestrogen Users",[89],"1997-04",[2246,15,21,6584,18,2117,2249,2216],"Depression",[6570],{"trials":6587,"activeCount":100},[],{"trials":6589,"activeCount":100},[],{"trials":6591,"activeCount":100},[],{"intervention":2335,"totalTrials":96,"cells":6593},{"EARLY_PHASE1":6594,"PHASE1":6596,"PHASE2":6598,"PHASE3":6604,"PHASE4":6606,"NA":6608},{"trials":6595,"activeCount":100},[],{"trials":6597,"activeCount":100},[],{"trials":6599,"activeCount":100},[6600],{"nctId":2324,"briefTitle":2325,"status":467,"phases":6601,"primaryCompletion":2327,"completion":2328,"start":2329,"enrollment":2330,"conditions":6602,"interventions":6603},[89],[2332],[2334,2335],{"trials":6605,"activeCount":100},[],{"trials":6607,"activeCount":100},[],{"trials":6609,"activeCount":100},[],{"intervention":6611,"totalTrials":96,"cells":6612},"Campath-1H",{"EARLY_PHASE1":6613,"PHASE1":6615,"PHASE2":6617,"PHASE3":6631,"PHASE4":6633,"NA":6635},{"trials":6614,"activeCount":100},[],{"trials":6616,"activeCount":100},[],{"trials":6618,"activeCount":100},[6619],{"nctId":6620,"briefTitle":6621,"status":496,"phases":6622,"primaryCompletion":6623,"completion":6624,"start":6625,"enrollment":6626,"conditions":6627,"interventions":6628},"NCT00065260","Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia",[89],"2010-12-29","2016-02-05","2003-11-06",54,[530],[6611,6629,6630],"r-ATG","CsA",{"trials":6632,"activeCount":100},[],{"trials":6634,"activeCount":100},[],{"trials":6636,"activeCount":100},[],{"intervention":6629,"totalTrials":96,"cells":6638},{"EARLY_PHASE1":6639,"PHASE1":6641,"PHASE2":6643,"PHASE3":6649,"PHASE4":6651,"NA":6653},{"trials":6640,"activeCount":100},[],{"trials":6642,"activeCount":100},[],{"trials":6644,"activeCount":100},[6645],{"nctId":6620,"briefTitle":6621,"status":496,"phases":6646,"primaryCompletion":6623,"completion":6624,"start":6625,"enrollment":6626,"conditions":6647,"interventions":6648},[89],[530],[6611,6629,6630],{"trials":6650,"activeCount":100},[],{"trials":6652,"activeCount":100},[],{"trials":6654,"activeCount":100},[],{"intervention":6630,"totalTrials":96,"cells":6656},{"EARLY_PHASE1":6657,"PHASE1":6659,"PHASE2":6661,"PHASE3":6667,"PHASE4":6669,"NA":6671},{"trials":6658,"activeCount":100},[],{"trials":6660,"activeCount":100},[],{"trials":6662,"activeCount":100},[6663],{"nctId":6620,"briefTitle":6621,"status":496,"phases":6664,"primaryCompletion":6623,"completion":6624,"start":6625,"enrollment":6626,"conditions":6665,"interventions":6666},[89],[530],[6611,6629,6630],{"trials":6668,"activeCount":100},[],{"trials":6670,"activeCount":100},[],{"trials":6672,"activeCount":100},[],{"intervention":1177,"totalTrials":96,"cells":6674},{"EARLY_PHASE1":6675,"PHASE1":6677,"PHASE2":6679,"PHASE3":6685,"PHASE4":6687,"NA":6689},{"trials":6676,"activeCount":100},[],{"trials":6678,"activeCount":100},[],{"trials":6680,"activeCount":100},[6681],{"nctId":1169,"briefTitle":1170,"status":496,"phases":6682,"primaryCompletion":1172,"completion":1172,"start":638,"enrollment":433,"conditions":6683,"interventions":6684},[89],[1174],[534,1176,601,1177],{"trials":6686,"activeCount":100},[],{"trials":6688,"activeCount":100},[],{"trials":6690,"activeCount":100},[],{"intervention":6692,"totalTrials":96,"cells":6693},"Octreotide",{"EARLY_PHASE1":6694,"PHASE1":6696,"PHASE2":6698,"PHASE3":6709,"PHASE4":6711,"NA":6713},{"trials":6695,"activeCount":100},[],{"trials":6697,"activeCount":100},[],{"trials":6699,"activeCount":100},[6700],{"nctId":6701,"briefTitle":6702,"status":496,"phases":6703,"primaryCompletion":6170,"start":1067,"enrollment":736,"conditions":6704,"interventions":6708},"NCT00005906","Treatment With Octreotide in Patients With Lymphangioleiomyomatosis",[89],[1539,6705,6706,6707],"Lymphangiomyomas","Pleural Effusions","Ascites",[6692],{"trials":6710,"activeCount":100},[],{"trials":6712,"activeCount":100},[],{"trials":6714,"activeCount":100},[],{"intervention":6716,"totalTrials":96,"cells":6717},"Zoster Vaccine Recombinant, Adjuvanted",{"EARLY_PHASE1":6718,"PHASE1":6720,"PHASE2":6722,"PHASE3":6733,"PHASE4":6735,"NA":6737},{"trials":6719,"activeCount":100},[],{"trials":6721,"activeCount":100},[],{"trials":6723,"activeCount":100},[6724],{"nctId":6725,"briefTitle":6726,"status":496,"phases":6727,"primaryCompletion":6728,"completion":6729,"start":5960,"enrollment":541,"conditions":6730,"interventions":6732},"NCT03702231","Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)",[89],"2020-09-09","2023-07-12",[5964,6731,1224,1842],"Compare SHINGRIX Vaccine Response Rates",[6716],{"trials":6734,"activeCount":100},[],{"trials":6736,"activeCount":100},[],{"trials":6738,"activeCount":100},[],{"intervention":6740,"totalTrials":96,"cells":6741},"Umbilical Cord Blood",{"EARLY_PHASE1":6742,"PHASE1":6744,"PHASE2":6746,"PHASE3":6759,"PHASE4":6761,"NA":6763},{"trials":6743,"activeCount":100},[],{"trials":6745,"activeCount":100},[],{"trials":6747,"activeCount":100},[6748],{"nctId":6749,"briefTitle":6750,"status":496,"phases":6751,"primaryCompletion":6752,"completion":6753,"start":6754,"enrollment":6755,"conditions":6756,"interventions":6758},"NCT00604201","Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome",[89],"2016-10-25","2021-09-14","2008-05-21",31,[6757,489],"Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)",[6740],{"trials":6760,"activeCount":100},[],{"trials":6762,"activeCount":100},[],{"trials":6764,"activeCount":100},[],{"intervention":6766,"totalTrials":96,"cells":6767},"EPA-rich fish oil",{"EARLY_PHASE1":6768,"PHASE1":6770,"PHASE2":6772,"PHASE3":6786,"PHASE4":6788,"NA":6790},{"trials":6769,"activeCount":100},[],{"trials":6771,"activeCount":100},[],{"trials":6773,"activeCount":100},[6774],{"nctId":6775,"briefTitle":6776,"status":496,"phases":6777,"primaryCompletion":6778,"completion":6778,"start":6779,"enrollment":5079,"conditions":6780,"interventions":6784},"NCT02514070","Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults",[89],"2019-07-23","2015-10-30",[6781,6782,6783],"Lipoprotein Metabolism","PCSK9","Proteomics",[6766,6785],"DHA-rich fish oil",{"trials":6787,"activeCount":100},[],{"trials":6789,"activeCount":100},[],{"trials":6791,"activeCount":100},[],{"intervention":6785,"totalTrials":96,"cells":6793},{"EARLY_PHASE1":6794,"PHASE1":6796,"PHASE2":6798,"PHASE3":6804,"PHASE4":6806,"NA":6808},{"trials":6795,"activeCount":100},[],{"trials":6797,"activeCount":100},[],{"trials":6799,"activeCount":100},[6800],{"nctId":6775,"briefTitle":6776,"status":496,"phases":6801,"primaryCompletion":6778,"completion":6778,"start":6779,"enrollment":5079,"conditions":6802,"interventions":6803},[89],[6781,6782,6783],[6766,6785],{"trials":6805,"activeCount":100},[],{"trials":6807,"activeCount":100},[],{"trials":6809,"activeCount":100},[],{"intervention":6811,"totalTrials":96,"cells":6812},"Topical Dexamethasone",{"EARLY_PHASE1":6813,"PHASE1":6815,"PHASE2":6817,"PHASE3":6828,"PHASE4":6830,"NA":6832},{"trials":6814,"activeCount":100},[],{"trials":6816,"activeCount":100},[],{"trials":6818,"activeCount":100},[6819],{"nctId":6820,"briefTitle":6821,"status":496,"phases":6822,"primaryCompletion":6823,"completion":6823,"start":6824,"enrollment":6825,"conditions":6826,"interventions":6827},"NCT00391170","Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease",[89],"2021-02-01","2006-11-24",62,[392],[6811],{"trials":6829,"activeCount":100},[],{"trials":6831,"activeCount":100},[],{"trials":6833,"activeCount":100},[],{"intervention":627,"totalTrials":96,"cells":6835},{"EARLY_PHASE1":6836,"PHASE1":6838,"PHASE2":6840,"PHASE3":6846,"PHASE4":6848,"NA":6850},{"trials":6837,"activeCount":100},[],{"trials":6839,"activeCount":100},[],{"trials":6841,"activeCount":100},[6842],{"nctId":616,"briefTitle":617,"status":496,"phases":6843,"primaryCompletion":619,"completion":619,"start":563,"enrollment":620,"conditions":6844,"interventions":6845},[89],[622,623,624,625],[627,394,628,629,549],{"trials":6847,"activeCount":100},[],{"trials":6849,"activeCount":100},[],{"trials":6851,"activeCount":100},[],{"intervention":628,"totalTrials":96,"cells":6853},{"EARLY_PHASE1":6854,"PHASE1":6856,"PHASE2":6858,"PHASE3":6864,"PHASE4":6866,"NA":6868},{"trials":6855,"activeCount":100},[],{"trials":6857,"activeCount":100},[],{"trials":6859,"activeCount":100},[6860],{"nctId":616,"briefTitle":617,"status":496,"phases":6861,"primaryCompletion":619,"completion":619,"start":563,"enrollment":620,"conditions":6862,"interventions":6863},[89],[622,623,624,625],[627,394,628,629,549],{"trials":6865,"activeCount":100},[],{"trials":6867,"activeCount":100},[],{"trials":6869,"activeCount":100},[],{"intervention":2364,"totalTrials":96,"cells":6871},{"EARLY_PHASE1":6872,"PHASE1":6874,"PHASE2":6876,"PHASE3":6882,"PHASE4":6884,"NA":6886},{"trials":6873,"activeCount":100},[],{"trials":6875,"activeCount":100},[],{"trials":6877,"activeCount":100},[6878],{"nctId":2356,"briefTitle":2357,"status":496,"phases":6879,"completion":2359,"start":2360,"conditions":6880,"interventions":6881},[89],[15,21,18,2117],[2185,2363,2347,2364,2365],{"trials":6883,"activeCount":100},[],{"trials":6885,"activeCount":100},[],{"trials":6887,"activeCount":100},[],{"intervention":6889,"totalTrials":96,"cells":6890},"Immunosuppression",{"EARLY_PHASE1":6891,"PHASE1":6893,"PHASE2":6895,"PHASE3":6903,"PHASE4":6905,"NA":6907},{"trials":6892,"activeCount":100},[],{"trials":6894,"activeCount":100},[],{"trials":6896,"activeCount":100},[6897],{"nctId":6898,"briefTitle":6899,"status":496,"phases":6900,"primaryCompletion":5200,"completion":5200,"start":2682,"conditions":6901,"interventions":6902},"NCT00029393","Induction of Stable Chimerism for Sickle Cell Anemia",[89],[4090,625,623],[6889],{"trials":6904,"activeCount":100},[],{"trials":6906,"activeCount":100},[],{"trials":6908,"activeCount":100},[],{"intervention":6910,"totalTrials":96,"cells":6911},"all trans retinoic acid",{"EARLY_PHASE1":6912,"PHASE1":6914,"PHASE2":6916,"PHASE3":6926,"PHASE4":6928,"NA":6930},{"trials":6913,"activeCount":100},[],{"trials":6915,"activeCount":100},[],{"trials":6917,"activeCount":100},[6918],{"nctId":6919,"briefTitle":6920,"status":496,"phases":6921,"primaryCompletion":2610,"completion":2610,"start":3355,"conditions":6922,"interventions":6924},"NCT00000621","Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)",[89],[6923,27,4191,3944],"Emphysema",[6910,6925],"13 cis retinoic acid",{"trials":6927,"activeCount":100},[],{"trials":6929,"activeCount":100},[],{"trials":6931,"activeCount":100},[],{"intervention":6925,"totalTrials":96,"cells":6933},{"EARLY_PHASE1":6934,"PHASE1":6936,"PHASE2":6938,"PHASE3":6944,"PHASE4":6946,"NA":6948},{"trials":6935,"activeCount":100},[],{"trials":6937,"activeCount":100},[],{"trials":6939,"activeCount":100},[6940],{"nctId":6919,"briefTitle":6920,"status":496,"phases":6941,"primaryCompletion":2610,"completion":2610,"start":3355,"conditions":6942,"interventions":6943},[89],[6923,27,4191,3944],[6910,6925],{"trials":6945,"activeCount":100},[],{"trials":6947,"activeCount":100},[],{"trials":6949,"activeCount":100},[],{"intervention":6951,"totalTrials":96,"cells":6952},"antihypertensive drug",{"EARLY_PHASE1":6953,"PHASE1":6955,"PHASE2":6957,"PHASE3":6965,"PHASE4":6967,"NA":6969},{"trials":6954,"activeCount":100},[],{"trials":6956,"activeCount":100},[],{"trials":6958,"activeCount":100},[6959],{"nctId":6960,"briefTitle":6961,"status":496,"phases":6962,"primaryCompletion":5200,"completion":5200,"start":2729,"conditions":6963,"interventions":6964},"NCT00269269","Conditioned Placebo Effects and Treatment of Hypertension",[89],[15,18,24],[6951],{"trials":6966,"activeCount":100},[],{"trials":6968,"activeCount":100},[],{"trials":6970,"activeCount":100},[],{"intervention":1137,"totalTrials":96,"cells":6972},{"EARLY_PHASE1":6973,"PHASE1":6975,"PHASE2":6977,"PHASE3":6983,"PHASE4":6985,"NA":6987},{"trials":6974,"activeCount":100},[],{"trials":6976,"activeCount":100},[],{"trials":6978,"activeCount":100},[6979],{"nctId":1129,"briefTitle":1130,"status":496,"phases":6980,"primaryCompletion":1132,"completion":1133,"start":1134,"enrollment":401,"conditions":6981,"interventions":6982},[89],[810,811],[1137,549],{"trials":6984,"activeCount":100},[],{"trials":6986,"activeCount":100},[],{"trials":6988,"activeCount":100},[],{"intervention":6990,"totalTrials":96,"cells":6991},"control fish oil",{"EARLY_PHASE1":6992,"PHASE1":6994,"PHASE2":6996,"PHASE3":7008,"PHASE4":7010,"NA":7012},{"trials":6993,"activeCount":100},[],{"trials":6995,"activeCount":100},[],{"trials":6997,"activeCount":100},[6998],{"nctId":6999,"briefTitle":7000,"status":496,"phases":7001,"primaryCompletion":7002,"completion":7003,"start":7004,"enrollment":1374,"conditions":7005,"interventions":7006},"NCT03043365","Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults",[89],"2019-05-29","2019-11-21","2017-06-15",[6781,6782,6783],[6990,7007],"LCMUFA-rich saury oil",{"trials":7009,"activeCount":100},[],{"trials":7011,"activeCount":100},[],{"trials":7013,"activeCount":100},[],{"intervention":7007,"totalTrials":96,"cells":7015},{"EARLY_PHASE1":7016,"PHASE1":7018,"PHASE2":7020,"PHASE3":7026,"PHASE4":7028,"NA":7030},{"trials":7017,"activeCount":100},[],{"trials":7019,"activeCount":100},[],{"trials":7021,"activeCount":100},[7022],{"nctId":6999,"briefTitle":7000,"status":496,"phases":7023,"primaryCompletion":7002,"completion":7003,"start":7004,"enrollment":1374,"conditions":7024,"interventions":7025},[89],[6781,6782,6783],[6990,7007],{"trials":7027,"activeCount":100},[],{"trials":7029,"activeCount":100},[],{"trials":7031,"activeCount":100},[],{"intervention":4820,"totalTrials":851,"cells":7033},{"EARLY_PHASE1":7034,"PHASE1":7036,"PHASE2":7061,"PHASE3":7063,"PHASE4":7065,"NA":7067},{"trials":7035,"activeCount":100},[],{"trials":7037,"activeCount":100},[7038,7042,7051],{"nctId":4813,"briefTitle":4814,"status":496,"phases":7039,"primaryCompletion":4816,"completion":4816,"start":4817,"enrollment":1292,"conditions":7040,"interventions":7041},[88],[403],[4695,4820],{"nctId":7043,"briefTitle":7044,"status":496,"phases":7045,"completion":7046,"start":7047,"enrollment":3161,"conditions":7048,"interventions":7049},"NCT00102271","Nitrite Infusion Studies",[88],"2011-04-12","2005-01-19",[2272],[7050,4820],"Oxypurinol",{"nctId":7052,"briefTitle":7053,"status":467,"phases":7054,"primaryCompletion":7055,"completion":7055,"start":7056,"enrollment":797,"conditions":7057,"interventions":7060},"NCT00105222","Effect of Nitrite on Exercise Physiology and Metabolism",[88],"2013-08-16","2005-03-08",[2272,7058,7059],"Healthy Volunteer","HV",[4820],{"trials":7062,"activeCount":100},[],{"trials":7064,"activeCount":100},[],{"trials":7066,"activeCount":100},[],{"trials":7068,"activeCount":100},[],{"intervention":7070,"totalTrials":96,"cells":7071},"Gardasil",{"EARLY_PHASE1":7072,"PHASE1":7074,"PHASE2":7087,"PHASE3":7089,"PHASE4":7091,"NA":7093},{"trials":7073,"activeCount":100},[],{"trials":7075,"activeCount":100},[7076],{"nctId":7077,"briefTitle":7078,"status":496,"phases":7079,"primaryCompletion":7080,"completion":7080,"start":7081,"enrollment":1771,"conditions":7082,"interventions":7086},"NCT01092195","Gardasil Vaccination in Post Stem Cell Transplant Patients",[88],"2016-07-19","2010-06-02",[7083,7084,7085],"Gardasil Vaccine","Stem Cell Transplant","Immunogenicity",[7070],{"trials":7088,"activeCount":100},[],{"trials":7090,"activeCount":100},[],{"trials":7092,"activeCount":100},[],{"trials":7094,"activeCount":100},[],{"intervention":4785,"totalTrials":96,"cells":7096},{"EARLY_PHASE1":7097,"PHASE1":7099,"PHASE2":7105,"PHASE3":7107,"PHASE4":7109,"NA":7111},{"trials":7098,"activeCount":100},[],{"trials":7100,"activeCount":100},[7101],{"nctId":4773,"briefTitle":4774,"status":496,"phases":7102,"primaryCompletion":4776,"completion":4776,"start":4777,"enrollment":4778,"conditions":7103,"interventions":7104},[88],[4780,4781,4782,1174,4783],[601,4785],{"trials":7106,"activeCount":100},[],{"trials":7108,"activeCount":100},[],{"trials":7110,"activeCount":100},[],{"trials":7112,"activeCount":100},[],{"intervention":7114,"totalTrials":96,"cells":7115},"Miconazole, L-NMMA, Bradykinin",{"EARLY_PHASE1":7116,"PHASE1":7118,"PHASE2":7128,"PHASE3":7130,"PHASE4":7132,"NA":7134},{"trials":7117,"activeCount":100},[],{"trials":7119,"activeCount":100},[7120],{"nctId":7121,"briefTitle":7122,"status":496,"phases":7123,"completion":7124,"start":7125,"enrollment":797,"conditions":7126,"interventions":7127},"NCT00004575","Effects of Miconazole on Blood Flow",[88],"2001-10","2000-02",[2272],[7114],{"trials":7129,"activeCount":100},[],{"trials":7131,"activeCount":100},[],{"trials":7133,"activeCount":100},[],{"trials":7135,"activeCount":100},[],{"intervention":5564,"totalTrials":96,"cells":7137},{"EARLY_PHASE1":7138,"PHASE1":7140,"PHASE2":7151,"PHASE3":7153,"PHASE4":7155,"NA":7157},{"trials":7139,"activeCount":100},[],{"trials":7141,"activeCount":100},[7142],{"nctId":7143,"briefTitle":7144,"status":496,"phases":7145,"primaryCompletion":7146,"completion":7147,"start":7148,"enrollment":1692,"conditions":7149,"interventions":7150},"NCT00023296","Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension",[88],"2006-11-02","2015-11-09","2001-07-27",[403,942],[5564],{"trials":7152,"activeCount":100},[],{"trials":7154,"activeCount":100},[],{"trials":7156,"activeCount":100},[],{"trials":7158,"activeCount":100},[],{"intervention":7160,"totalTrials":96,"cells":7161},"REG1",{"EARLY_PHASE1":7162,"PHASE1":7164,"PHASE2":7174,"PHASE3":7176,"PHASE4":7178,"NA":7180},{"trials":7163,"activeCount":100},[],{"trials":7165,"activeCount":100},[7166],{"nctId":7167,"briefTitle":7168,"status":496,"phases":7169,"completion":7170,"start":4609,"enrollment":7171,"conditions":7172,"interventions":7173},"NCT00113997","Safety and Dosing Evaluation of REG1 Anticoagulation System",[88],"2005-10",106,[2272],[7160],{"trials":7175,"activeCount":100},[],{"trials":7177,"activeCount":100},[],{"trials":7179,"activeCount":100},[],{"trials":7181,"activeCount":100},[],{"intervention":7183,"totalTrials":96,"cells":7184},"Nitric Oxide\u002FINP Pulse Delivery",{"EARLY_PHASE1":7185,"PHASE1":7187,"PHASE2":7198,"PHASE3":7200,"PHASE4":7202,"NA":7204},{"trials":7186,"activeCount":100},[],{"trials":7188,"activeCount":100},[7189],{"nctId":7190,"briefTitle":7191,"status":496,"phases":7192,"primaryCompletion":7193,"completion":7193,"start":7194,"enrollment":6755,"conditions":7195,"interventions":7196},"NCT00352430","Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension",[88],"2010-03-10","2006-07-09",[942],[7183,7197],"Nitric Oxide\u002FINO Pulse Delivery",{"trials":7199,"activeCount":100},[],{"trials":7201,"activeCount":100},[],{"trials":7203,"activeCount":100},[],{"trials":7205,"activeCount":100},[],{"intervention":7197,"totalTrials":96,"cells":7207},{"EARLY_PHASE1":7208,"PHASE1":7210,"PHASE2":7216,"PHASE3":7218,"PHASE4":7220,"NA":7222},{"trials":7209,"activeCount":100},[],{"trials":7211,"activeCount":100},[7212],{"nctId":7190,"briefTitle":7191,"status":496,"phases":7213,"primaryCompletion":7193,"completion":7193,"start":7194,"enrollment":6755,"conditions":7214,"interventions":7215},[88],[942],[7183,7197],{"trials":7217,"activeCount":100},[],{"trials":7219,"activeCount":100},[],{"trials":7221,"activeCount":100},[],{"trials":7223,"activeCount":100},[],{"intervention":7225,"totalTrials":96,"cells":7226},"MS-325",{"EARLY_PHASE1":7227,"PHASE1":7229,"PHASE2":7242,"PHASE3":7244,"PHASE4":7246,"NA":7248},{"trials":7228,"activeCount":100},[],{"trials":7230,"activeCount":100},[7231],{"nctId":7232,"briefTitle":7233,"status":496,"phases":7234,"primaryCompletion":7235,"start":7236,"enrollment":1891,"conditions":7237,"interventions":7241},"NCT00459446","Imaging of Totally Blocked Arteries",[88],"2008-11-25","2007-04-05",[30,7238,7239,7240],"Peripheral Artery Disease","Intermittent Claudication","Chronic Total Aterial Occlusion",[7225],{"trials":7243,"activeCount":100},[],{"trials":7245,"activeCount":100},[],{"trials":7247,"activeCount":100},[],{"trials":7249,"activeCount":100},[],{"intervention":5048,"totalTrials":96,"cells":7251},{"EARLY_PHASE1":7252,"PHASE1":7254,"PHASE2":7260,"PHASE3":7262,"PHASE4":7264,"NA":7266},{"trials":7253,"activeCount":100},[],{"trials":7255,"activeCount":100},[7256],{"nctId":5042,"briefTitle":5043,"status":937,"phases":7257,"primaryCompletion":5045,"completion":5045,"start":4965,"enrollment":100,"conditions":7258,"interventions":7259},[88],[942],[5048,5035],{"trials":7261,"activeCount":100},[],{"trials":7263,"activeCount":100},[],{"trials":7265,"activeCount":100},[],{"trials":7267,"activeCount":100},[],{"intervention":7269,"totalTrials":96,"cells":7270},"WT1 and PR1 Peptide Vaccine",{"EARLY_PHASE1":7271,"PHASE1":7273,"PHASE2":7283,"PHASE3":7285,"PHASE4":7287,"NA":7289},{"trials":7272,"activeCount":100},[],{"trials":7274,"activeCount":100},[7275],{"nctId":7276,"briefTitle":7277,"status":496,"phases":7278,"primaryCompletion":7279,"completion":7279,"start":7280,"enrollment":5355,"conditions":7281,"interventions":7282},"NCT00270452","Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome",[88],"2007-10-26","2005-12-22",[1377],[7269],{"trials":7284,"activeCount":100},[],{"trials":7286,"activeCount":100},[],{"trials":7288,"activeCount":100},[],{"trials":7290,"activeCount":100},[],{"intervention":7292,"totalTrials":96,"cells":7293},"Erythropoietin and Hydroxyurea",{"EARLY_PHASE1":7294,"PHASE1":7296,"PHASE2":7306,"PHASE3":7308,"PHASE4":7310,"NA":7312},{"trials":7295,"activeCount":100},[],{"trials":7297,"activeCount":100},[7298],{"nctId":7299,"briefTitle":7300,"status":496,"phases":7301,"primaryCompletion":1134,"completion":1134,"start":7302,"enrollment":363,"conditions":7303,"interventions":7305},"NCT00270478","Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia",[88],"2005-12-21",[389,7304,942],"Chronic Kidney Disease",[7292],{"trials":7307,"activeCount":100},[],{"trials":7309,"activeCount":100},[],{"trials":7311,"activeCount":100},[],{"trials":7313,"activeCount":100},[],{"intervention":4707,"totalTrials":96,"cells":7315},{"EARLY_PHASE1":7316,"PHASE1":7318,"PHASE2":7324,"PHASE3":7326,"PHASE4":7328,"NA":7330},{"trials":7317,"activeCount":100},[],{"trials":7319,"activeCount":100},[7320],{"nctId":4697,"briefTitle":4698,"status":496,"phases":7321,"primaryCompletion":4700,"completion":4700,"start":4701,"enrollment":4702,"conditions":7322,"interventions":7323},[88],[4704,4705],[4707,4680],{"trials":7325,"activeCount":100},[],{"trials":7327,"activeCount":100},[],{"trials":7329,"activeCount":100},[],{"trials":7331,"activeCount":100},[],{"intervention":7333,"totalTrials":96,"cells":7334},"Sodium Nitrite Cream",{"EARLY_PHASE1":7335,"PHASE1":7337,"PHASE2":7349,"PHASE3":7351,"PHASE4":7353,"NA":7355},{"trials":7336,"activeCount":100},[],{"trials":7338,"activeCount":100},[7339],{"nctId":7340,"briefTitle":7341,"status":496,"phases":7342,"primaryCompletion":7343,"completion":7344,"start":840,"enrollment":7345,"conditions":7346,"interventions":7348},"NCT01316796","Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders",[88],"2015-09-18","2018-10-12",28,[403,389,7347],"Chronic Hemolytic Disorders",[7333],{"trials":7350,"activeCount":100},[],{"trials":7352,"activeCount":100},[],{"trials":7354,"activeCount":100},[],{"trials":7356,"activeCount":100},[],{"intervention":7358,"totalTrials":96,"cells":7359},"DNA Plasmid Vector",{"EARLY_PHASE1":7360,"PHASE1":7362,"PHASE2":7374,"PHASE3":7376,"PHASE4":7378,"NA":7380},{"trials":7361,"activeCount":100},[],{"trials":7363,"activeCount":100},[7364],{"nctId":7365,"briefTitle":7366,"status":496,"phases":7367,"completion":7368,"start":7369,"enrollment":647,"conditions":7370,"interventions":7372},"NCT00080392","EW-A-401 to Treat Intermittent Claudication",[88],"2011-12-29","2004-03-27",[7239,7371],"Arteriosclerosis",[7358,7373],"EW-A-401 DNA Plasmid Vector",{"trials":7375,"activeCount":100},[],{"trials":7377,"activeCount":100},[],{"trials":7379,"activeCount":100},[],{"trials":7381,"activeCount":100},[],{"intervention":7373,"totalTrials":96,"cells":7383},{"EARLY_PHASE1":7384,"PHASE1":7386,"PHASE2":7392,"PHASE3":7394,"PHASE4":7396,"NA":7398},{"trials":7385,"activeCount":100},[],{"trials":7387,"activeCount":100},[7388],{"nctId":7365,"briefTitle":7366,"status":496,"phases":7389,"completion":7368,"start":7369,"enrollment":647,"conditions":7390,"interventions":7391},[88],[7239,7371],[7358,7373],{"trials":7393,"activeCount":100},[],{"trials":7395,"activeCount":100},[],{"trials":7397,"activeCount":100},[],{"trials":7399,"activeCount":100},[],{"intervention":7401,"totalTrials":96,"cells":7402},"Insulin",{"EARLY_PHASE1":7403,"PHASE1":7405,"PHASE2":7415,"PHASE3":7417,"PHASE4":7419,"NA":7421},{"trials":7404,"activeCount":100},[],{"trials":7406,"activeCount":100},[7407],{"nctId":7408,"briefTitle":7409,"status":496,"phases":7410,"completion":7411,"start":952,"enrollment":456,"conditions":7412,"interventions":7414},"NCT00001624","Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation",[88],"2000-03",[7413],"Hyperinsulinemia",[7401],{"trials":7416,"activeCount":100},[],{"trials":7418,"activeCount":100},[],{"trials":7420,"activeCount":100},[],{"trials":7422,"activeCount":100},[],{"intervention":7424,"totalTrials":96,"cells":7425},"ON 01910 Na",{"EARLY_PHASE1":7426,"PHASE1":7428,"PHASE2":7439,"PHASE3":7441,"PHASE4":7443,"NA":7445},{"trials":7427,"activeCount":100},[],{"trials":7429,"activeCount":100},[7430],{"nctId":7431,"briefTitle":7432,"status":496,"phases":7433,"primaryCompletion":7434,"completion":7434,"start":7435,"enrollment":7436,"conditions":7437,"interventions":7438},"NCT00533416","Safety of ON 01910.Na in Patients With Myelodysplasia",[88],"2012-06-04","2007-09-14",14,[1377],[7424],{"trials":7440,"activeCount":100},[],{"trials":7442,"activeCount":100},[],{"trials":7444,"activeCount":100},[],{"trials":7446,"activeCount":100},[],{"intervention":2418,"totalTrials":96,"cells":7448},{"EARLY_PHASE1":7449,"PHASE1":7451,"PHASE2":7457,"PHASE3":7459,"PHASE4":7461,"NA":7463},{"trials":7450,"activeCount":100},[],{"trials":7452,"activeCount":100},[7453],{"nctId":2406,"briefTitle":2407,"status":496,"phases":7454,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":736,"conditions":7455,"interventions":7456},[88],[2413,2414,2415,531,2416],[2418,2399],{"trials":7458,"activeCount":100},[],{"trials":7460,"activeCount":100},[],{"trials":7462,"activeCount":100},[],{"trials":7464,"activeCount":100},[],{"intervention":7466,"totalTrials":96,"cells":7467},"Interleukin-2",{"EARLY_PHASE1":7468,"PHASE1":7470,"PHASE2":7480,"PHASE3":7482,"PHASE4":7484,"NA":7486},{"trials":7469,"activeCount":100},[],{"trials":7471,"activeCount":100},[7472],{"nctId":7473,"briefTitle":7474,"status":496,"phases":7475,"primaryCompletion":7476,"completion":7476,"start":7477,"enrollment":612,"conditions":7478,"interventions":7479},"NCT01445561","Ultra Low Dose Interleukin-2 in Healthy Volunteers",[88],"2013-07-15","2011-09-28",[622],[7466],{"trials":7481,"activeCount":100},[],{"trials":7483,"activeCount":100},[],{"trials":7485,"activeCount":100},[],{"trials":7487,"activeCount":100},[],{"intervention":7050,"totalTrials":96,"cells":7489},{"EARLY_PHASE1":7490,"PHASE1":7492,"PHASE2":7498,"PHASE3":7500,"PHASE4":7502,"NA":7504},{"trials":7491,"activeCount":100},[],{"trials":7493,"activeCount":100},[7494],{"nctId":7043,"briefTitle":7044,"status":496,"phases":7495,"completion":7046,"start":7047,"enrollment":3161,"conditions":7496,"interventions":7497},[88],[2272],[7050,4820],{"trials":7499,"activeCount":100},[],{"trials":7501,"activeCount":100},[],{"trials":7503,"activeCount":100},[],{"trials":7505,"activeCount":100},[],{"intervention":7507,"totalTrials":96,"cells":7508},"ON01910 Na",{"EARLY_PHASE1":7509,"PHASE1":7511,"PHASE2":7523,"PHASE3":7525,"PHASE4":7527,"NA":7529},{"trials":7510,"activeCount":100},[],{"trials":7512,"activeCount":100},[7513],{"nctId":7514,"briefTitle":7515,"status":496,"phases":7516,"primaryCompletion":7517,"completion":7517,"start":7518,"enrollment":456,"conditions":7519,"interventions":7522},"NCT00861510","A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies",[88],"2012-10-19","2009-03-05",[5771,1197,7520,7521,1174],"Leukemia, Hairy Cell","Waldenstrom Macroglobulinemia",[7507],{"trials":7524,"activeCount":100},[],{"trials":7526,"activeCount":100},[],{"trials":7528,"activeCount":100},[],{"trials":7530,"activeCount":100},[],{"intervention":7532,"totalTrials":96,"cells":7533},"Recombinant Methionyl Human Stem Cell Factor",{"EARLY_PHASE1":7534,"PHASE1":7536,"PHASE2":7546,"PHASE3":7548,"PHASE4":7550,"NA":7552},{"trials":7535,"activeCount":100},[],{"trials":7537,"activeCount":100},[7538],{"nctId":7539,"briefTitle":7540,"status":496,"phases":7541,"completion":7542,"start":7543,"enrollment":443,"conditions":7544,"interventions":7545},"NCT00001398","Stem Cell Factor Medication for Aplastic Anemia",[88],"2002-06","1993-10",[530,532],[7532],{"trials":7547,"activeCount":100},[],{"trials":7549,"activeCount":100},[],{"trials":7551,"activeCount":100},[],{"trials":7553,"activeCount":100},[],{"intervention":7555,"totalTrials":96,"cells":7556},"Transduced CD34+ Cells",{"EARLY_PHASE1":7557,"PHASE1":7559,"PHASE2":7568,"PHASE3":7570,"PHASE4":7572,"NA":7574},{"trials":7558,"activeCount":100},[],{"trials":7560,"activeCount":100},[7561],{"nctId":7562,"briefTitle":7563,"status":496,"phases":7564,"completion":4714,"start":7565,"enrollment":5355,"conditions":7566,"interventions":7567},"NCT00001399","Gene Therapy for the Treatment of Fanconi's Anemia Type C",[88],"1993-12-03",[1096,532],[7555],{"trials":7569,"activeCount":100},[],{"trials":7571,"activeCount":100},[],{"trials":7573,"activeCount":100},[],{"trials":7575,"activeCount":100},[],{"intervention":7577,"totalTrials":96,"cells":7578},"ULD IL-2",{"EARLY_PHASE1":7579,"PHASE1":7581,"PHASE2":7595,"PHASE3":7597,"PHASE4":7599,"NA":7601},{"trials":7580,"activeCount":100},[],{"trials":7582,"activeCount":100},[7583],{"nctId":7584,"briefTitle":7585,"status":496,"phases":7586,"primaryCompletion":7587,"completion":2410,"start":7588,"enrollment":5277,"conditions":7589,"interventions":7594},"NCT02226861","Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation",[88],"2018-05-23","2014-08-26",[7590,7591,1224,7592,7593],"Acute Lymphoblastic Leukemia (ALL)","Acute Myelogenous Leukemia (AML)","Chronic Myelogenous Leukemia (CML)","MDS",[7577],{"trials":7596,"activeCount":100},[],{"trials":7598,"activeCount":100},[],{"trials":7600,"activeCount":100},[],{"trials":7602,"activeCount":100},[],{"intervention":7604,"totalTrials":96,"cells":7605},"MVST",{"EARLY_PHASE1":7606,"PHASE1":7608,"PHASE2":7620,"PHASE3":7622,"PHASE4":7624,"NA":7626},{"trials":7607,"activeCount":100},[],{"trials":7609,"activeCount":100},[7610],{"nctId":7611,"briefTitle":7612,"status":467,"phases":7613,"primaryCompletion":7614,"completion":7615,"start":7616,"enrollment":1419,"conditions":7617,"interventions":7618},"NCT02231853","Phase I\u002FII Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections",[88],"2017-11-17","2017-12-29","2014-09-03",[545,5480,5483,546,5481],[7604,7619],"MVSTr",{"trials":7621,"activeCount":100},[],{"trials":7623,"activeCount":100},[],{"trials":7625,"activeCount":100},[],{"trials":7627,"activeCount":100},[],{"intervention":7619,"totalTrials":96,"cells":7629},{"EARLY_PHASE1":7630,"PHASE1":7632,"PHASE2":7638,"PHASE3":7640,"PHASE4":7642,"NA":7644},{"trials":7631,"activeCount":100},[],{"trials":7633,"activeCount":100},[7634],{"nctId":7611,"briefTitle":7612,"status":467,"phases":7635,"primaryCompletion":7614,"completion":7615,"start":7616,"enrollment":1419,"conditions":7636,"interventions":7637},[88],[545,5480,5483,546,5481],[7604,7619],{"trials":7639,"activeCount":100},[],{"trials":7641,"activeCount":100},[],{"trials":7643,"activeCount":100},[],{"trials":7645,"activeCount":100},[],{"intervention":7647,"totalTrials":96,"cells":7648},"Biotin label",{"EARLY_PHASE1":7649,"PHASE1":7660,"PHASE2":7662,"PHASE3":7664,"PHASE4":7666,"NA":7668},{"trials":7650,"activeCount":100},[7651],{"nctId":7652,"briefTitle":7653,"status":496,"phases":7654,"primaryCompletion":7655,"completion":7656,"start":7657,"enrollment":612,"conditions":7658,"interventions":7659},"NCT04476277","Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease",[87],"2022-12-20","2023-02-14","2021-04-19",[389,403],[7647],{"trials":7661,"activeCount":100},[],{"trials":7663,"activeCount":100},[],{"trials":7665,"activeCount":100},[],{"trials":7667,"activeCount":100},[],{"trials":7669,"activeCount":100},[],{"intervention":7671,"totalTrials":96,"cells":7672},"Tuberculin Purified Protein Derivative",{"EARLY_PHASE1":7673,"PHASE1":7685,"PHASE2":7687,"PHASE3":7689,"PHASE4":7691,"NA":7693},{"trials":7674,"activeCount":100},[7675],{"nctId":7676,"briefTitle":7677,"status":496,"phases":7678,"primaryCompletion":7679,"completion":7680,"start":7681,"enrollment":1792,"conditions":7682,"interventions":7684},"NCT05027958","Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung",[87],"2024-11-07","2024-12-08","2022-05-03",[2272,7683],"Latent Tuberculosis Infection (LTBI)",[7671],{"trials":7686,"activeCount":100},[],{"trials":7688,"activeCount":100},[],{"trials":7690,"activeCount":100},[],{"trials":7692,"activeCount":100},[],{"trials":7694,"activeCount":100},[],{"intervention":2218,"totalTrials":363,"cells":7696},{"EARLY_PHASE1":7697,"PHASE1":7699,"PHASE2":7701,"PHASE3":7703,"PHASE4":7729,"NA":7731},{"trials":7698,"activeCount":100},[],{"trials":7700,"activeCount":100},[],{"trials":7702,"activeCount":100},[],{"trials":7704,"activeCount":100},[7705,7709,7713,7717,7721,7725],{"nctId":2210,"briefTitle":2211,"status":496,"phases":7706,"completion":1067,"start":2213,"conditions":7707,"interventions":7708},[90],[2215,15,21,18,2216],[2218,2199,2219,2220],{"nctId":2222,"briefTitle":2223,"status":496,"phases":7710,"completion":2225,"start":2226,"conditions":7711,"interventions":7712},[90],[15,2228,21,18,2117,2216],[2218,2220,2199,2230],{"nctId":2284,"briefTitle":2285,"status":496,"phases":7714,"completion":2287,"start":2236,"conditions":7715,"interventions":7716},[90],[15,2228,21,18,2117,2216],[2218,2290,2219,2220,2291,2292,2293],{"nctId":2295,"briefTitle":2296,"status":496,"phases":7718,"completion":2298,"start":2299,"conditions":7719,"interventions":7720},[90],[2246,15,21,2178,18,2070,24,2117,2249,2301,2216],[2290,2239,2219,2218],{"nctId":2241,"briefTitle":2242,"status":496,"phases":7722,"primaryCompletion":2244,"conditions":7723,"interventions":7724},[90],[2246,2247,15,2248,21,18,2117,2249,2216],[2220,2199,2230,2218,2251,2252],{"nctId":2679,"briefTitle":2680,"status":496,"phases":7726,"completion":2682,"start":2683,"conditions":7727,"interventions":7728},[90],[15,21,18,2117,2216],[2218,2220,2686,2239],{"trials":7730,"activeCount":100},[],{"trials":7732,"activeCount":100},[7733],{"nctId":7734,"briefTitle":7735,"status":467,"phases":7736,"completion":5113,"start":7737,"enrollment":7738,"conditions":7739,"interventions":7741},"NCT00123539","Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery",[92],"2001-06",334,[21,15,18,7740],"Neurologic Manifestations",[7742],"Estrogen Replacement Therapy",{"intervention":2220,"totalTrials":363,"cells":7744},{"EARLY_PHASE1":7745,"PHASE1":7747,"PHASE2":7749,"PHASE3":7751,"PHASE4":7777,"NA":7779},{"trials":7746,"activeCount":100},[],{"trials":7748,"activeCount":100},[],{"trials":7750,"activeCount":100},[],{"trials":7752,"activeCount":100},[7753,7757,7761,7765,7769,7773],{"nctId":2210,"briefTitle":2211,"status":496,"phases":7754,"completion":1067,"start":2213,"conditions":7755,"interventions":7756},[90],[2215,15,21,18,2216],[2218,2199,2219,2220],{"nctId":2222,"briefTitle":2223,"status":496,"phases":7758,"completion":2225,"start":2226,"conditions":7759,"interventions":7760},[90],[15,2228,21,18,2117,2216],[2218,2220,2199,2230],{"nctId":2232,"briefTitle":2233,"status":496,"phases":7762,"completion":2235,"start":2236,"conditions":7763,"interventions":7764},[90],[15,2228,21,18,2117,2216],[2220,2199,2239],{"nctId":2284,"briefTitle":2285,"status":496,"phases":7766,"completion":2287,"start":2236,"conditions":7767,"interventions":7768},[90],[15,2228,21,18,2117,2216],[2218,2290,2219,2220,2291,2292,2293],{"nctId":2241,"briefTitle":2242,"status":496,"phases":7770,"primaryCompletion":2244,"conditions":7771,"interventions":7772},[90],[2246,2247,15,2248,21,18,2117,2249,2216],[2220,2199,2230,2218,2251,2252],{"nctId":2679,"briefTitle":2680,"status":496,"phases":7774,"completion":2682,"start":2683,"conditions":7775,"interventions":7776},[90],[15,21,18,2117,2216],[2218,2220,2686,2239],{"trials":7778,"activeCount":100},[],{"trials":7780,"activeCount":100},[7781],{"nctId":7782,"briefTitle":7783,"status":496,"phases":7784,"completion":7785,"start":4275,"conditions":7786,"interventions":7787},"NCT00041431","Estrogen, Cytokines and Heart Failure in Women",[92],"2003-12",[15,2791,18,2644],[7788],"Hormone Replacement Therapy",{"intervention":2363,"totalTrials":630,"cells":7790},{"EARLY_PHASE1":7791,"PHASE1":7793,"PHASE2":7795,"PHASE3":7801,"PHASE4":7815,"NA":7817},{"trials":7792,"activeCount":100},[],{"trials":7794,"activeCount":100},[],{"trials":7796,"activeCount":100},[7797],{"nctId":2356,"briefTitle":2357,"status":496,"phases":7798,"completion":2359,"start":2360,"conditions":7799,"interventions":7800},[89],[15,21,18,2117],[2185,2363,2347,2364,2365],{"trials":7802,"activeCount":100},[7803,7807,7811],{"nctId":2533,"briefTitle":2534,"status":496,"phases":7804,"completion":2536,"start":2537,"conditions":7805,"interventions":7806},[90],[2539,15,18,2104,2178],[2363,2185,2541,2542,2543,2393],{"nctId":3914,"briefTitle":3915,"status":496,"phases":7808,"completion":3917,"start":3918,"conditions":7809,"interventions":7810},[90],[15,21,18,2116,2117],[3921,3903,3922,2363],{"nctId":3980,"briefTitle":3981,"status":496,"phases":7812,"completion":2190,"start":3868,"conditions":7813,"interventions":7814},[90],[2539,15,2567,2102,2103,2228,21,18,2117,30],[3969,2363],{"trials":7816,"activeCount":100},[],{"trials":7818,"activeCount":100},[7819],{"nctId":7820,"briefTitle":7821,"status":496,"phases":7822,"completion":3917,"start":7823,"conditions":7824,"interventions":7825},"NCT00000483","Coronary Drug Project Mortality Surveillance",[92],"1981-06",[15,21,18,2116,2117],[3921,7826,3922,2363],"clofibrate",{"intervention":2393,"totalTrials":736,"cells":7828},{"EARLY_PHASE1":7829,"PHASE1":7831,"PHASE2":7833,"PHASE3":7835,"PHASE4":7854,"NA":7856},{"trials":7830,"activeCount":100},[],{"trials":7832,"activeCount":100},[],{"trials":7834,"activeCount":100},[],{"trials":7836,"activeCount":100},[7837,7841,7850],{"nctId":2533,"briefTitle":2534,"status":496,"phases":7838,"completion":2536,"start":2537,"conditions":7839,"interventions":7840},[90],[2539,15,18,2104,2178],[2363,2185,2541,2542,2543,2393],{"nctId":7842,"briefTitle":7843,"status":496,"phases":7844,"completion":3119,"start":3846,"conditions":7845,"interventions":7849},"NCT00000614","Prevention of Recurrent Venous Thromboembolism (PREVENT)",[90],[15,18,7846,7847,2104,7848],"Peripheral Vascular Diseases","Thromboembolism","Venous Thromboembolism",[2393],{"nctId":2386,"briefTitle":2387,"status":496,"phases":7851,"completion":2389,"start":2390,"conditions":7852,"interventions":7853},[90],[15,21,18,2117],[2106,2347,2393],{"trials":7855,"activeCount":100},[],{"trials":7857,"activeCount":100},[7858],{"nctId":7859,"briefTitle":7860,"status":496,"phases":7861,"completion":7862,"start":7863,"conditions":7864,"interventions":7866},"NCT00005684","Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis",[],"2001-01","1996-03",[7865,15,7848],"Venous Thrombosis",[2393,3093],{"intervention":6071,"totalTrials":736,"cells":7868},{"EARLY_PHASE1":7869,"PHASE1":7871,"PHASE2":7873,"PHASE3":7879,"PHASE4":7898,"NA":7900},{"trials":7870,"activeCount":100},[],{"trials":7872,"activeCount":100},[],{"trials":7874,"activeCount":100},[7875],{"nctId":6066,"briefTitle":6067,"status":496,"phases":7876,"completion":2682,"start":2298,"conditions":7877,"interventions":7878},[89],[472],[6057,6071,6072],{"trials":7880,"activeCount":100},[7881,7891],{"nctId":7882,"briefTitle":7883,"status":496,"phases":7884,"primaryCompletion":868,"completion":7885,"start":7785,"enrollment":7886,"conditions":7887,"interventions":7888},"NCT00075829","Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)",[90],"2013-03",710,[1174],[7889,7890],"Thalidomide","Dexamethasone",{"nctId":7892,"briefTitle":7893,"status":496,"phases":7894,"completion":3763,"start":7895,"conditions":7896,"interventions":7897},"NCT00000563","Prevention of Neonatal Respiratory Distress Syndrome With Antenatal Steroid Administration",[90],"1976-06",[27,4426],[6071],{"trials":7899,"activeCount":100},[],{"trials":7901,"activeCount":100},[7902],{"nctId":7903,"briefTitle":7904,"status":496,"phases":7905,"completion":619,"start":7906,"conditions":7907,"interventions":7909},"NCT00023530","Blood and Marrow Transplant Clinical Research Network",[92],"2001-09",[7908,4090,625,472,1174,676,392],"Bone Marrow Transplantation",[7910,7911,7912,6071],"fluconazole","voriconazole","thalidomide",{"intervention":3921,"totalTrials":851,"cells":7914},{"EARLY_PHASE1":7915,"PHASE1":7917,"PHASE2":7919,"PHASE3":7929,"PHASE4":7935,"NA":7937},{"trials":7916,"activeCount":100},[],{"trials":7918,"activeCount":100},[],{"trials":7920,"activeCount":100},[7921],{"nctId":7922,"briefTitle":7923,"status":496,"phases":7924,"completion":2225,"start":3846,"enrollment":620,"conditions":7925,"interventions":7926},"NCT00001752","Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women",[89],[2070,2216],[7927,7928],"L-arginine","Estrogen",{"trials":7930,"activeCount":100},[7931],{"nctId":3914,"briefTitle":3915,"status":496,"phases":7932,"completion":3917,"start":3918,"conditions":7933,"interventions":7934},[90],[15,21,18,2116,2117],[3921,3903,3922,2363],{"trials":7936,"activeCount":100},[],{"trials":7938,"activeCount":100},[7939],{"nctId":7820,"briefTitle":7821,"status":496,"phases":7940,"completion":3917,"start":7823,"conditions":7941,"interventions":7942},[92],[15,21,18,2116,2117],[3921,7826,3922,2363],{"intervention":7912,"totalTrials":843,"cells":7944},{"EARLY_PHASE1":7945,"PHASE1":7947,"PHASE2":7949,"PHASE3":7951,"PHASE4":7957,"NA":7959},{"trials":7946,"activeCount":100},[],{"trials":7948,"activeCount":100},[],{"trials":7950,"activeCount":100},[],{"trials":7952,"activeCount":100},[7953],{"nctId":7882,"briefTitle":7883,"status":496,"phases":7954,"primaryCompletion":868,"completion":7885,"start":7785,"enrollment":7886,"conditions":7955,"interventions":7956},[90],[1174],[7889,7890],{"trials":7958,"activeCount":100},[],{"trials":7960,"activeCount":100},[7961],{"nctId":7903,"briefTitle":7904,"status":496,"phases":7962,"completion":619,"start":7906,"conditions":7963,"interventions":7964},[92],[7908,4090,625,472,1174,676,392],[7910,7911,7912,6071],{"intervention":3789,"totalTrials":843,"cells":7966},{"EARLY_PHASE1":7967,"PHASE1":7969,"PHASE2":7971,"PHASE3":7973,"PHASE4":7979,"NA":7981},{"trials":7968,"activeCount":100},[],{"trials":7970,"activeCount":100},[],{"trials":7972,"activeCount":100},[],{"trials":7974,"activeCount":100},[7975],{"nctId":3783,"briefTitle":3784,"status":496,"phases":7976,"completion":3786,"start":3003,"conditions":7977,"interventions":7978},[90],[33,27],[3789,3772],{"trials":7980,"activeCount":100},[],{"trials":7982,"activeCount":100},[7983],{"nctId":7984,"briefTitle":7985,"status":496,"phases":7986,"primaryCompletion":7987,"completion":7987,"start":7988,"enrollment":7989,"conditions":7990,"interventions":7991},"NCT00319488","Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS)",[92],"2006-11","2004-02",238,[33,27],[7992,7993,7994],"Inhaled Corticosteroid","Leukotriene Receptor Antagonist","Inhaled Albuterol",{"intervention":3093,"totalTrials":843,"cells":7996},{"EARLY_PHASE1":7997,"PHASE1":7999,"PHASE2":8001,"PHASE3":8003,"PHASE4":8009,"NA":8011},{"trials":7998,"activeCount":100},[],{"trials":8000,"activeCount":100},[],{"trials":8002,"activeCount":100},[],{"trials":8004,"activeCount":100},[8005],{"nctId":3087,"briefTitle":3088,"status":496,"phases":8006,"completion":2565,"start":3090,"conditions":8007,"interventions":8008},[90],[2135,15,21,18,2116,2117],[3076,3093],{"trials":8010,"activeCount":100},[],{"trials":8012,"activeCount":100},[8013],{"nctId":7859,"briefTitle":7860,"status":496,"phases":8014,"completion":7862,"start":7863,"conditions":8015,"interventions":8016},[],[7865,15,7848],[2393,3093],{"intervention":3922,"totalTrials":843,"cells":8018},{"EARLY_PHASE1":8019,"PHASE1":8021,"PHASE2":8023,"PHASE3":8025,"PHASE4":8031,"NA":8033},{"trials":8020,"activeCount":100},[],{"trials":8022,"activeCount":100},[],{"trials":8024,"activeCount":100},[],{"trials":8026,"activeCount":100},[8027],{"nctId":3914,"briefTitle":3915,"status":496,"phases":8028,"completion":3917,"start":3918,"conditions":8029,"interventions":8030},[90],[15,21,18,2116,2117],[3921,3903,3922,2363],{"trials":8032,"activeCount":100},[],{"trials":8034,"activeCount":100},[8035],{"nctId":7820,"briefTitle":7821,"status":496,"phases":8036,"completion":3917,"start":7823,"conditions":8037,"interventions":8038},[92],[15,21,18,2116,2117],[3921,7826,3922,2363],{"intervention":8040,"totalTrials":843,"cells":8041},"Losartan",{"EARLY_PHASE1":8042,"PHASE1":8044,"PHASE2":8053,"PHASE3":8055,"PHASE4":8057,"NA":8059},{"trials":8043,"activeCount":100},[],{"trials":8045,"activeCount":100},[8046],{"nctId":8047,"briefTitle":8048,"status":496,"phases":8049,"completion":5936,"start":8050,"enrollment":4341,"conditions":8051,"interventions":8052},"NCT00001741","Study of Inherited Changes of Receptors Located on Blood Vessels",[88],"1997-11",[1471],[8040],{"trials":8054,"activeCount":100},[],{"trials":8056,"activeCount":100},[],{"trials":8058,"activeCount":100},[],{"trials":8060,"activeCount":100},[8061],{"nctId":8062,"briefTitle":8063,"status":496,"phases":8064,"completion":5936,"start":1036,"enrollment":8065,"conditions":8066,"interventions":8068},"NCT00001534","Long Term Effects of Enalapril and Losartan on Genetic Heart Disease",[],112,[6249,8067,2117],"Left Ventricular Hypertrophy",[8040],{"intervention":7927,"totalTrials":843,"cells":8070},{"EARLY_PHASE1":8071,"PHASE1":8073,"PHASE2":8075,"PHASE3":8081,"PHASE4":8083,"NA":8085},{"trials":8072,"activeCount":100},[],{"trials":8074,"activeCount":100},[],{"trials":8076,"activeCount":100},[8077],{"nctId":7922,"briefTitle":7923,"status":496,"phases":8078,"completion":2225,"start":3846,"enrollment":620,"conditions":8079,"interventions":8080},[89],[2070,2216],[7927,7928],{"trials":8082,"activeCount":100},[],{"trials":8084,"activeCount":100},[],{"trials":8086,"activeCount":100},[8087],{"nctId":8088,"briefTitle":8089,"status":496,"phases":8090,"completion":619,"start":7906,"conditions":8091,"interventions":8092},"NCT00051376","Vascular Interaction With Age in Myocardial Infarction",[92],[2116],[8093],"L-Arginine",{"intervention":7910,"totalTrials":96,"cells":8095},{"EARLY_PHASE1":8096,"PHASE1":8098,"PHASE2":8100,"PHASE3":8102,"PHASE4":8104,"NA":8106},{"trials":8097,"activeCount":100},[],{"trials":8099,"activeCount":100},[],{"trials":8101,"activeCount":100},[],{"trials":8103,"activeCount":100},[],{"trials":8105,"activeCount":100},[],{"trials":8107,"activeCount":100},[8108],{"nctId":7903,"briefTitle":7904,"status":496,"phases":8109,"completion":619,"start":7906,"conditions":8110,"interventions":8111},[92],[7908,4090,625,472,1174,676,392],[7910,7911,7912,6071],{"intervention":7911,"totalTrials":96,"cells":8113},{"EARLY_PHASE1":8114,"PHASE1":8116,"PHASE2":8118,"PHASE3":8120,"PHASE4":8122,"NA":8124},{"trials":8115,"activeCount":100},[],{"trials":8117,"activeCount":100},[],{"trials":8119,"activeCount":100},[],{"trials":8121,"activeCount":100},[],{"trials":8123,"activeCount":100},[],{"trials":8125,"activeCount":100},[8126],{"nctId":7903,"briefTitle":7904,"status":496,"phases":8127,"completion":619,"start":7906,"conditions":8128,"interventions":8129},[92],[7908,4090,625,472,1174,676,392],[7910,7911,7912,6071],{"intervention":8131,"totalTrials":96,"cells":8132},"Epsilon-Aminocaproic Acid",{"EARLY_PHASE1":8133,"PHASE1":8135,"PHASE2":8137,"PHASE3":8139,"PHASE4":8141,"NA":8143},{"trials":8134,"activeCount":100},[],{"trials":8136,"activeCount":100},[],{"trials":8138,"activeCount":100},[],{"trials":8140,"activeCount":100},[],{"trials":8142,"activeCount":100},[],{"trials":8144,"activeCount":100},[8145],{"nctId":8146,"briefTitle":8147,"status":496,"phases":8148,"primaryCompletion":1889,"completion":1889,"start":1035,"enrollment":8149,"conditions":8150,"interventions":8156},"NCT00320619","Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery",[92],182,[8151,8152,8153,8154,8155],"Scoliosis","Kyphosis","Lordosis","Spondylitis","Spinal Stenosis",[8131],{"intervention":8158,"totalTrials":96,"cells":8159},"Recombinant LCAT",{"EARLY_PHASE1":8160,"PHASE1":8162,"PHASE2":8164,"PHASE3":8166,"PHASE4":8168,"NA":8170},{"trials":8161,"activeCount":100},[],{"trials":8163,"activeCount":100},[],{"trials":8165,"activeCount":100},[],{"trials":8167,"activeCount":100},[],{"trials":8169,"activeCount":100},[],{"trials":8171,"activeCount":100},[8172],{"nctId":8173,"briefTitle":8174,"status":496,"phases":8175,"primaryCompletion":8176,"start":8177,"enrollment":96,"conditions":8178,"interventions":8180},"NCT04737720","Intravenous ACP-501 for Familial LCAT Deficiency (rhLCAT)",[],"2013-12-12","2013-01-24",[8179],"Familial LCAT Deficiency",[8158],{"intervention":8182,"totalTrials":96,"cells":8183},"13N-amonia",{"EARLY_PHASE1":8184,"PHASE1":8186,"PHASE2":8188,"PHASE3":8190,"PHASE4":8192,"NA":8194},{"trials":8185,"activeCount":100},[],{"trials":8187,"activeCount":100},[],{"trials":8189,"activeCount":100},[],{"trials":8191,"activeCount":100},[],{"trials":8193,"activeCount":100},[],{"trials":8195,"activeCount":100},[8196],{"nctId":8197,"briefTitle":8198,"status":496,"phases":8199,"primaryCompletion":8200,"start":8201,"enrollment":1022,"conditions":8202,"interventions":8203},"NCT01934660","Links Between Inflammation and Cardiometabolic Diseases",[],"2022-08-03","2013-12-02",[2178,1471,7058,6149],[8182,8204],"Fludeoxyglucose F18",{"intervention":8204,"totalTrials":96,"cells":8206},{"EARLY_PHASE1":8207,"PHASE1":8209,"PHASE2":8211,"PHASE3":8213,"PHASE4":8215,"NA":8217},{"trials":8208,"activeCount":100},[],{"trials":8210,"activeCount":100},[],{"trials":8212,"activeCount":100},[],{"trials":8214,"activeCount":100},[],{"trials":8216,"activeCount":100},[],{"trials":8218,"activeCount":100},[8219],{"nctId":8197,"briefTitle":8198,"status":496,"phases":8220,"primaryCompletion":8200,"start":8201,"enrollment":1022,"conditions":8221,"interventions":8222},[],[2178,1471,7058,6149],[8182,8204],{"intervention":7826,"totalTrials":96,"cells":8224},{"EARLY_PHASE1":8225,"PHASE1":8227,"PHASE2":8229,"PHASE3":8231,"PHASE4":8233,"NA":8235},{"trials":8226,"activeCount":100},[],{"trials":8228,"activeCount":100},[],{"trials":8230,"activeCount":100},[],{"trials":8232,"activeCount":100},[],{"trials":8234,"activeCount":100},[],{"trials":8236,"activeCount":100},[8237],{"nctId":7820,"briefTitle":7821,"status":496,"phases":8238,"completion":3917,"start":7823,"conditions":8239,"interventions":8240},[92],[15,21,18,2116,2117],[3921,7826,3922,2363],{"intervention":8242,"totalTrials":96,"cells":8243},"Melatonin",{"EARLY_PHASE1":8244,"PHASE1":8246,"PHASE2":8248,"PHASE3":8250,"PHASE4":8252,"NA":8254},{"trials":8245,"activeCount":100},[],{"trials":8247,"activeCount":100},[],{"trials":8249,"activeCount":100},[],{"trials":8251,"activeCount":100},[],{"trials":8253,"activeCount":100},[],{"trials":8255,"activeCount":100},[8256],{"nctId":8257,"briefTitle":8258,"status":420,"phases":8259,"primaryCompletion":5717,"completion":5717,"start":8260,"enrollment":8261,"conditions":8262,"interventions":8264},"NCT00387179","Effectiveness of Combining Light and Non-Light Treatments for Jet Lag and Sleep Disorders",[92],"2006-10",48,[8263],"Sleep Disorders, Circadian Rhythm",[8242,8265],"Methylxanthine",{"intervention":8265,"totalTrials":96,"cells":8267},{"EARLY_PHASE1":8268,"PHASE1":8270,"PHASE2":8272,"PHASE3":8274,"PHASE4":8276,"NA":8278},{"trials":8269,"activeCount":100},[],{"trials":8271,"activeCount":100},[],{"trials":8273,"activeCount":100},[],{"trials":8275,"activeCount":100},[],{"trials":8277,"activeCount":100},[],{"trials":8279,"activeCount":100},[8280],{"nctId":8257,"briefTitle":8258,"status":420,"phases":8281,"primaryCompletion":5717,"completion":5717,"start":8260,"enrollment":8261,"conditions":8282,"interventions":8283},[92],[8263],[8242,8265],{"intervention":8285,"totalTrials":96,"cells":8286},"fluoxetine",{"EARLY_PHASE1":8287,"PHASE1":8289,"PHASE2":8291,"PHASE3":8293,"PHASE4":8295,"NA":8297},{"trials":8288,"activeCount":100},[],{"trials":8290,"activeCount":100},[],{"trials":8292,"activeCount":100},[],{"trials":8294,"activeCount":100},[],{"trials":8296,"activeCount":100},[],{"trials":8298,"activeCount":100},[8299],{"nctId":8300,"briefTitle":8301,"status":496,"phases":8302,"completion":2269,"start":8303,"conditions":8304,"interventions":8305},"NCT00113737","Fluoxetine as a Quit Smoking AID for Depression Prone",[92],"1998-02",[15,18],[8285],{"intervention":8307,"totalTrials":96,"cells":8308},"inhaled corticosteroids",{"EARLY_PHASE1":8309,"PHASE1":8311,"PHASE2":8313,"PHASE3":8315,"PHASE4":8317,"NA":8319},{"trials":8310,"activeCount":100},[],{"trials":8312,"activeCount":100},[],{"trials":8314,"activeCount":100},[],{"trials":8316,"activeCount":100},[],{"trials":8318,"activeCount":100},[],{"trials":8320,"activeCount":100},[8321],{"nctId":8322,"briefTitle":8323,"status":496,"phases":8324,"completion":3786,"start":7862,"conditions":8325,"interventions":8326},"NCT00272441","Prevention of Early Asthma in Kids (PEAK)",[92],[33,27],[8307],{"intervention":8328,"totalTrials":96,"cells":8329},"Nicotine Patch",{"EARLY_PHASE1":8330,"PHASE1":8332,"PHASE2":8334,"PHASE3":8336,"PHASE4":8338,"NA":8340},{"trials":8331,"activeCount":100},[],{"trials":8333,"activeCount":100},[],{"trials":8335,"activeCount":100},[],{"trials":8337,"activeCount":100},[],{"trials":8339,"activeCount":100},[],{"trials":8341,"activeCount":100},[8342],{"nctId":8343,"briefTitle":8344,"status":496,"phases":8345,"start":8346,"enrollment":8347,"conditions":8348,"interventions":8350},"NCT00403312","Increasing Physical Activity as Part of a Smoking Cessation Program",[92],"2003-01",400,[8349],"Smoking Cessation",[8328],{"intervention":7993,"totalTrials":96,"cells":8352},{"EARLY_PHASE1":8353,"PHASE1":8355,"PHASE2":8357,"PHASE3":8359,"PHASE4":8361,"NA":8363},{"trials":8354,"activeCount":100},[],{"trials":8356,"activeCount":100},[],{"trials":8358,"activeCount":100},[],{"trials":8360,"activeCount":100},[],{"trials":8362,"activeCount":100},[],{"trials":8364,"activeCount":100},[8365],{"nctId":7984,"briefTitle":7985,"status":496,"phases":8366,"primaryCompletion":7987,"completion":7987,"start":7988,"enrollment":7989,"conditions":8367,"interventions":8368},[92],[33,27],[7992,7993,7994],{"intervention":7994,"totalTrials":96,"cells":8370},{"EARLY_PHASE1":8371,"PHASE1":8373,"PHASE2":8375,"PHASE3":8377,"PHASE4":8379,"NA":8381},{"trials":8372,"activeCount":100},[],{"trials":8374,"activeCount":100},[],{"trials":8376,"activeCount":100},[],{"trials":8378,"activeCount":100},[],{"trials":8380,"activeCount":100},[],{"trials":8382,"activeCount":100},[8383],{"nctId":7984,"briefTitle":7985,"status":496,"phases":8384,"primaryCompletion":7987,"completion":7987,"start":7988,"enrollment":7989,"conditions":8385,"interventions":8386},[92],[33,27],[7992,7993,7994],{"intervention":8388,"totalTrials":96,"cells":8389},"Inhaled Fluticasone",{"EARLY_PHASE1":8390,"PHASE1":8392,"PHASE2":8394,"PHASE3":8396,"PHASE4":8398,"NA":8400},{"trials":8391,"activeCount":100},[],{"trials":8393,"activeCount":100},[],{"trials":8395,"activeCount":100},[],{"trials":8397,"activeCount":100},[],{"trials":8399,"activeCount":100},[],{"trials":8401,"activeCount":100},[8402],{"nctId":8403,"briefTitle":8404,"status":496,"phases":8405,"completion":3386,"start":8406,"enrollment":6626,"conditions":8407,"interventions":8409},"NCT00301171","Treatment of Persistent Wheezing in Infants and Children",[92],"2003-09",[33,8408],"Respiratory Sounds",[8388],{"intervention":8411,"totalTrials":96,"cells":8412},"Estrogen hormone therapy",{"EARLY_PHASE1":8413,"PHASE1":8415,"PHASE2":8417,"PHASE3":8419,"PHASE4":8421,"NA":8423},{"trials":8414,"activeCount":100},[],{"trials":8416,"activeCount":100},[],{"trials":8418,"activeCount":100},[],{"trials":8420,"activeCount":100},[],{"trials":8422,"activeCount":100},[],{"trials":8424,"activeCount":100},[8425],{"nctId":8426,"briefTitle":8427,"status":496,"phases":8428,"primaryCompletion":8429,"completion":6341,"start":2639,"enrollment":8430,"conditions":8431,"interventions":8433},"NCT00685009","The Women's Health Initiative Memory Study (The WHIMS Study)",[],"1997-09",7525,[8432],"Dementia Syndromes",[8411,8434],"Estrogen plus progesterone hormone therapy",{"intervention":8434,"totalTrials":96,"cells":8436},{"EARLY_PHASE1":8437,"PHASE1":8439,"PHASE2":8441,"PHASE3":8443,"PHASE4":8445,"NA":8447},{"trials":8438,"activeCount":100},[],{"trials":8440,"activeCount":100},[],{"trials":8442,"activeCount":100},[],{"trials":8444,"activeCount":100},[],{"trials":8446,"activeCount":100},[],{"trials":8448,"activeCount":100},[8449],{"nctId":8426,"briefTitle":8427,"status":496,"phases":8450,"primaryCompletion":8429,"completion":6341,"start":2639,"enrollment":8430,"conditions":8451,"interventions":8452},[],[8432],[8411,8434],{"intervention":8454,"totalTrials":96,"cells":8455},"Intensive control of SBP",{"EARLY_PHASE1":8456,"PHASE1":8458,"PHASE2":8460,"PHASE3":8462,"PHASE4":8464,"NA":8466},{"trials":8457,"activeCount":100},[],{"trials":8459,"activeCount":100},[],{"trials":8461,"activeCount":100},[],{"trials":8463,"activeCount":100},[],{"trials":8465,"activeCount":100},[],{"trials":8467,"activeCount":100},[8468],{"nctId":8469,"briefTitle":8470,"status":496,"phases":8471,"primaryCompletion":2427,"completion":8472,"start":8473,"enrollment":8474,"conditions":8475,"interventions":8476},"NCT01206062","Systolic Blood Pressure Intervention Trial",[92],"2019-03","2010-10",9361,[24],[8454,8477],"Standard control of SBP",{"intervention":8477,"totalTrials":96,"cells":8479},{"EARLY_PHASE1":8480,"PHASE1":8482,"PHASE2":8484,"PHASE3":8486,"PHASE4":8488,"NA":8490},{"trials":8481,"activeCount":100},[],{"trials":8483,"activeCount":100},[],{"trials":8485,"activeCount":100},[],{"trials":8487,"activeCount":100},[],{"trials":8489,"activeCount":100},[],{"trials":8491,"activeCount":100},[8492],{"nctId":8469,"briefTitle":8470,"status":496,"phases":8493,"primaryCompletion":2427,"completion":8472,"start":8473,"enrollment":8474,"conditions":8494,"interventions":8495},[92],[24],[8454,8477],{"intervention":8497,"totalTrials":96,"cells":8498},"13N Amonia",{"EARLY_PHASE1":8499,"PHASE1":8501,"PHASE2":8503,"PHASE3":8505,"PHASE4":8507,"NA":8509},{"trials":8500,"activeCount":100},[],{"trials":8502,"activeCount":100},[],{"trials":8504,"activeCount":100},[],{"trials":8506,"activeCount":100},[],{"trials":8508,"activeCount":100},[],{"trials":8510,"activeCount":100},[8511],{"nctId":8512,"briefTitle":8513,"status":467,"phases":8514,"primaryCompletion":8515,"completion":8516,"start":8517,"enrollment":456,"conditions":8518,"interventions":8520},"NCT04870827","Effect of Chronic Inflammation on Myocardial Perfusion and Function",[],"2022-05-06","2022-05-18","2021-06-07",[8519],"Psoriasis",[8497],{"intervention":8522,"totalTrials":96,"cells":8523},"Acipimox",{"EARLY_PHASE1":8524,"PHASE1":8526,"PHASE2":8528,"PHASE3":8530,"PHASE4":8532,"NA":8534},{"trials":8525,"activeCount":100},[],{"trials":8527,"activeCount":100},[],{"trials":8529,"activeCount":100},[],{"trials":8531,"activeCount":100},[],{"trials":8533,"activeCount":100},[],{"trials":8535,"activeCount":100},[8536],{"nctId":8537,"briefTitle":8538,"status":496,"phases":8539,"completion":619,"start":2729,"enrollment":620,"conditions":8540,"interventions":8544},"NCT00246402","Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV",[92],[8541,15,18,3059,8542,8543],"Insulin Resistance","Hypertriglyceridemia","Hyperlipidemia",[8522]]